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Summary 
Over the past decade, the population of Australia rose by about 3.1 million people, from 19.5 
million in June 2002 to 22.6 million in June 2012. And the proportion of the population aged 
65 years and over, increased from 12.7% to 14.2%. Population ageing is projected to have 
significant implications for health. As life expectancy improves, people are living longer with 
disease, so management of older patients with multiple chronic diseases will form an 
increasing part of the general practitioner’s (GP’s) workload.  
GPs are usually the first port of call in the Australian healthcare system, generally receiving 
payment on a fee-for-service basis. There are no formal patient lists or registration. A 
universal medical insurance scheme (managed by Medicare Australia) covers all, or part of a 
person’s costs for a GP visit. 
In the April 2012–March 2013 year, about 85% of the Australian population claimed for at 
least one GP service from Medicare. Medicare paid rebates for about 126.8 million claimed 
general practice service items (excluding practice nurse items), an average of 5.59 GP visits 
per head of population, or 6.57 visits per person who visited at least once. A decade earlier, 
total Medicare claims for GP–patient encounters numbered 96.3 million, an average 
attendance rate of 4.3 per head of population. Administrative statistics provide information 
about frequencies and costs of visits claimed from GP services and some prescribed 
pharmaceuticals. BEACH (Bettering the Evaluation and Care of Health) gives us an 
understanding of the content of encounters and the services and treatments GPs provide.  
BEACH is a continuous national study of general practice activity in which ever-changing 
random samples of about 1,000 general practitioners (GPs) participate in a year. Each 
participating GP records details of 100 consecutive GP–patient encounters with consenting 
patients. The BEACH program began in April 1998 and is now in its 16th year.  
This book investigates results of each of 10 years of data to identify changes that occurred 
over the decade 2003–04 to 2012–13. The report is based on information from 9,772 
participating GPs, almost one million GP–patient encounters.  
The GP participants and their practices (Chapter 4) 
Between 2003–04 and 2012–13: 
• reflecting changes in the age and sex distributions of the recognised GP workforce, 
females made up an increasing proportion of participants (33% in 2003–04 to 43% in 
2012–13) as did the proportion aged 55 years and over (from 32.7% to 41.3%) 
• average hours in direct patient care decreased—from 41 hours to 38 hours per week, 
resulting from a decreased proportion working 40 hours or more (from 47% to 33%)  
• GPs who had gained their primary medical degree in Australia decreased from 73.6% to 
66.2% over the 10 years, and there were significant changes in the geographic 
distribution of country of graduation among those trained overseas 
• the proportion of GP participants holding Fellowship of the Royal Australian College of 
general practitioners increased from 33.5% to 55.7% 
• the proportion of participants in solo practice stayed steady at about 10% and the 
proportion working in smaller practices (of 2–4 individual GPs) decreased. The 
proportion working in practices of ten or more individuals rose from 12% to 21%  
  x 
• decreased proportions of GPs worked in practices that provide their own after-hours 
services (from 43% to 31%); and/or provided such care in cooperation with other 
practices (from 17% to 13%)  
• the proportion of GPs with a computer available at their major practice increased from 
95% to 98%. Since first measured in 2004–05, the proportion of GPs indicating they use a 
computer to some extent in their clinical activity increased from 89% to 96%.  
The encounters (Chapter 5) 
Over the decade there was significant change in the average length of patient encounters 
claimable from the Medicare Benefits Scheme (MBS) or the Department of Veterans’ Affairs 
(DVA), the mean each year sitting at around 15 minutes. However, the distribution of 
services claimed differed to some degree with the introduction of new MBS item numbers. 
over the years. 
The patients at encounters (Chapter 6) 
Between 2003–04 and 2012–13, the proportion of encounters with patients: 
• aged 65 years and over took up an increasing proportion of encounters, rising 
significantly (from 27% to 30%) 
• who were new to the practice significantly decreased (from 9.3% to 7.2%)  
• holding a Commonwealth concession card was relatively stable  
• holding a Repatriation Health Card decreased by over one-third, 3.9% to 2.3% 
There was a significant increase in the overall rate of patient reasons for encounter (RFEs), 
from 150 per 100 encounters in 2003–04 to 155 per 100 encounters in 2012–13.  
Problems managed at encounters (Chapter 7) 
GPs managed significantly more problems at encounters in 2012–13 (155 per 100 encounters) 
than in 2003–04 (146 per 100). This suggests there were 55 million more problems managed 
at GP–patient encounters in Australia in 2012–13 than in 2003–04.  
In all years 2003–04 to 2012–13, the most frequently managed problems were hypertension, 
check-up, upper respiratory tract infection and immunisation/vaccination. Statistically 
significant increases occurred in management rates of general check-up, diabetes, gastro-
oesophageal reflux disease, test results, vitamin/nutritional deficiency, administrative 
procedure, atrial fibrillation/flutter, pregnancy, abnormal test results and lacerations/cuts. 
Marginal increases in the management rates of depression and anxiety were also apparent. 
The management rate of chronic conditions rose from 52 per 100 encounters in 2003–04, to 56 
per 100 in 2012–13, this change accounting for about 40% of the increase in problems 
managed overall. This may be partly attributed to the changes in the age distribution of 
presenting patients. The most common chronic problems managed were non-gestational 
hypertension, non-gestational diabetes, depressive disorder, chronic arthritis and lipid 
disorders. 
There were significant increases in management rates of non-gestational diabetes (equating 
to 2.1 million more contacts in 2012–13 than in 2003–04); depressive disorder (1.7 million 
more); atrial fibrillation/flutter (1.0 million more); hypothyroidism/myxoedema; shoulder 
syndrome; and unspecified chronic pain.  
  
 xi 
Medications (Chapter 9) 
Between 2003–04 and 2012–13, there was a significant decrease in total medication and 
prescribed medication rates per 100 problems managed. There were no significant changes in 
these as a rate per 100 encounters, suggesting that the GPs are now managing more problems 
at encounter but prescribing fewer medications in the management of these problems.  
This hypothesis aligns with the increased attendance rate reported in the Background and 
with the increase in the number of medications given with five repeats (reported below). 
There were significant increases in the GP prescribing rate per 100 problems managed for: 
• agents acting on the renin-angiotensin system, psychoanaleptics, lipid modifying agents, 
and corticosteroids for systemic use  
• individual medication types including: antibiotic cephalexin, the opioid oxycodone, the 
proton pump inhibitor esomeprazole, the lipid modifying agent rosuvastatin, and the 
non-steroid anti-inflammatory meloxicam.  
There were significant decreases in the prescribing rate per 100 problems managed of:  
• drugs for obstructive airway disease, anti-inflammatory and antirheumatic products, sex 
hormones and modulators of the genital system, calcium channel blockers, vaccines, 
diuretics, drugs for functional gastrointestinal disorders, and cardiac therapy  
• some individual medication types including: the beta-blocking agent atenolol, the lipid 
modifying agent simvastatin, the cephalosporin antibiotic cefaclor monohydrate.  
There was a significant decrease in the proportion of prescribed medications with no repeats, 
two, three or four repeats ordered. On the other hand, the proportion of prescriptions given 
with five repeats increased from 29.2% in 2003–04 to 36.6% in 2012–13. This is probably 
associated with the increased management rate of chronic problems. 
There was little change in the rate of GP–supplied medications per 100 problems managed  
(6.4 per 100 in 2003–04 and 6.3 per 100 in 2012–13. The majority were vaccines.  
The rate at which GPs advised over-the-counter medications remained relatively steady, the 
exception being a four-fold increase in the rate at which vitamin D3 (cholecalciferol) was 
advised per 100 encounters. This has occurred recently, in parallel with a three-fold increase 
in the management rate of nutritional/vitamin deficiency. 
Clinical treatments (Chapter 10) 
While there was no statistically significant difference in the rate at which clinical treatments 
were provided in 2003–04 and 2012–13, there were major changes within the decade.  
The clinical treatment rate was steady from 2003–04 to 2004–05. After the introduction of 
practice nurse item numbers in November 2004, in 2005–06 there was a sudden significant 
decrease in clinical treatments provided by the GP or the practice nurse at GP–patient 
encounters, from 27 to 20 per 100 problems. This was followed by a significant increase from 
2006–07 to 2007–08 and then a slow (but steady) increase to 24 per 100 problems in 2012–13, 
the level provided 10 years earlier. 
This pattern of change was reflected in some specific types of clinical treatments including: 
general advice and education; other administrative procedure/document and sick 
certificates; counselling/advice about nutrition/weight. 
In contrast, there were significant decreases in the rate of counselling/advice about 
nutrition/weight, the drop occurring in 2006–07, with no reversion to earlier levels. 
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Procedures (Chapter 10) 
There was a significant increase in the rate at which procedures were performed from  
2003–04 (10.1 per 100 problems) to 2012–13 (11.2 per 100 problems) (Table 10.3a). However, 
the most frequently recorded group, excision/removal tissue/biopsy/destruction/ 
debridement/cauterisation, was provided at a similar rate throughout the decade.  
The provision of local injections/infiltration (excluding those performed for immunisations) 
significantly increased over the decade, from 1.1 to 1.5 per 100 problems. When extrapolated, 
the change equates to provision of 1.4 million more local injections/infiltrations nationally in 
2012–13 than in 2003–04. There were also significant increases in international normalised 
ratio (INR) tests, other preventive procedures/high-risk medication and PN/AHW check-
ups, per 100 problems managed. 
Practice nurse/Aboriginal health worker involvement (PN/AHW) (Chapter 10) 
PN/AHW involvement in care provided at, or in association with, GP–patient encounters, 
rose from 4.2% in 2005–06 to peak at 9.0%of encounters in 2009–10. It then significantly 
decreased to 7.4% in 2011–12, and remained steady in 2012–13. The proportion of problems 
managed with PN/AHW at GP encounters also increased significantly from 2.8% in 2005–06, 
to peak at 6.1% in 2009–10, with no significant change by 2012–13 (5.0%).  
In 2005–06, GPs recorded one or more PN/AHW MBS item numbers at 39% of encounters 
with recorded PN/AHW activity. By 2009–10, this proportion had risen to 45.5%. The 
removal of many PN/AHW item numbers in early 2012, meant that in 2012–13 claims for 
PN/AHW services for chronic disease accounted for 92% of recorded PN/AHW items.  
While PN/AHW provision of clinical treatments (for example, advice, education, 
administrative) remained rare, they did increase from 2 per 1,000 encounters in 2005–06, to 
11 per 1000 in 2012–13. Overall in 2012–13 PNs/AHWs provided 14% of all ‘other 
treatments’ recorded, a significantly greater proportion than in 2005–06 (9%). 
Changes in the problems for which PNs/AHWs were involved in management largely 
reflect the changes in the activities undertaken. There were significant increases in the rate at 
which they were involved in management of check-ups, diabetes, atrial fibrillation/flutter 
and preventive procedures with high-risk patients (reflecting the increasing rate of INRs, 
particularly in the last four years). Some of these increases may well have been stimulated by 
the introduction of MBS item 10997 for services provided for a chronic disease in 2007–08.  
Referrals (Chapter 11) 
Over the 10 years, there were significant increases in the likelihood that GP–patient 
encounters would involve one or more referrals and that a problem being managed at 
encounter would be referred (from 8% to 9.5%).  
A significant increase in the overall rate of referrals, from 7.9 per 100 problems managed in 
2003–04, to 9.5 per 100 in 2012–13, was largely due to an increase in the referrals to allied 
health professionals, rather than to medical specialists. The rate of referral to allied health 
services increased from 1.8 per 100 problems managed in 2003–04 to 3.0 per 100 in 2012–13, 
and increases were highest among referrals to psychologists and podiatrists/chiropodists, 
with a marginally significant increase in referral rates to dietitians/nutritionists. However, 
there were marginal increases in referrals rates per 100 problems to orthopaedic surgeons, 
cardiologists and gastroenterologists; and marginal decreases in referrals to surgeons and 
ophthalmologists. 
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Overall, referrals increased significantly, from 12 per 100 encounters in 2003–04 to 15 per 100 
in 2012–13. Extrapolation of this change suggests there were about 7.6 million more GP 
referrals nationally in 2012–13 than in 2003–04, including about 3.7 million more referrals to 
medical specialists and 3.5 million more to allied health services.  
Tests and investigations (Chapter 12) 
Between 2003–04 and 2012–13: 
• there was a significant increase in the proportion of problems managed for which 
pathology (from 12% to 14%) or imaging (5% to 6%) was ordered 
• results suggest that nationally there were about 8 million more GP–patient encounters 
involving pathology orders and 4.2 million more involving imaging requests  
• the number of pathology tests ordered increased from 24.1 to 30.4 tests/batteries of tests 
per 100 problems managed  
• the largest increase was in orders for chemical pathology, (from 13 to 18 per 
100 problems managed)  
• haematology orders increased at a slower rate, (from 4.6 to 5.4 per 100)  
• imaging test orders increased significantly from 5.6 to 6.7 per 100 problems: orders for 
ultrasound imaging showed the largest growth; orders for computerised tomography 
and for magnetic resonance imaging also significantly increased; while orders for 
diagnostic radiology decreased marginally.  
Substudies of patient risk factors (Chapter 13) 
Body mass index: 
Adults (n = 30,000–32,000 per year): prevalence of overweight/obesity in sampled adults 
(aged 18 years and over) increased significantly from 57% to 61%.The prevalence of obesity 
rose from 22% in 2003–04 to 27% in 2010–11 and then remained static. The increase was 
apparent among both male and female patients.  
Children (n = 3,000–4,000 per year): prevalence of obesity among sampled children aged 2–17 
years decreased significantly from 12% in 2003–04 to 9% in 2012–13, but this decrease was 
noted only for male children (from 14% to 10%). The prevalence of overweight in children 
remained stable over the decade at 17–19%.  
Smoking (n = 31,000–34,000 per year): among sampled adults aged 18 years and over, there 
were significant decreases in the prevalence of current daily smoking (from 18% to 14%) and 
occasional smoking (from 4.3% to 2.6%) over the decade. Daily smoking was significantly 
more common among males than females in all years. 
Alcohol consumption (n = 30,000–34,000 per year): among sampled adults (18+ years), 
prevalence of at-risk levels of alcohol consumption declined from 27% in 2003–04 to 24% in 
2012–13. The prevalence among male patients significantly decreased from 33% to 29%, 
while there was a marginal decrease for female patients from 23% to 21%. 
Risk profile in adults (n = 29,000–32,000 per year): there was a significant increase in the 
proportion of adults with one risk factor (from 49.0% in 2003–04 to 52.0% in 2012–13) and a 
marginal decrease in the proportion with three risk factors (from 4.0% to 3.4%).  
FEATURE—Type 2 diabetes 
Many aspects of the above data are brought together in a feature investigating the prevalence 
and management of Type 2 diabetes, and changes in management over time. See Chapter 14 
of General practice activity in Australia 2012–13, available at <hdl.handle.net/2123/9365> 

  
1 Introduction 
This report is the 34th book in the General Practice Series from the Bettering the Evaluation of 
Care and Health (BEACH) program. It includes summary results from the most recent 10 
years of the program, from 2003–04 to 2012–13 inclusive. 
Released in parallel with this report is a more detailed report of results for 2012–13 in the 
BEACH program, General practice activity in Australia 2012–13, 1 available at 
<hdl.handle.net/2123/9365>. 
BEACH is a continuous national study of general practice activity in which ever-changing 
random samples of about 1,000 general practitioners (GPs) participate in a year. Each 
participating GP records details of 100 consecutive GP–patient encounters with consenting 
patients. BEACH is run by the Family Medicine Research Centre (FMRC) at the University of 
Sydney. The program is supported financially by government instrumentalities and private 
industry (see Acknowledgments). 
The BEACH program began in April 1998 and was the culmination of about 20 years 
research and development work at the University of Sydney. At the end of its 15th year 
(March 2013), its database included records for about 1.5 million GP-patient encounters from 
14,793 GP participants, representing 9,630 individuals.  
From April 1998 to March 2011, BEACH was conducted by the FMRC, University of Sydney, 
in collaboration with the Australian Institute of Health and Welfare (AIHW), under the 
AIHW Act. Since April 2011 it has been conducted by the FMRC. BEACH is currently 
supported financially by government and private industry (see Acknowledgments). 
This book investigates results of each of 10 years of data to identify changes that occurred 
over the decade 2003–04 to 2012–13. The report is based on information from 9,772 
participating GPs, about almost 1 million GP–patient encounters.  
The structure of this report follows the usual approach of the annual BEACH reports.  
Ten years of results are provided about the GPs, the patients and the problems managed, 
followed by an overview of management, and specific chapters for each type of management 
action. Changes in prevalence of some patient risk factors are also presented. 
Each chapter contains an overview of the section (including definitions where relevant), and 
a brief description of the major findings, followed by the results tables. In the tables, 
statistically significant changes between 2003–04 and 2012–13 are marked. The national effect 
of significant change can be estimated by extrapolating the BEACH results to all GP 
Medicare claimed encounters. The method adopted for extrapolation of the effect of a change 
is described in Section 2.9. Examples of extrapolation of a measured change are also 
provided in each of chapters 5 to 12 inclusive. The reader can apply this method to any 
significant change in the BEACH data presented in terms of rate per 100 encounters, to gain 
an estimate of the size of the national effect of this change. 
In this report, changes over time in, for example, GP management actions for a specific 
problem, or changes in the problems managed for a selected group of patients, are not 
generally investigated. However, an example of this type of specific analysis for a selected 
topic is given for Type 2 diabetes in Chapter 14 of the companion report, General practice 
activity in Australia 2012–13.1 Such analyses can be requested from the FMRC. Details are 
provided on the FMRC web site: sydney.edu.au/medicine/fmrc/. 
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1.1 Background 
In June 2012, the population of Australia was estimated to be 22.6 million people.2, up from 
19.5 million in June 2002. Like the rest of the developed world, Australia has an ageing 
population. Between June 2002 and June 2012, the proportion of the population that was 
aged 65 years and over increased from 12.7% to 14.2, and this included an increase in 
proportion aged 85 years or more, from 1.4 % to 1.9% of the total population.2 Over the next 
several decades, population ageing is projected to have significant implications for Australia, 
including for health.3 As life expectancy improves, people are living longer with disease, so a 
greater part of the GP workload will involve management of older patients with multiple 
chronic diseases. 
Australia’s health expenditure in 2010–11 was $130.3 billion, an average $5,796 per 
Australian, and accounted for 9.3% of GDP. Governments funded 69.9%, with the remainder 
(30.1%) being paid by the non-government sector.4 Government expenditure on general 
practice services (including those of the practice nurses) was almost $5.6 billion dollars in the 
2011–12 financial year.5 
GPs are usually the first port of call in the Australian healthcare system. Payment for GP 
visits is largely on a fee-for-service system, there being no compulsory patient lists or 
registration. People are free to see multiple practitioners and visit multiple practices of their 
choice. There is a universal medical insurance scheme (managed by Medicare Australia), 
which covers all or most of an individual’s costs for a GP visit.  
In 2011 in Australia, there were 25,056 practising GPs (medical practitioners self-identifying 
as GPs), making up 25,063 full-time equivalents (FTE, based on a 40-hour week), or 109.7 FTE 
GPs per 100,000 people.6  
In the April 2012–March 2013 year, about 85% of the Australian population claimed at least 
one GP service from Medicare (personal communication, Department of Health and Ageing 
[DoHA], June 2013). From April 2012 to March 2013, Medicare paid rebates for about 
126.8 million claimed general practice service items (excluding practice nurse items),7 at an 
average of about 5.59 GP visits per head of population or 6.57 visits per person who visited 
at least once. This equates to about 2.44 million GP–patient encounters per week. A decade 
earlier, in the 2003–04 financial year, total Medicare claims for GP–patient encounters 
numbered 96.3 million, an average attendance rate of 4.3 per head of population.7 
 Medicare statistics provide information about frequencies and costs of visits claimed from 
Medicare for GP services. BEACH gives us an understanding of the content of GP–patient 
encounters and the services and treatments that GPs provide. The BEACH program aims to: 
• provide a reliable and valid data collection process for general practice that is responsive 
to the ever-changing needs of information users 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and their relationship with service activity. 
Users of BEACH data might wish to consolidate information from multiple sources. 
Integration can provide a more comprehensive picture of the health and health care of the 
Australian community. Readers need to be aware of how the BEACH data differ from those 
drawn from other sources. A summary of differences between the BEACH datasets and 
those in national administrative datasets and studies is available in General practice activity in 
Australia 2012–13 (Section 1.3).1  
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2 Methods  
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in 
any one week, 50 weeks a year (with two weeks break over Christmas) 
• each GP can be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each 3-year period) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice 
(Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice 
registrars who claimed a minimum of 375 Medicare general practice items of service in the 
most recently available 3-month Medicare data period (which equates to 1,500 such claims in 
a year). This ensures inclusion of the majority of part-time GPs, while excluding those who 
are not in private practice but claim for a few consultations a year. 
The Medicare statistics section of the DoHA updates the sample frame quarterly from the 
Medicare claims data. They then remove from the sample frame any GPs already randomly 
sampled in the current triennium, and draw a new sample from those remaining in the 
sample frame. This ensures the timely addition of new entries to the profession, and timely 
exclusion of those GPs who have stopped practising, or have already participated or been 
approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by 
DoHA. 
• Over the following 10 days, the telephone numbers generated from the Medicare data 
are checked using the electronic white and yellow pages. This is necessary because many 
of the telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the 
approach letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has 
moved elsewhere, but is still in practice. Where a new address and/or telephone number 
can be obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
• Each GP receives a telephone reminder early in the agreed recording period – this also 
provides the GP with an opportunity to ask questions about the recording process. 
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• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions 
during their recording period. 
• Non-returns are followed up by regular telephone calls for three months. 
• Participating GPs earn clinical audit points towards their QI & CPD requirements 
through the Royal Australian College of General Practitioners (RACGP) and/or the 
Australian College of Rural and Remote Medicine (ACRRM). As part of this QI process, 
each receives an analysis of his or her results compared with those of nine other de-
identified GPs who recorded at about the same time. Comparisons with the national 
average and with targets relating to the National Health Priority Areas are also 
provided. In addition, GPs receive some educational material related to the identification 
and management of patients who smoke or consume alcohol at hazardous levels. 
Additional points can be earned if the participant chooses to do a follow-up audit of 
smoking and alcohol consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2012–13 was obtained from the Human Ethics Committee of 
the University of Sydney.  
Although the data collected by the GPs is not sufficient to identify an individual patient, 
informed consent for GP recording of the encounter details is required from each patient. 
GPs are instructed to ensure that all patients presenting during their recording period are 
provided with a Patient Information Card (Appendix 3) and to ask the patient if they are 
happy for their data to be included in the study. If the patient refuses, details of the 
encounter are not recorded. This is in accordance with the Ethics requirements for the 
BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and 
patient health status. An example of the form used to collect the encounter data and the data 
on patient health status is included in Appendix 1. The GP characteristics questionnaire is 
provided in Appendix 2. The GP characteristics and encounter data collected are 
summarised below. Patient health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care 
hours worked per week, intended changes in hours of direct patient care in five years, 
country of graduation, general practice registrar status, Fellow of the RACGP status, 
Fellow of the ACRRM status, use of computers at work, work undertaken in other 
clinical settings, number of practice locations worked in a regular week. 
• Practice characteristics: postcode of major practice; number of individual, and number 
of full-time equivalent GPs working in the practice; number of individual and number of 
full-time equivalent practice nurses working in the practice; usual after-hours care 
arrangements, other health services located at the major practice. 
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Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box 
options), up to three MBS/DVA item numbers (where applicable), and other payment 
source (where applicable) (tick boxes). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) 
are provided for Commonwealth concession card holders, holders of a Repatriation 
Health Card (from DVA), non-English-speaking background (patient self-report–a 
language other than English is the primary language at home), Aboriginal person (self-
identification), and Torres Strait Islander person (self-identification). Space is provided 
for up to three patient reasons for encounter (RFEs). (See ‘Glossary’). 
• The problems managed at encounter (at least one and up to four). Tick boxes are 
provided to denote the status of each problem as new or continuing for the patient and 
whether the problem is considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter 
purchase including brand name, form (where required), strength, regimen, status 
(new or continuing medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and 
education, and procedures undertaken, and whether the recorded other treatment 
was provided by practice nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, 
and hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient 
characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may 
describe one RFE (such as ‘repeat prescriptions’) that is related to multiple problems 
managed, or several RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single 
problem (such as upper respiratory tract infection) managed (see Section 6.3). 
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The encounter 
• date 
• direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
• indirect (e.g. telephone) 
Patient substudies (SAND) 
• risk factors 
— body mass 
— smoking status 
— alcohol consumption  
• other topics 
Management of each problem 
Medications (up to four per problem) 
• prescribed 
• over-the-counter advised 
• provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
• procedural treatments 
• clinical treatments (e.g. advice, 
counselling) 
• practice nurse involvement 
 
Other management 
• referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
• pathology tests ordered (up to five) 
• imaging ordered (up to three) 
GP characteristics 
• age and sex 
• years in general practice 
• country of graduation 
• direct patient care hours/week 
• FRACGP status (yes/no) 
• FACRRM status (yes/no) 
• currently a registrar (yes/no) 
• clinical use of computers  
 
Practice characteristics 
• practice size (no. & FTE GPs) 
• practice nurse(s) (no. & FTE) 
• after-hours arrangements 
• postcode  
• presence of other health services 
Problems managed 
• diagnosis/problem label 
• problem status (new/old) 
• work-related problem status 
The patient 
• age and sex 
• practice status (new/old) 
• Commonwealth concession 
card status 
• Repatriation Health Card 
status 
• postcode of residence 
• NESB/Indigenous status 
  f  t  
Note: FRACGP – Fellow of the Royal Australian College of General 
Practitioners; FACRRM – Fellow of the Australian College of Rural 
and Remote Medicine; FTE – full-time equivalent; DVA – Department 
of Veterans’ Affairs; NESB – non-English-speaking background;  
SAND – Supplementary Analysis of Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or 
health care delivery in general practice not covered by the consultation-based data. These 
substudies are referred to as SAND(Supplementary Analysis of Nominated Data). 
• Each year, the 12-month data period is divided into 10 blocks, each of 5 weeks, with 
three substudies per block. The research team aims to include data from about 100 GPs 
in each block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish times 
of the encounter, and include questions about patient risk factors: patient height and 
weight (used to calculate body mass index, BMI), alcohol intake and smoking status 
(patient self-report). The methods and results of topics in the SAND substudies for 
alcohol consumption, smoking status and BMI are reported in Chapter 13. The start and 
finish times collected on these encounters are used to calculate the length of consultation. 
The length of consultation for Medicare-claimable encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND 
block includes about 3,000 records. Some topics are repeated to increase sample size. 
Different questions are asked of the patient in each block and these vary throughout 
the year. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk 
factor forms may appear first, second or third in the pad. Rotation of ordering ensures 
there was no order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2012 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia8 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–20069 
• conducted between August 2006 and March 2012 have been published in each of the 
general practice activity annual reports10-15 
• conducted in the 2012–13 BEACH year are provided in Chapter 15 of the companion 
report: General practice activity in Australia 2012–13.1 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts. 
2.7 Statistical methods 
The analysis of the 2012–13 BEACH data was conducted with Statistical Analysis System 
(SAS) version 9.3,16 When originally published, data from 2001–02 to 2004–05 were analysed 
using SAS version 6.1217 (with additional programming to adjust for the cluster sample study 
design). Previously published data from 2005–06 to 2010–11 were analysed using 
SAS version 9.1.3.18 At each change in SAS version, all past data have been re-analysed. This 
has resulted in slightly tighter confidence intervals and minor variations in point estimates 
(of up to 0.1) when data published in this report are compared with data published in earlier 
annual reports.  
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BEACH has a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
correlation between observations within clusters. Procedures in SAS version 9.3 were used to 
calculate the intracluster correlation, and adjust the confidence intervals accordingly.16  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex 
distribution of the participating GPs and those in the sample frame from which the samples 
were drawn; and for the varying activity level of each GP (measured by number of claims 
each has made in the previous 12 months from Medicare Australia). Each year, the age-sex 
distribution of patients at the sampled encounters has excellent precision when compared 
with the age-sex distribution of patients at all Medicare claimed services of this type.  
The encounter is the primary unit of inference. Proportions are used only when describing 
the distribution of an event that can arise only once at a consultation (for example, patient or 
GP age and sex), or to describe the distribution of events within a class of events (for 
example, problem A as a percentage of total problems). Due to rounding, proportions may 
not always add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, RFEs, problems managed or medications). Rates per 100 problems 
are also used when a management event can occur more than once per problem managed.  
Statistical significance is tested by chi-square statistic for GP characteristics, but significance 
of differences in/for rates is judged by non-overlapping confidence intervals of the results 
being compared. The magnitude of this difference can be described as at least p < 0.05. 
Assessment using non-overlapping CIs is a conservative measure of significance,19-21 
particularly when differences are assessed by comparing results from independent random 
samples, as is the case when changes over time are investigated using BEACH data. Due to 
the number of comparisons made in this and the companion publication, we believe this 
more conservative approach is warranted. 
• Changes over time in the frequency of these events are judged significant (that is, a real 
change has occurred) if the two sets of confidence intervals do not overlap. For example, 
Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is significantly less than Result B: 
11.9 per 100 encounters (95% CI: 11.8–12.0). 
• If the two sets of confidence intervals butt together the difference is regarded as 
marginal. For example, Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is 
marginally lower than Result B: 11.9 (95% CI: 11.7–12.1). 
• If the two sets of 95% confidence intervals overlap, then no change was measured. 
• Differences discussed in this report are statistically significant unless otherwise stated. 
2.8 Changes over time 
For the 10 years from 2003–04 to 2012–13, patient reasons for encounter and problems 
managed have been reported as rates per 100 encounters. In earlier years, rates per 100 
encounters were also used when measuring changes in each of the management actions 
(prescriptions, other treatments, referrals, pathology and imaging). However, there has been 
a significant increase in the number of problems managed per encounter (see Chapter 7). 
This means that at each encounter, there is an increased chance of a management action 
occurring, without any change in the management practise of GPs. All management actions 
are therefore reported in two ways —as rates per 100 problems managed (used as the 
primary measure of change in GP behaviour) and as rates per 100 encounters (used as the 
basis of extrapolation).  
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Data presented in this report are comparable for each result across all data years. Where 
methodological changes have occurred, the data have either: 
• been recalculated across all years using the new method (for example, body mass index 
was recalculated due to a change in the World Health Organization’s (WHO) body mass 
index groupings) 
• been regrouped for comparability. Where this occurs, it is noted in the footnotes of the 
table. An example is the combined presentation of home visits and institutional visits in 
Chapter 5 because the MBS now has only one item number for both. In previously 
published data it was possible to differentiate the two 
• been omitted from this report (if recalculation or grouping was not possible). Where data 
are omitted, this is noted as not applicable (N/A) or not available (NAv), as appropriate. 
In measuring changes over time, the 2012–13 results are compared with those from 2003–04 
wherever possible. However, as in any long-term research program, changes occur over the 
years. For example, practice nurse activity data were not collected until 2005–06, so the 
changes are only considered between 2005–06 and 2012–13. 
Each table includes the most frequent events occurring in 2012–13, and the comparative 
results for each of the earlier years. In addition, each table includes data for events that were 
more frequent in past year(s), but were no longer in the most frequent in 2012–13. In general, 
results are presented in decreasing 2012–13 order of frequency. 
The direction and type of change between 2003–04 and 2012–13 is indicated for each result in 
the far right column of the tables: 
• / indicates a statistically significant change (increase or decrease) in 2012–13 when 
compared with the first year of data reported 
• / indicates a marginally significant change in 2012–13 when compared with the first 
year of data reported 
• — indicates there was no significant change in 2012–13 when compared with the first 
year of data reported 
• and § indicates a noteworthy change during the decade. 
2.9 Extrapolated national estimates 
Extrapolations can be used to estimate the number of occurrences of a selected event at  
GP–patient encounters in Australia at a single time point, or to estimate the total national 
effect of a measured change. 
Where the results demonstrate a significant change over time, the estimated national change 
across total GP Medicare services from 2003–04 to 2012–13 can be calculated using the 
method detailed below. Note that extrapolations are always based on rate per 100 encounters 
rather than rate per 100 problems, because there is no independent measure of the number of 
problems managed in Australian general practice. In contrast, the number of national 
encounters can be drawn from Medicare claims data.  
Examples of extrapolated national change are given in each chapter in the report from 
Chapter 5 to Chapter 12 inclusive. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2003–04 by 100, and then 
multiply by the total number of general practitioner service items claimed through 
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Medicare in 2003–04 (rounded to the nearest 100,000). As shown in Table 2.1, this was 
96.3 million. This provides the estimated national number of events in 2003–04 
• repeat the process using data from 2012–13. 
The difference between the two estimates gives the estimated national change in the 
frequency of that event between 2003–04 and 2012–13. Estimated national number of events 
is rounded to the nearest 100,000 if more than one million and to the nearest 10,000 if below 
one million. It is possible to use this method to calculate the national effect of any significant 
change in a single result over any two time points.  
Change is expressed as the estimated increase or decrease over the study period, in the 
number of general practice contacts for that event (for example, an increase or decrease in the 
number of GP management contacts with problem X); or an increase or decrease in the 
number of times a particular management action (for example, a selected generic 
medication) was prescribed in Australia in 2012–13, when compared with (usually) 2003–04. 
Extrapolations can also be made using data from a single time point to estimate the number 
of occasions that an event occurs in general practice encounters nationally in a specific year. 
When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and multiply by the 
total number of general practitioner service items claimed through Medicare that year 
(rounded to nearest 100,000) to give the estimated national number of events in that year. 
Table 2.1 provides the total (rounded) number of general practice professional service items 
claimed from Medicare in each financial year from 2003–04 to 2012–13.  
Table 2.1: Rounded number of general practice professional services claimed from Medicare 
Australia each financial year, 2003–04 to 2012–13 (million) 
 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13(a) 
Rounded number of 
MBS GP items of 
service claimed 
96.3 98.2 101.1 103.4 109.5 113.0 116.6 119.2 123.9 126.8 
(a) Medicare data for the 2012–13 year included data from the April 2012 to March 2013 quarters because the 2012–13 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare statistics5,7 
Example 1: Change in the number of GP referrals to allied health services 
nationally (with 95% confidence intervals) 
There was a significant increase in the number of referrals to allied health services at 
encounter, from 2.6 (95% CI: 2.4–2.8) per 100 encounters in 2003–04 to 4.7 (95% CI: 4.4–5.0) 
per 100 in 2012–13 (see Table 5.1). The calculation used to extrapolate the effect of this change 
across Australia is:  
In 2003–04 (2.6/100) x 96.3 million = 2.50 million such referrals nationally  
• Lower confidence interval: 2.4/100 x 96.3 million = possibly as few as 2.31 million 
• Upper confidence interval: 2.8/100 x 96.3 million = possibly as many as 2.70 million 
In 2012–13, (4.7/100) x 126.8 million = 5.96 million such referrals nationally  
• Lower confidence interval: 4.4/100 x 126.8 million = possibly as few as 5.58 million 
• Upper confidence interval: 5.0/100 x 126.8 million = possibly as many as 6.34 million 
This suggests there were 3.46 million (5.96 million minus 2.50 million) more GP referrals to 
allied health services made at GP–patient encounters in Australia in 2012–13 than in 2003–04. 
This is our best estimate of the change, but we are 95% confident that the true result is 
between 3.27 and 3.64 million additional such referrals in 2012–13. 
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This is the result of the compound effect of the increase in the number of referrals to allied 
health services being given by GPs at encounters plus the increased number of visits over the 
decade across Australia. 
Example 2: Change in the number of GP–patient encounters at which upper 
respiratory tract infection was managed nationally (with 95% confidence 
intervals)  
The management rate of upper respiratory tract infection (URTI) did not change between 
2003–04 (5.5 per 100 encounters, 95% CI: 5.1–5.8) and 2012–13 (5.8 per 100, 95% CI: 5.3–6.3).  
• For 2003–04 our best estimate for the total national encounters involving management of 
URTI is: 5.30 million [(5.5/100) x 96.3 million], but we are 95% confident that the true 
number lies between 4.91million [(5.1/100) x 96.9 million] and 5.59 million [(5.8/100) x 
96.9 million]. 
• For 2012–13 our best estimate for the total national encounters involving URTI is: 7.35 
million times [(5.8/100) x 126.8 million], but we are 95% confident that the true number 
lies between 6.72 million [(5.3/100) x 126.8 million] and 7.99 million [(6.3/100) x 126.8 
million]. 
Therefore we estimate that even though GP management rate of URTI did not change, 
because of the increased number of attendances nationally in 2012–13 URTI was managed at 
2.05 (95% CI: 1.81 million–2.4 million more GP–patient encounters than it was in 2003–04. 
Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. 
They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the 
extrapolations are made to GP Medicare items claimed, not to the total number of GP–
patient encounters per year – an additional 5% of BEACH encounters annually include 
encounters paid by sources other than Medicare, such as DVA, state governments, 
workers compensation insurance, and employers 
• an underestimate of activities of relatively low frequency with a skewed distribution 
across individual GPs.  
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than one million and to 
the nearest 10,000 if below one million. However, the rounding has been applied to all years, 
so the effect on measures of change will be very small. Therefore, the extrapolation still 
provides an indication of the size of the effect of measured change nationally. 
Extrapolations are based on the unit of the encounter because the number of national 
encounters is quantifiable using Medicare claims data. However, the reader should be aware 
that where an event can occur more than once per encounter (e.g. GPs can record up to two 
referrals per encounter), the extrapolation represents the number of occurrences of that event 
nationally (e.g. number of referrals nationally), rather than the number of encounters 
nationally where at least one event (e.g. referral) occurred. 
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2.10 Changes to data elements and reporting 
methods 
Some changes in data elements and reporting methods have occurred since the BEACH 
study began in April 1998. 
Two changes were made to the BEACH form from 2005–06 onwards to capture practice 
nurse activity associated with the GP–patient consultations. From 2005–06 onwards: 
• GPs could record multiple (up to three) Medicare item numbers 
• in the ‘other treatments’ section, for each problem managed, the GP was asked to tick the 
practice nurse box if the treatment recorded was provided by the practice nurse rather 
than by the GP. If the box was not ticked, the research team assumed that the GP 
provided the recorded treatment. 
These changes have implications for the reporting of Medicare/DVA-claimable encounters 
(Chapter 5), other treatments (Chapter 10) and practice nurse activity (Chapter 10). 
Medicare/DVA-claimable encounters 
For the first 7 years of the BEACH program (1998–99 to 2004–05), where a Medicare item 
number was claimable for the encounter, the GP was instructed to record only one item 
number. Where multiple item numbers (for example, an item for ‘standard surgery 
consultation’ and a procedural item number) were claimable for an encounter, the GP was 
instructed to record the lower of these (usually an A1 item number). For reporting purposes 
Medicare-claimable encounters were broken down according to the item number recorded 
by the GP as claimable (either through Medicare or through DVA) for the encounter. 
In this report, the Medicare/DVA claimable encounters count only one item number per 
Medicare/DVA-claimable encounter for comparability with previous years (see Chapter 5). 
Practice nurse Medicare-claimable encounters are not reported in Chapter 5. 
The selection of one item number was done on a priority basis: consultation item numbers 
override incentive item numbers, which override procedural item numbers, which override 
other Medicare item numbers. 
Practice nurse activity 
The research team began to capture practice nurse activity (in 2005–06) due to the 
introduction of four new MBS item numbers in November 2004, which covered some 
selected activities done by a practice nurse on behalf of a medical practitioner.22 
The primary aim of BEACH is to describe general practice activity. Before 2005–06, ‘general 
practice activity’ was described in terms of GP–patient encounters. However, the 
introduction of the practice nurse item numbers meant that, if we had no record of practice 
nurse activity associated with the GP–patient encounter, the content of the consultation was 
not fully described. 
Over the years, new PN item numbers were added to the MBS and some items were 
broadened to include work done by Aboriginal health workers (AHWs). In past years we 
have reported the results referring to PNs alone. However, in 2012–13 a few GPs indicated 
(of their own accord) that the recorded action was done by an AHW rather than a PN. This 
information is now included, and refers to work undertaken at encounters by PNs and 
AHWs in conjunction with the GPs, though the vast majority will have been done by PNs. 
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There is a limitation to this approach. Few GPs specifically indicated that the work was done 
by an AHW. Others may have thought that because the question referred specifically to PNs, 
recording of work done by AHWs was not specifically requested. These results therefore 
have the potential to be an underestimate of the work undertaken at GP–patient encounters 
by PNs and AHWs. 
Chapter 10 provides a breakdown of the PN/AHW Medicare items claimed, the morbidity 
managed with the assistance of the PN/AHW, and the other treatments given by the 
PN/AHW as recorded by the GP participants from 2005–06 to 2012–13. 
These results do not include activities done by the PN or AHW that were performed 
independently of the recorded encounter. 
Other treatments 
In Chapter 10 ‘Other treatments’, all recorded clinical and procedural treatments are 
included, irrespective of whether they were provided by the GP or by the PN or AHW. The 
exception is Section 10.3, where those activities reported by the GP to have been done by a 
PN or AHW are analysed separately. 
2.11 Classification of data 
The following data elements are classified according to the International Classification of 
Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors 
(Wonca):23 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in 
primary care. It is accepted by the World Health Organization in the WHO Family of 
International Classifications,24 and is the declared national standard in Australia for 
reporting of health data from general practice and patient self-reported health information.25  
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic 
code) and seven components on the other (numeric codes) (Figure 2.2). Chapters are based 
on body systems, with additional chapters for psychological and social problems. 
Component 1 includes symptoms and complaints. Component 7 covers diagnoses – it can 
also be expanded to provide data about infections, injuries, neoplasms, congenital anomalies 
and ‘other’ diagnoses.  
Component 2 (diagnostic, screening and prevention) is often applied in describing the 
problem managed (for example, check-up, immunisation). Components 3 to 6 cover other 
processes of care, including referrals, other (non-pharmacological) treatments and orders for 
pathology and imaging. The components are standard and independent throughout all 
chapters. The updated component groupings of ICPC-2 codes, released by the Wonca 
International Classification Committee in 200426 have been used in this report. 
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The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have 
been selected for inclusion on the basis of their relative frequency in primary care settings, or 
because of their relative importance in describing the health of the community. ICPC has 
about 1,370 rubrics and these are sufficient for meaningful analyses. However, reliability of 
data entry, using ICPC-2 alone, requires a thorough knowledge of the classification, for 
correct classification of a concept to be ensured. 
In 1995, recognising a need for a coding and classification system for general practice 
electronic health records, the Family Medicine Research Centre (FMRC) (then Unit) 
developed an extended clinical terminology classified according to the ICPC, now called 
ICPC-2 PLUS.27 This is an interface terminology, developed from all the terms used by GPs 
in studies such as The Australian Morbidity and Treatment Survey 1990–91 (113,468 
encounters),28 A comparison of country and metropolitan general practice 1990–91 
(51,277 encounters),29 the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool that 
was available to GPs) (approximately 400,000 encounters), and BEACH 1998–2013 (about 
1.5 million encounters). Together, these make up about 2.5 to 3 million encounter records, 
involving about 4 million free text descriptions of problems managed and a further 4 million 
for patient reasons for encounter. These terms are classified according to ICPC-2 to ensure 
data can be compared internationally. Readers interested in seeing how coding works can 
download the ICPC-2 PLUS Demonstrator at <sydney.edu.au/medicine/fmrc/icpc-2-
plus/demonstrator>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students), code the data in specific terms using ICPC-2 PLUS. This ensures 
high coder reliability and automatic classification of the concept, and allows us to ‘ungroup’ 
such ICPC-2 rubrics as ‘other diseases of the circulatory system’ and select a specific disease 
from the terms within it. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
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Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute 
otitis media/myringitis is ICPC-2 code H71). However, there are some exceptions where 
data are grouped either above the ICPC-2 level or across the ICPC-2 level. These grouped 
morbidity, pathology and imaging codes are defined in Appendix 4 available at:  
<purl.library.usyd.edu.au/sup/9781743323793>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in 
recording the management of hypertension, they may simply record the problem as 
‘hypertension’. In ICPC-2, ‘hypertension, unspecified’ is classified as ‘uncomplicated 
hypertension’ (code K86). There is another code for ‘complicated hypertension’ (K87). In 
some cases, the GP may simply have failed to specify that the patient had hypertension with 
complications. The research team therefore feels that for national data reporting, it is more 
reliable to group the codes K86 and K87 and label this ‘Hypertension*’ – the asterisk 
indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) 
are included. Appendix 4, Table A4.1 lists the codes included in these groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. 
For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, 
such as L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of 
shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the 
more specific osteoarthritis ICPC-2 PLUS terms classified within all the appropriate ICPC-2 
codes are grouped. This group is labelled ‘Osteoarthritis*’ – the asterisk again indicating 
multiple codes, but in this case they are PLUS codes rather than ICPC-2 codes. Appendix 4, 
Table A4.1 lists the codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life.  
To identify chronic conditions, a chronic condition list30 classified according to ICPC-2 was 
applied to the BEACH data set. In general reporting, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may have been grouped together 
when reporting (for example, diabetes – all*). When reporting chronic morbidity, only 
problems regarded as chronic have been included in the analysis. Where the group used for 
the chronic analysis differs from that used in other analyses in this report, they are marked 
with a double asterisk. Codes included in the chronic groups are provided in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 
classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes is 
classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the 
lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal 
system).  
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In Australia, the MBS classifies pathology and imaging tests in groups that are relatively well 
recognised. We therefore regrouped all pathology and imaging ICPC-2 PLUS codes into MBS 
standard groups. This allows comparison of data between data sources. The groups are 
marked with an asterisk, and inclusions are provided in Appendix 4, Tables A4.8 and A4.9. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter 
purchase are coded and classified according to an in-house classification, the Coding Atlas 
for Pharmaceutical Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic name/composition, and brand name. 
The generic name of a medication is its non-proprietary name, which describes the 
pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
When strength and regimen are combined with the CAPS code, we can derive the prescribed 
daily dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)31 classification, which is the 
Australian standard for classifying medications at the generic level.25 The ATC has a 
hierarchical structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
An extension code identifies the brand of the product (where the GP has recorded brand). 
Reporting pharmaceutical data 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme 
or the ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately 
allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic drug type may initially enter the classification at any level (1 to 5), 
not necessarily always at the generic level. Reclassification to more specific ATC levels may 
occur later. Therefore, the ATC uses a top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a 
higher ATC level will not be identifiable in that data period, and may result in 
under-enumeration of that drug during earlier data collection periods. Therefore in 
measuring changes in medications over time, we have chosen to report at Level 2 of the ATC 
(which is more stable over time than Level 3), except when reporting at the generic level, 
when we use CAPS.  
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2.12 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff who enter key 
words or word fragments, and select the term or label that matches the recorded 
information, from a pick list. On selection of the term, it was then automatically coded and 
classified. A quality assurance program to ensure reliability of data entry includes ongoing 
development of computer-aided error checks (‘locks’) at the data entry stage, and a physical 
check of samples of data entered against those on the original recording form. We also 
conduct logical data checks through SAS on a regular basis. 
2.13 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published 
elsewhere.32 This section touches on some aspects of reliability and validity of active data 
collection from general practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific 
stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary 
coding and data entry. At each stage the data can be invalidated by the application of 
inappropriate methods. The methods adopted to ensure maximum reliability of coding and 
data entry have been described above. The statistical techniques adopted to ensure valid 
analysis and reporting of recorded data were described in Section 2.7. Previous work has 
demonstrated the extent to which a random sample of GPs recording information about a 
cluster of patients represents all GPs and all patients attending GPs,33 the degree to which GP-
reported patient RFEs and problems managed accurately reflect those recalled by the patient,34 
and reliability of secondary coding of RFEs35 and problems managed.28 The validity of ICPC as 
a tool with which to classify the data has also been investigated in earlier work.36 
However, the question of the extent to which the GP-recorded data are a reliable and valid 
reflection of the content of the encounter must also be considered. In many primary care 
consultations, a clear pathophysiological diagnosis is not reached. Bentsen37 and Barsky38 
suggest that a firm and clear diagnosis is not apparent in about half of GPs’ consultations, 
and others suggest the proportion may be even greater.39 As a result, it is often necessary for 
a practitioner to record a problem in terms of symptoms, signs, patient concerns, or the 
service that is requested, such as immunisation. For this reason, this report refers to patient 
‘problems’ rather than ‘diagnoses’. 
A number of studies have demonstrated wide variance in the way a GP perceives the patient’s 
RFE and the manner in which the GP describes the problem under management. Bentsen 
demonstrated that practitioners differ in the way they labelled problems, and suggested that 
clinical experience may be an important influence on the identification of problems within the 
consultation.37 Two other factors that might affect GPs’ descriptions of patient RFEs have 
been identified: although individuals may select the same stimuli, some label each stimulus 
separately, whereas others cluster them under one label; and individuals differ in the 
number of stimuli they select (selective perception).40 
17
   
The extent to which therapeutic decisions may influence the diagnostic label selected has also 
been discussed. Howie41 and Anderson42 argue that, while it is assumed that the diagnostic 
process used in general practice is one of symptom  diagnosis  management, the 
therapeutic method may well be selected on the basis of the symptom, and the diagnostic label 
chosen last. They suggest that the selection of the diagnostic label is therefore influenced by the 
management decision already made. 
Crombie identified ‘enormous variability in the rates at which doctors perceive and record 
illnesses’. He was unable to account statistically for this variation by the effect of geography, 
age, sex or class differences in the practice populations.43 Differences in the way male and 
female GPs label problems also appear to be independent of such influences.44 
These problems are inherent in the nature of general practice. Knottnerus argues that the GP 
is confronted with a fundamentally different pattern of problems from the medical specialist, 
and often has to draw up general diagnostic hypotheses related to probability, severity and 
consequences.45 Anderson suggests that morbidity statistics from family practice should 
therefore be seen as ‘a reflection of the physician’s diagnostic opinions about the problems that 
patients bring to them rather than an unarguable statement of the problems managed’.42  
While these findings regarding limitations in the reliability and validity of practitioner–
recorded morbidity should be kept in mind, they apply equally to data drawn from health 
records, whether paper or electronic, as they do to active data collection methods.46,47  
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3 The samples 
For annual response rates and measures of representativeness of individual annual GP 
samples, please see the annual report for each year in question (available at: 
<sydney.edu.au/medicine/fmrc/publications/books/GP-series>). 
More detailed analyses of the samples in 2012–13 can be found in Chapter 3 in General 
practice activity in Australia 2012–13.1  
Table 3.1 shows the number of encounter records contained in each year of the BEACH 
program since April 2003, and the size of the database for those 10 years for each variable 
(weighted), upon which all comparisons over time described in this report are based. 
Table 3.1: Annual summary of data sets, 2003–04 to 2012–13 (final weighted data) 
Variable 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
Total 10 
years 
General 
practitioners 1,000 953 1,017 930 953 1,011 988 958 984 978 9,772 
Encounters 98,877 94,386 101,993 91,805 95,898 96,688 101,349 95,839 99,030 98,564 974,429 
Reasons for 
encounter 148,521 141,215 153,309 138,434 146,696 151,282 157,071 149,005 153,218 152,278 1,491,029 
Problems 
managed 144,674 137,330 149,088 136,333 145,078 149,462 155,373 146,141 152,286 152,517 1,468,282 
Medications 103,210 95,816 106,493 93,193 98,439 102,737 108,001 100,817 106,007 101,065 1,015,778 
Other 
treatments 50,775 51,632 44,504 41,011 49,130 49,048 53,243 50,235 53,395 53,163 496,136 
Referrals & 
admissions 11,507 10,890 12,242 11,230 12,017 13,251 13,481 13,526 14,382 14,561 127,087 
Pathology 34,831 34,652 39,358 38,963 41,375 44,066 45,594 43,313 46,544 46,398 415,094 
Imaging 8,121 7,840 9,003 8,229 9,143 9,469 9,877 9,370 9,978 10,163 91,193 
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4 The participating GPs 
4.1 Characteristics of the participating GPs 
In BEACH, each GP participant completes a profile questionnaire about themselves and the 
major practice at which they are employed (see Appendix 2). Over the 10 years, the questions 
have occasionally been altered to improve the quality and clarity of the data collected, or to 
investigate topics not previously surveyed as they became relevant. Therefore, for some 
characteristics we have data over the full 10-year period, and for some, we have data over 
shorter periods. 
In this chapter, statistical significance of change is tested with the Χ2 (chi-square) statistic, 
with a decision level of α < 0.05. More detailed analyses of the participating GPs in 2012–13 
can be found in Chapter 4 in General practice activity in Australia 2012–13.1  
Over the period 2003–04 to 2012–13 some trends emerged in the characteristics of GP 
BEACH participants (Table 4.1). The most noticeable changes over the 10 years are listed 
below and some are presented in Figure 4.1. 
• The feminisation of the general practice workforce is reflected in the growing proportion 
of GP participants who are female. The proportion of female participants increased from 
32.7% in 2003–04 to 43.1% in 2012–13. This change reflects change in the sex distribution 
of all recognised GPs claiming more than 375 general practice Medicare items of service 
in the previous quarter (33.4% in 2003–0448 and 40.2% in 2012–13), as provided each year 
by DoHA, from Medicare claims data. In Table 4.1, there was a ‘spike’ in the proportion 
of female GPs among the participating sample in 2009–10. As previously reported, this 
was the result of female GPs being over-represented in the sample provided by DoHA 
when compared with the national sample frame (as may occasionally happen in the 
random sampling process).13  
• From 2003–04 to 2012–13 there was a significant change in the age distribution of 
participants, with a decrease in the proportion aged 35–44 years (from 24.9% to 17.0%), 
and an increase in the proportion aged 55 years and over (from 32.7% to 41.3%). Again, 
these changes reflect the changes in the practising GP population (as defined for 
BEACH) from Medicare claims data, in which the proportion aged 35–44 years 
decreased from 25.8%49 to 20.4%, and the proportion aged 55 years or more increased 
from 30.0%49 to 42.1%. The mean age of GP participants in 2003–04, was 50.5 years 
(median of 50 years) while in 2012–13, it was 51.5 years (median of 52 years). 
• The ageing workforce was reflected in the increasing proportion of GPs who had worked 
in general practice for 20 years or longer, from 54.6% in 2003–04 to 59.4% in 2012–13.  
• There was a significant increase in the proportion of GPs working 21–40 hours per week 
in direct patient care (from 42.4% in 2003–04 to 55.4% in 2012–13), and a significant 
decrease in the proportion working 41–60 hours (42.3% in 2003–04 to 31.2% in 2012–13),  
the dramatic drop occurring in 2009–10 (from 40.2% to 30.8%). The proportion working 
more than 60 hours per week in direct patient care also steadily decreased (from 4.9% to 
1.9%). When the last two results are combined, there was a decrease from 47.2% of 
participants working more than 40 hours per week in direct patient care in 2003–04 to 
33.1% working these hours in 2012–13. There was a significant decrease in the mean 
number of hours spent in direct patient care from 40.5 hours in 2003–04 to 37.6 hours in 
2012–13. This has implications for workforce planning. 
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• There was a significant decrease over the decade in the proportion of Australian GPs 
who had gained their primary medical degree in Australia, from 73.6% in 2003–04 to 
66.2% in 2012–13. There were also significant changes in the geographic distribution of 
country of graduation for those trained overseas. 
• The proportion of GP participants holding Fellowship of the RACGP significantly 
increased, from 33.5% in 2003–04 to 55.7% in 2012–13. Since 1995, Fellowship of the 
RACGP has been mandatory for new clinicians entering general practice, so this change 
reflects the inclusion of new GPs into practice who hold FRACGP. 
4.2 Characteristics of participants’ major practice 
From 2003–04 to 2012–13, some trends emerged in the characteristics of the GP participants’ 
major practices (Table 4.2). The most noticeable changes over the 10 years are listed below.  
• The proportion of participants in solo practice, and the proportion in smaller practices of 
2–4 GPs significantly decreased. There was an associated significant increase in the 
proportion working in practices of 10 or more individual GPs (from 12.9% in 2003–04 to 
28.3%). Data were not available for 2007–08 and 2008–09, as the question was altered to 
capture full-time equivalent GPs at the practice instead of number of individuals. 
However from 2009–10, both data elements were captured. 
• There was a significant reduction in the proportion of GPs working in practices that 
provide their own after-hours services (from 43.6% to 30.7%), and in the proportion at 
practices providing these services in cooperation with other practices (from 20.0% to 
14.9%). However, the proportion of GPs working in practices using a deputising service 
for after-hours care provision increased significantly, from 43.8% in 2003–04 to 53.3% in 
2012–13. Multiple responses were allowed to this question. 
• The proportion of GPs with a computer available at their major practice increased 
significantly from 95.1% in 2003–04 to 97.8% in 2012–13. Actual use of the computer has 
only been collected since 2004–05. From that time, the proportion of GPs indicating that 
they use a computer to some extent in their clinical activity (89.0%) significantly 
increased to 96.2% in 2012–13.  
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(a) Multiple responses across these options were allowed. 
Note:  FRACGP – Fellows of the Royal Australian College of General Practitioners; own A.H. – the practice provides its own after-hours 
service for their patients; Co-op A.H. – the practice provides after-hours services in a cooperative arrangement with  
other practices. 
Figure 4.1: Selected characteristics of participating GPs and their practices,  
2003–04 and 2012–13 
 
Female <45 years 55+ years Solo GP 10+ GPs FRACGP OwnA.H.(a)
Co-op
A.H.(a)
Deputising
A.H.(a)
2003–04 32.7 30.7 32.7 10.6 12.9 33.5 43.6 20.0 43.8
2012–13 43.1 25.5 41.3 9.8 28.3 55.7 30.7 14.9 53.3
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5 The encounters 
This chapter includes details about the encounters in general practice from each of the most 
recent 10 years of the BEACH study from 2003–04 to 2012–13. The direction and type of 
change from 2003–04 to 2012–13 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant change (increase or decrease) in 2012–13 
compared with 2003–04; / indicates a marginally significant change in 2012–13 
compared with 2003–04; — indicates there was no significant change in 2012–13 compared 
with 2003–04; and § indicates a noteworthy change during the decade. 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the measured event between 2003–04 and 2012–13. Some examples of 
extrapolated change are provided. The method used to extrapolate to national change 
estimates is described in Section 2.9. More detailed analyses of the GP–patient encounters in 
2012–13 can be found in Chapter 5 in General practice activity in Australia 2012–13.1 
5.1 Content of the encounters 
Table 5.1 provides an overview of the changes over time from data in BEACH between  
2003–04 and 2012–13. The number of patient reasons for encounter recorded by the GP 
increased significantly over the decade, from 150.2 RFEs per 100 encounters in 2003–04 to 
154.5 per 100 encounters in 2012–13. Changes in types of RFEs are reported in Chapter 6. 
The rate of problems managed increased from 146.3 per 100 encounters in 2003–04 to 154.7 
per 100 encounters in 2012–13. This represents an additional 55 million problems managed in 
general practice in 2012–13 than a decade earlier. There was also a marginal increase in the 
rate of chronic problem management, from 51.9 per 100 encounters in 2003–04 to 55.7 per 100 
in 2012–13. This represents an estimated additional 20.6 million chronic problems managed 
in general practice nationally in 2012–13 than in 2003–04. Further details about changes in the 
types of problems managed are presented in Chapter 7. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at 
encounters, it may be more informative to consider changes in management actions in terms 
of rates per 100 problems managed as described in Chapters 8 to 12, inclusive. 
There was no change in the rate of medications recorded per 100 encounters over the decade. 
Specific changes in the types of medications recorded are detailed in Chapter 9. 
There was a significant increase in the number of procedural treatments performed in 
general practice between 2003–04 and 2012–13, from 14.7 per 100 encounters to 17.4 per 
100 encounters. This increase represents an additional 7.9 million procedures performed in 
2012–13 compared with a decade earlier. More detail can be found in Chapter 10. 
Between 2003–04 and 2004–05 there was no change in the rate of clinical treatments (such as 
advice and counselling), but the rate then dropped dramatically from 39.2 per 100 encounters 
in 2004–05 to 29.2 per 100 encounters in 2005–06. It then gradually increased, and in 2012–13 
was 36.5 per 100 encounters, no different from the 2003–04 rate. This pattern was reflected in 
the fluctuation of the total of other treatments (of which clinical treatments are the major 
component). These changes are described in further detail in Chapter 10. 
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Referrals increased over the decade 2003–04 to 2012–13, from 11.6 per 100 encounters to 14.8 
per 100. This represented 7.6 million more referrals nationally in 2012–13 than a decade 
earlier. The increase was reflected in increased referrals to medical specialists and to allied 
health services and is described further in Chapter 11. 
Orders for pathology and imaging tests also increased significantly between 2003–04 and 
2012–13. These changes are reported in greater detail in Chapter 12. 
5.2 Medicare/DVA–claimable encounters 
Table 5.2 provides a summary of Medicare/DVA-claimable encounters recorded in BEACH, 
expressed as a proportion of all Medicare/DVA-claimable encounters. Between 2003–04 and 
2004–05, only one item number was recorded on the BEACH encounter form. In 2005–06 this 
increased to three items, to capture practice nurse item numbers and other additional 
information about the Medicare items used in general practice.  
To allow comparability of data over time, only one item number per Medicare/DVA-
claimable item per encounter is counted in Table 5.2. The selection of one item number per 
encounter was based on priority whereby: consultation item numbers override Practice 
Incentives Program payment item numbers, which override procedural item numbers, which 
override other Medicare item numbers. Table 5.2 includes only items claimed by GPs 
(excluding items claimed for practice nurses etc.) and shows that: 
• short surgery consultations increased significantly from 1.1% of Medicare/DVA-
claimable encounters in 2003–04 to 1.7% in 2012–13. Previous research suggests that part 
of this increase is related to increasing practice nurse involvement in GP–patient 
encounters50 
• the proportion of long surgery consultations did not change overall. However, after 
peaking at 10.5% in 2004–05, the proportion remained steady until 2007–08 then dropped 
significantly in 2008–09 and in 2012–13 represented 9.4% of Medicare/DVA-claimable 
encounters 
• the proportion of encounters claimable under chronic disease management items, GP 
mental healthcare items, health assessments and incentive payments all significantly 
increased. 
In May 2010 changes were made to the Medicare Benefits Schedule (MBS) that combined the 
existing Medicare items for home visits, consultations at hospitals and consultations at other 
institutions.51 Unfortunately, this change no longer allows a discrete measure of GP home 
visit frequency through MBS. To allow the comparison of changes over time we have applied 
this change to all previous years in the decade, and now report a single line for ‘Home and 
institution visits’. There was a significant decrease in the proportion of home and institution 
visits (together) from 1.8% to 1.0% between 2003–04 and 2012–13. This equates to 500,000 
fewer home and institutional visits carried out by GPs in 2012–13 than in 2003–04.  
5.3 Consultation length 
In a subsample of consultations, start and finish times were recorded. There was no 
significant change in the mean length of consultation between 2003–04 and 2012–13 for A1 
Medicare/DVA-claimable encounters, nor for all Medicare/DVA-claimable encounters 
(Table 5.3).
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6 The patients 
This chapter includes data about the patients who participated in the BEACH study, 
including their characteristics and their reasons for encounter (RFEs), from each of the most 
recent 10 years of the BEACH study from 2003–04 to 2012–13: / indicates a statistically 
significant change (increase or decrease) in 2012–13 compared with 2003–04; / indicates a 
marginally significant change in 2012–13 compared with 2003–04; — indicates there was no 
significant change in 2012–13 compared with 2003–04; and § indicates a noteworthy change 
during the decade. 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the measured event between 2003–04 and 2012–13. In 2012–13, there 
were 30.5 million more encounters claimed through Medicare than there were in 2003–04 
(126.8 million versus 96.3 million). It should be noted that because of this increase, a lower 
rate of events per 100 encounters could result in an increase in the estimated total number of 
events nationally. Some examples of extrapolated change are provided. The method used to 
extrapolate to national change estimates is described in Section 2.9. 
6.1 Age and sex of patients at encounter 
Figure 6.1 and Table 6.1 show the age and sex distribution of patients at BEACH encounters 
from 2003–04 to 2012–13. Over this period there was no significant change in the proportions 
of encounters with male and female patients. The proportion of encounters with patients 
aged less than 45 years decreased from 46.0% to 41.9%, while over the same period the 
proportion with patients aged 45 years and over increased from 54.0% to 58.1%. Specifically, 
the largest growth occurred in encounters with patients aged 65–74 years and the largest 
decrease was in encounters with patients aged 25–44 years of age. When extrapolated, even 
with the increased number of encounters nationally, the number of encounters with patients 
aged less than 45 years only increased by about 8.8 million over the decade, while the 
number of encounters with patients aged 45 years and over increased by about 21.7 million 
nationally. The relationship between patient age, general practice attendance rates and the 
age distribution of the Australian population was investigated in Chapter 4 of General practice 
in Australia, health priorities and policies 1998 to 2008.52 
6.2 Other patient characteristics 
Over the decade there was a significant decrease in the proportion of encounters that were 
with patients new to the practice (from 9.3% in 2003–04 to 7.2% in 2012–13). The proportion 
of encounters with patients holding a Commonwealth concession card was relatively stable 
across the decade. Between 2003–04 and 2012–13, the proportion of encounters with patients 
holding a Repatriation Health Card decreased by one-third (3.9% to 2.3%). There was no 
significant change in the proportion of encounters that were with patients from a non-
English-speaking background or with Indigenous patients (Table 6.1). 
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Note: Missing data removed.  
Figure 6.1: Age and sex distribution of patients at encounters, 2003–04 and 2012–13 (95% 
confidence interval) 
6.3 Patient reasons for encounter 
Reasons for encounter (RFEs) are those concerns and expectations patients bring to the GP. 
RFEs reflect the patient’s demand for care, and can provide an indication of service use 
patterns that may benefit from intervention at a population level. 
Participating GPs were asked to record at least one, and up to three, patient RFEs in words as 
close as possible to those used by the patient, before the diagnostic or management process 
had begun. RFEs can be expressed in terms of one or more symptoms (for example, ‘itchy 
eyes’, ‘chest pain’), in diagnostic terms (for example, ‘about my diabetes’, ‘for my 
hypertension’), a request for a service (‘I need more scripts’, ‘I want a referral’), an expressed 
fear of disease, or a need for a check-up. 
Patient RFEs can have a one-to-one, one-to-many, many-to-one or many-to-many 
relationship to problems managed. That is, the patient may describe a single RFE that relates 
to a single problem managed at the encounter, a single RFE that relates to multiple problems, 
multiple symptoms that relate to a single problem managed at the encounter, or multiple 
RFEs that relate to multiple problems managed at the encounter. GPs may also manage a 
problem that was unrelated to the patient’s RFE (for example, a patient presents about their 
diabetes but while they are there the GP also provides an immunisation and performs a  
Pap smear). 
Male Female <1 year 1–4 years 
5–14 
years 
15–24 
years 
25–44 
years 
45–64 
years 
65–74 
years 
75+
years
2003–04 42.6 57.4 1.8 4.6 5.9 9.6 24.1 27.2 12.4 14.4
2012–03 43.3 56.7 1.8 4.5 5.2 8.2 22.2 27.6 14.2 16.3
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Number of reasons for encounter 
Table 6.2 shows that between 2003–04 and 2012–13 there was a significant decrease in the 
proportion of encounters involving a single RFE, from 61.0% to 58.0% in 2012–13, and an 
increase in the proportion with two or three RFEs over the decade. The proportion of 
encounters with two RFEs increased from 27.7% in 2003–04 to 29.4% of all encounters in 
2012–13. The proportion of encounters with three RFEs increased from 11.3% in 2003–04 to 
12.5% in 2012–13. Extrapolation of the effect of this change suggests there were about 
15.7 million more encounters nationally where two or three RFEs were reported in 2012–13 
than in 2003–04. 
This increase in multiple RFEs encounters resulted in a significant increase in the overall rate 
of RFEs, from 150.2 per 100 encounters in 2003–04 to 154.5 per 100 encounters in 2012–13 
(Tables 6.3 and 6.4). This increase, when extrapolated, equates to about 51.3 million more 
RFEs nationally in 2012–13 than in 2003–04. 
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3. 
Symptoms and diagnoses 
• RFEs expressed in terms of a symptom or complaint (for example, ‘tired’, ‘feeling 
anxious’) were the most frequent in all years. However, their presentation rate 
significantly decreased, from 69.1 per 100 encounters in 2003–04 to 64.3 per 100 
encounters in 2012–13. 
• With one exception, the rate of RFEs relating to specific diagnoses (including infections, 
injuries, neoplasms, congenital anomalies, and other diagnoses) did not significantly 
change across the decade. The exception was a significant increase in the rate of other 
diagnoses RFEs, from 14.7 to 16.8 per 100 encounters. 
Processes of care 
• Patient requests for diagnostic and preventive procedures (such as immunisation) 
significantly increased from 24.0 per 100 encounters in 2003–04 to 27.0 in 2009–10, then 
decreased to 24.6 per 100 encounters in 2012–13, a rate similar to the 2003–04 rate. 
• Patient requests for medications, treatments and therapeutics (such as repeat 
prescriptions) did not significantly change across the decade. 
• Presentations for test results increased by about 50%, from 6.0 to 9.1 per 100 encounters. 
When extrapolated, we estimate 5.8 million more encounters nationally with an RFE of 
this type in 2012–13 than a decade earlier. 
• The rate of requests for an administrative procedure (such as a sickness certificate) 
increased by about 80%, from 1.8 to 3.2 per 100 encounters. This change equates to an 
estimated national increase of approximately 2.3 million more requests for an 
administrative procedure nationally in 2012–13 than in 2003–04. 
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Reasons for encounter by ICPC-2 chapter 
Table 6.4 shows that between 2003–04 and 2012–13,: 
• the rate at which patients described RFEs of a general and unspecified nature increased 
by about 20%. When extrapolated to national estimates, this equates to about 21.4 million 
more general and unspecified RFEs in 2012–13 than in 2003–04. 
• RFEs related to psychological problems increased by about 25%. This equates to 
approximately 4.8 million more RFEs related to psychological problems nationally in 
2012–13 than in 2003–04. The increased role of GPs in the management of mental health 
was the focus of Chapter 14 in the book General practice activity in Australia, health 
priorities and policies 1998 to 200852 
• the rate at which patients presented RFEs relating to the blood system increased by 
about 30%. This is probably linked to increased INR testing (as discussed in Chapter 10) 
• RFEs related to the male genital system and to social issues both increased marginally. 
Table 6.4 also shows that between 2003–04 and 2012–13, there were significant decreases in: 
• the rate of RFEs relating to digestive and circulatory problems but mainly over the last 
year. It will be interesting to see whether these decreases persist in the future 
• the rate of RFE relating to the female genital system and neurological problems, both of 
which decreased by about 15% 
• the rate of eye problem RFEs, decreasing by about one-quarter over the decade. 
Most frequent patient reasons for encounter 
Table 6.5 shows that between 2003–04 and 2012–13: 
• requests for a check-up (all types) significantly increased from 13.4 per 100 encounters in 
2004–05 to 15.2 in 2008–09, then decreased to 13.1 per 100 encounters in 2012–13, a rate 
not significantly different from either the 2003–04 or 2004–05 rate 
• the rate of presentations for immunisation/vaccination did not significantly change, 
except there was a significant spike in 2009–10 coinciding with the swine flu pandemic. 
Over the decade there were significant increases in: 
• requests for test results (by about 50%) and requests for blood tests (by nearly 40%) 
• patient requests for administrative procedures (such as doctor’s certificates) (by about 
80%) and requests for a referral (by about 90%) 
• patients presenting for depression and anxiety (by about 30% and 40% respectively). The 
increase in both these common psychological conditions probably explains the increase 
in the psychological chapter reported above, and may have resulted from the 
introduction of both the Better Outcomes and Better Access general practice mental 
health care initiatives53 
• patients presenting for diabetes (by about 50%), equating to an extrapolated estimated 
900,000 more encounters for diabetes in 2013–14 than a decade earlier 
• patients presenting with shoulder symptoms or complaints (by about 30%). 
From 2003–04 to 2012–13: 
• there were significant decreases in the RFE rates for throat complaints (by about 25%), 
abdominal pain (20%), headache (about 25%), chest pain (not otherwise specified) (about 
30%),vomiting (40%) and oral contraception (about 30%) 
• there were marginally significant decreases in presentations for ear pain/earache, 
diarrhoea, vertigo/dizziness, and neck complaint.
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7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health 
problem presented by the patient, family or community, and can be described in terms of a 
disease, symptom or complaint, social problem, or ill-defined condition. GPs were instructed 
to record each problem at the most specific level possible from the information available. As 
such, the problem managed may be limited to the level of a presenting symptom rather than 
a diagnosis. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of 
one problem was compulsory. The status of each problem to the patient – new (first 
presentation to a medical practitioner) or old (follow-up of previously managed problem) – 
was also indicated. The concept of a principal diagnosis, which is often used in hospital 
statistics, is not adopted in studies of general practice where multiple problem management 
is the norm rather than the exception. Further, the range of problems managed at the 
encounter often crosses multiple body systems and may include undiagnosed symptoms, 
psychosocial problems, chronic disease or preventive health, which makes the designation of 
a principal diagnosis difficult. Thus the order in which the problems were recorded by the 
GP is not significant. 
This chapter includes data about the problems managed in general practice from each of the 
most recent 10 years of the BEACH study from 2003–04 to 2012–13. The direction and type of 
change from 2003–04 to 2012–13 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant change (increase or decrease) in 2012–13 
compared with 2003–04; / indicates a marginally significant change in 2012–13 
compared with 2003–04; — indicates there was no significant change in 2012–13 compared 
with 2003–04; and § indicates a noteworthy change during the decade. 
Significant changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the measured event between 2003–04 and 2012–13. Examples 
of extrapolated change are given. The method used to extrapolate to national change 
estimates is described in Section 2.9. The number of GP–patient encounters claimed through 
the MBS nationally increased by 30.5 million (31.7%) between 2003–04 (96.3 million 
encounters) and 2012–13 (126.8 million encounters). As a result, a decreased rate of a 
particular ‘measured event’ per 100 encounters may occasionally yield a national increased 
absolute number of those events. 
Detailed analyses of ‘problems managed’ by participating GPs in the 2012–13 BEACH year 
can be found in the companion report General practice activity in Australia 2012–13.1  
There are two ways to describe the relative frequency of problems managed: as a percentage 
of all problems managed in the study, or as a rate of problems managed per 100 encounters. 
Where groups of problems are reported (for example, cardiovascular problems), it must be 
remembered that more than one of that type of problem (such as hypertension and heart 
failure) may have been managed at a single encounter.  
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In considering these results, the reader must be mindful that a rate per 100 encounters for a 
single ungrouped problem, for example ‘asthma, 2.2 per 100 encounters,’ can be regarded as 
equivalent to ‘asthma is managed at 2.2% of encounters’, and can be extrapolated (with the 
methods described in Section 2.9) to accurately estimate the number of national encounters 
involving management of the selected problem. This is not the case for grouped concepts 
(ICPC-2 chapters and those marked with asterisks in the tables) for which extrapolations 
represent the number of problem contacts involving the management of any of the problems 
within the group at general practice encounters nationally. In these cases an extrapolated 
result may be an overestimate of the number of encounters involving management of these 
problems. This is because multiple problems (within the selected group) can be recorded 
within a single encounter. To estimate more precisely the number of encounters nationally 
that involve management of the grouped concept, the extrapolation would have to be based 
on the proportion of encounters involving at least one of the concepts within the group.  
Figure 7.1 shows statistically significant increases in the rate at which all problems and 
chronic problems were managed per 100 encounters over the 10 years to 2012–13. The figure 
indicates that most of the increase in the rate of all problems managed occurred between 
2003–04 and 2008–09, and then remained stable for the rest of the decade. This pattern is 
reflected in the rate of chronic problems managed. No significant changes were evident in 
the rate at which new problems were managed (Table 7.5). 
 
 
 
 
Note: Data are drawn from Tables 7.2 and 7.6. 
Figure 7.1: Changes in the management rates of all problems and chronic problems,  
2003–04 to 2012–13 (95% confidence intervals) 
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7.1 Number of problems managed 
GPs are asked to record information about the management of up to four problems at each 
encounter. Table 7.1 shows the number of problems managed at encounters over the decade. 
There were increases in the proportion of encounters at which two, three and four problems 
were managed, and a decrease in encounters where only one problem was managed. When 
extrapolated to all GP–patient encounters in Australia, this suggests there were about 
9.7 million more occasions on which two problems were managed, 4.6 million more 
occasions where three problems were managed, and 1.9 million more occasions where four 
problems were managed by GPs in Australia in 2012–13 than in 2003–04. 
These results led to a significant increase in the average number of problems managed at 
encounter, from 146.3 per 100 encounters in 2003–04 to 154.7 in 2012–13 (Table 7.2). This 
suggests there were an additional 55.3 million problems managed at GP–patient encounters 
in Australia in 2012–13 than in 2003–04.  
7.2 Problems managed by ICPC-2 component 
Problems managed in general practice may also be examined using the components of the 
ICPC-2 classification to provide a better understanding of the types of problems managed 
during general practice encounters. The component structure of ICPC-2 is described in detail 
in Section 2.8. Table 7.2 shows the distribution of problems managed by ICPC-2 component.  
There were significant increases in the management rate of problems classified as ‘symptoms 
and complaints’, ‘results’ and ‘administrative’ between 2003–04 and 2012–13 (Table 7.2). 
There was also a marginal increase in the management rate of problems classified as 
‘diagnosis, diseases’. Extrapolated to the national general practice encounters, these increases 
represent about: 
• 34.9 million additional contacts with problems classified as ‘diagnosis, diseases’ in  
2012–13 than in 2003–04 
• 11.0 million more GP contact with problems described in terms of ‘symptoms and 
complaints’ in 2012–13 than in 2003–04 
• 1.4 million more contacts described as ‘test results’ in 2012–13 than in 2003–04 
• 1.2 million more contacts with problems classified as ‘administrative’ in 2012–13 than  
in 2003–04. 
The ‘diagnosis, diseases’ component can be broken down into various subtypes (also 
described in Section 2.8). Changes in problems managed between 2003–04 and 2012–13 were 
also evident in these subtypes, with the management of problems classified as ‘other 
diagnoses, diseases’ increasing. The management rate of ‘infections’ decreased. However, 
due to an overall increase in the number of encounters in Australian general practice (as 
described in the introduction to this chapter), there were actually 5.6 million more contacts 
with problems classified as infections in 2012–13 than in 2003–04. 
The management rate of problems described and classified as ‘diagnostic and preventive 
procedures’ showed changes across the decade, peaking in 2009–10. 
There was no change in the management rate of problems described and classified as 
‘medications, treatments and therapeutics’ or ‘referrals and other reasons for encounter’. 
(Table 7.2). 
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7.3 Problems managed by ICPC-2 chapter and 
individual problems managed 
Problems managed at general practice encounters classified by ICPC-2 chapter are described 
in Table 7.3 for all years from 2003–04 to 2012–13. Problems related to the respiratory system 
have consistently been the most frequent type of problem managed since 2003–04. Although 
there was no overall change in the rate of management of respiratory problems between 
2003–04 and 2012–13, changes did occur during the decade, including an increase from  
2007–08 to 2008–09, and a subsequent decrease from 2009–10 to 2010–11. It is likely that the 
peak in the management rate of respiratory problems in 2009–10 was related to concern 
regarding H1N1 influenza. A similar pattern of change is shown in the management rate of 
immunisation/vaccination problems (described in Table 7.4).  
There were significant increases in the management rate of problems classified as ‘general 
and unspecified’, ‘endocrine and metabolic’, ‘psychological’ and ‘urological’ (Table 7.3). 
When extrapolated to general practice encounters across Australia, these changes represent: 
• 10.0 million more contacts with problems classified as ‘general and unspecified’ in  
2012–13 than in 2003–04 
• 6.6 million more contacts with endocrine and metabolic problems 
• 6.2 million more contacts with psychological problems  
• 1.5 million more contacts with urological problems. 
There were significant decreases in the management rate of problems classified to the ‘eye’ 
chapter (Table 7.3). However, due to the overall increase in the number of GP–patient 
encounters claimed through the MBS (described in the introduction to this chapter), there 
was an increase in the number of contacts for this when extrapolated to general practice 
encounters across Australia. This equated to 320,000 more contacts with eye problems in 
2012–13 than in 2003–04. 
The individual problems managed most frequently are described in Table 7.4. This 
demonstrates that in all years from 2003–04 to 2012–13, the most frequently managed were 
hypertension, check-up, upper respiratory tract infection and immunisation/vaccination.  
There were statistically significant increases in the management rates of general check-up, 
diabetes, gastro-oesophageal reflux disease, test results, vitamin/nutritional deficiency, 
administrative procedure, atrial fibrillation/flutter, pregnancy, abnormal test results and 
lacerations/cuts. Marginal increases in the rates of depression and anxiety are also notable.  
When extrapolated to all GP encounters across Australia, these changes represent: 
• 1.9 million more general check-ups in 2012–13 than in 2003–04. It is likely that the 
introduction of specific MBS items for health assessments may have contributed to this 
increase. These health assessments are targeted towards particular groups of patients, 
including those aged 75 years and over, the ‘Healthy Kids Check’ for children of pre-
school age and those aged 45–49 at risk of developing chronic disease54  
• 2.1 million more occasions of diabetes management 
• 1.2 million more occasions where gastro-oesophageal reflux disease was managed 
• 1.4 million more contacts for test results and 880,000 more contacts for abnormal test 
results. These increases may be explained by increased orders for pathology tests over 
the decade described in Chapter 12 
• 1.4 million more occasions where vitamin/nutritional deficiency was managed 
• 1.2 million more contacts for problems regarded as administrative procedures 
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• 1.0 million more contacts for atrial fibrillation/flutter 
• 880,000 more occasions where pregnancy was managed 
• 590,000 more contacts for laceration/cut. 
In contrast, over the decade there were significant decreases in the management rates of 
cardiovascular check-ups, asthma, gastroenteritis, other or unspecified viral disease, 
headache, tonsillitis and menopausal complaints. When extrapolated to general practice 
encounters across Australia, these changes represent:  
• 140,000 fewer cardiovascular check-ups in 2012–13 than in 2003–04 
• 80,000 fewer occasions where menopausal complaints were managed 
• 40,000 fewer occasions of tonsillitis management. 
Due to the overall increase in the number of GP–patient encounters claimed through the 
MBS (described in the introduction to this chapter), for some problems managed there was 
an increase in the number of contacts for the problem over the decade, despite a decrease in 
the management rate over the decade, including: 
• 290,000 more contacts for asthma in 2012–13 than in 2003–04 
• 50,000 more contacts for headache management in 2012–13 than in 2003–04 
• 10,000 more occasions of gastroenteritis management 
• 20,000 more contacts for other or unspecified viral disease. 
The management rate of immunisation/vaccination did not change significantly between 
2003–04 (4.7 per 100 encounters) and 2012–13 (5.0). However there was a significant spike in 
2009–10 (7.3 per 100) that coincided with the concern about H1N1 influenza.  
7.4 Most common new problems 
There was no change in the management rate of all new problems combined over the decade. 
Table 7.5 shows the most frequently managed new problems between 2003–04 and 2012–13. 
The most common new problems managed in general practice in all years were upper 
respiratory tract infection, immunisation/vaccination, check-up and acute bronchitis/ 
bronchiolitis. Few significant changes in the management rate of the most common new 
problems were identified when comparing 2012–13 with 2003–04.  
The management rate of new check-ups increased significantly (from 2.1 to 2.9 per 100 
encounters). This is likely to be due to the ageing population and new MBS items for check-
ups (as discussed above). When extrapolated, this increase represents 1.7 million additional 
occasions where a check-up was managed as a new problem in Australia in 2012–13 
compared with 2003–04. 
The rate of new immunisation/vaccination did not change from 2003–04 to 2012–13, 
however in 2009–10 there was a spike in the rate that coincided with the concern regarding 
H1N1 influenza (as discussed above). 
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7.5 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work 
undertaken by O’Halloran et al. in 200430 and regularly updated by O’Halloran (see ‘Chronic 
conditions’ grouper G84 <sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator>), was 
applied to the BEACH data set. In other parts of this chapter, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may have been grouped together 
when reporting (for example, diabetes – all*, Table 7.4). In this section, only problems 
regarded as chronic have been included in the analysis. For this reason, the condition labels 
in Table 7.6 may differ from those in Table 7.4. Where the group used for the chronic analysis 
differs from that used in other analyses in this report, they are marked with a double asterisk 
(for example, Diabetes [non-gestational]**). Codes included can be found in Appendix 4, 
Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems between 2003–04 and  
2012–13. The management rate of chronic conditions significantly increased from 51.9 per 
100 encounters in 2003–04 to 55.7 per 100 in 2012–13, suggesting approximately 20.6 million 
more contacts with chronic problems in Australia in 2012–13 than in 2003–04. This may be 
due in part to increases in the proportion of GP–patient encounters with older patients (aged 
65–74 years and 75 years and over), seen in Chapter 6.  
The most common chronic problems managed were non-gestational hypertension, non-
gestational diabetes, depressive disorder, chronic arthritis and lipid disorders.  
From 2003–04 to 2012–13, there were significant increases in the management rates of: 
• non-gestational diabetes (equating to an additional 2.1 million contacts in 2012–13 than 
in 2003–04) 
• depressive disorder (representing 1.7 million more occasions of management in 2012–13 
than in 2003–04) 
• atrial fibrillation/flutter (representing 1.0 million more occasions of management) 
• hypothyroidism/myxoedema (representing 660,000 more contacts for this problem) 
• shoulder syndrome (equating to 380,000 more occasions where this problem was 
managed) 
• unspecified chronic pain (representing 440,000 more contacts for this problem). 
The Australian Government has invested considerable resources in the prevention and 
management of chronic disease (such as the National Chronic Disease Strategy,55 and MBS 
items for chronic disease management).54 A major reason for this focus is the ageing 
population56 and the associated expected fiscal pressures (especially healthcare costs).3  
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57
.0
) 

 
(a
) 
Th
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e 
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d 
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lt:
 
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at
is
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al
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t c
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r d
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 c
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w
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04
; 
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di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; R
FE
 –
 re
as
on
 fo
r e
nc
ou
nt
er
.  
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99
,0
30
) 
 (
n 
= 
98
,5
64
) 
M
al
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n 
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 o
f c
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ng
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m
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ca
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 
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at
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r d
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 c
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 c
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 n
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e 
in
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2–
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 c
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pa
re
d 
w
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 2
00
3–
04
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
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th
e 
de
ca
de
. 
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) 
 
0.
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.8
) 
 
0.
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Th
e 
di
re
ct
io
n 
an
d 
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pe
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f c
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e 
fro
m
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3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
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pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
93
66
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 w
er
e 
m
an
ag
ed
 a
t ≥
 1
.0
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
 y
ea
r. 
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 p
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f c
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m
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ca
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 
/
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at
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r d
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e)
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2–
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 c
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re
d 
w
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3–
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s 
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e 
w
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 n
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ca
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e 
in
 2
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2–
13
 c
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pa
re
d 
w
ith
 2
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3–
04
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 in
di
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s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
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P
C
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C
P
C
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S
 c
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1,
 <
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l.h
an
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e.
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t/2
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. 
N
ot
e:
 C
I –
 c
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fid
en
ce
 in
te
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al
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O
S
 –
 n
ot
 o
th
er
w
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e 
sp
ec
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ed
. T
hi
s 
ta
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e 
in
cl
ud
es
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di
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al
 n
ew
 p
ro
bl
em
s 
th
at
 w
er
e 
m
an
ag
ed
 a
t >
= 
1.
0 
pe
r 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
 y
ea
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8 Overview of management 
This chapter provides an overview of management of problems in general practice from each 
of the most recent 10 years of the BEACH study from 2003–04 to 2012–13. More detailed 
analyses of the overview of management in 2012–13 can be found in Chapter 8 in General 
practice activity in Australia 2012–13.1  
As discussed in Chapter 2 – Methods, we can consider changes in GP management actions 
over time in terms of the number of the selected actions per 100 GP–patient encounters, or in 
terms of the number of problems managed. If the number of problems managed on average 
at encounters had not altered it would not matter which way we measure(d) change. 
However, as reported in Chapter 7, there was a significant increase in the number of 
problems managed at GP–patient encounters over the decade of this study. If we simply 
compared management actions (for example, number of prescriptions) as a rate per 100 
encounters, we would be ignoring the fact that more problems were managed in 2012–13 
than in  
2003–04. If more problems are managed, more management actions should result, without 
any change having occurred in GP management actions. 
In this, and the following management chapters, we report changes over time in two ways: 
• rate (of the selected action) per 100 problems managed 
• rate (of the selected action) per 100 encounters. 
The rate per 100 problems managed gives the clearer idea of how GP management actions 
have (or have not) changed. The rate per 100 encounters is used as the basis of extrapolation 
to national estimated change.  
The direction and type of change from 2003–04 to 2012–13 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) in 2012–13 compared with 2003–04; / indicates a marginally significant change 
in 2012–13 compared with 2003–04; — indicates there was no significant change in 2012–13 
compared with 2003–04; and § indicates a noteworthy change during the decade. 
Examples of extrapolations are provided in each of the specific management chapters 
(Chapters 9 to 12, inclusive). The method used to extrapolate to national change estimates is 
described in Section 2.9. 
Between 2003–04 and 2012–13, some trends emerged in management actions per 100 
problems managed (Table 8.1a), and per 100 encounters (Table 8.1b). The most noticeable 
changes in rates per 100 problems managed (from Table 8.1a) are listed below. 
• There was a significant decrease in the rate of medications being prescribed/supplied by 
the GP/advised for over-the-counter purchase, from 71.3 per 100 problems managed in 
2003–04 to 66.3 per 100 problems in 2012–13. 
• The major contributor to the above change was a significant decrease in the rate of 
prescribed medications over the time period, from 58.8 to 53.8 per 100 problems.  
GP- supplied medications had significantly increased in 2008–09 and 2009–10, but 
decreased in 2010–11 to a rate not significantly different to the 2003–04 result. 
  
62
  
• The introduction of MBS item numbers for practice nurse activity in 2005–06 led to a 
significant decrease in the rate at which clinical treatments were given by GPs, from a 
peak of 27.0 in 2004–05 to a low point of 19.9 per 100 problems managed in 2006–07. 
However, the rate of GP-provided clinical treatments then gradually increased such that 
there was no significant difference between the start and end of the decade. The original 
impact of practice nurses on this area of GP workload was no longer observed, 
suggesting that by 2012–13 GPs were again performing clinical treatments at a similar 
rate to that prior to the introduction of practice nurse item numbers. 
• There was a significant increase in the rate at which procedural treatments were 
undertaken, from 10.1 per 100 problems managed in 2003–04 to 11.2 per 100 problems  
in 2012–13.  
• The rate of referrals to other health providers significantly increased, from 8.0 to 9.5 per 
100 problems between 2003–04 and 2012–13, influenced by referrals to allied health 
services, which almost doubled over the period (1.8 to 3.0 per 100 problems managed).  
It was further influenced by a marginal increase in referrals to emergency departments 
(0.1 to 0.2), and in ‘other referrals’ (0.3 to 0.4 per 100 problems managed). Conversely, the 
rate of referrals to hospital halved between 2003–04 and 2012–13. 
• The rate of pathology tests/batteries orders significantly increased by 26%, from 24.1 
tests/batteries per 100 problems managed in 2003–04 to 30.4 in 2012–13.  
• The rate at which imaging was ordered increased significantly, from 5.6 imaging orders 
per 100 problems managed in 2003–04 to 6.7 per 100 in 2012–13. 
Similar changes between 2003–04 and 2012–13 were apparent in the percentage of problems 
for which at least one management type was provided (Table 8.2a), and the proportion of 
encounters where at least one management type was recorded (Table 8.2b).  
The proportion of problems for which: 
• at least one medication or other treatment type was provided decreased significantly, 
from 75.0% of problems in 2003–04 to 71.2% in 2012–13 
• at least one medication was provided decreased significantly (from 56.6% of problems in 
2003–04 to 52.2% in 2012–13), mainly influenced by a significant decrease in the 
proportion of problems for which medication was prescribed, from 47.8% to 43.3% over 
this time. Both of these results influenced the finding above 
• at least one GP–supplied medication was recorded did not increase significantly over the 
decade, but spiked in 2009–10 at the time of the H1N1 virus concerns. This correlates 
with the observed spike in vaccinations for the same period (Chapter 9) 
• at least one procedure was undertaken, significantly increased from 9.4% in 2003–04 to 
10.5% in 2012–13 
• at least one referral was given, increased significantly (from 8.0% of problems in 2003–04 
to 9.5% in 2012–13), particularly to allied health services (1.8% to 3.0%), and emergency 
departments (0.1% to 0.2%) 
• at least one investigation was ordered, increased significantly from 16.5% in 2003–04 to 
18.6% in 2012–13. In 2003–04, the likelihood of at least one pathology test being ordered 
was 11.9%, but this increased significantly to 13.5%. For imaging tests, the likelihood of 
at least one being ordered also increased significantly, from 5.1% to 5.9% of problems by 
2012–13. There was a marginal decrease in the proportion of problems for which other 
investigations were ordered, from 0.7% to 0.5% over the 10-year data period. 
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9 Medications 
This chapter summarises the medications prescribed, advised or supplied by general 
practitioners in each year of the BEACH study from 2003–04 to 2012–13. The direction and 
type of change over the study period is indicated for each result in the far right column of the 
tables: / indicates a statistically significant change (increase or decrease) in 2012–13 
compared with 2003–04; / indicates a marginally significant change in 2012–13 
compared with 2003–04; — indicates there was no significant change in 2012–13 compared 
with 2003–04; and § indicates a noteworthy change during the decade. 
Significant change in the rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the number of prescribed, supplied, or advised medications between 
the first and last years of the study period. Some examples of extrapolated changes are given 
in this chapter. The method used to extrapolate to national change estimates is described 
fully in Section 2.9. In 2012–13, there were 30.5 million more encounters claimed through 
Medicare than there were in 2003–04 (126.8 million versus 96.3 million). It should be noted 
that because of this increase, it is possible that a rate of medication per 100 encounters that 
shows a decrease over time can result in an increase in the extrapolated national estimates of 
that medication.  
GPs could record up to four medications for each of four problems – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP, or recommended for over-the-counter (OTC) purchase. 
Medication data for the 10 years 2003–04 to 2012–13, are reported in two ways in this 
chapter: as rates per 100 problems managed and as rates per 100 encounters. In describing 
data over time, the rates per 100 problems are reported as the primary measure, because 
there was a significant increase in the number of problems managed per encounter over the 
decade (see Chapter 7).  
The tables with rates per 100 encounters are included to show the basis for the extrapolations 
discussed above. Changes discussed in the examples below are per 100 problems managed 
and are taken from results shown in Tables 9.1a, 9.2a, 9.3a, 9.4a, 9.5a and 9.6a. On the other 
hand, the extrapolations are based on rate per 100 encounters so that they are equivalent to 
the national encounter data from Medicare. These extrapolations are therefore based on 
results shown in Tables 9.1b, 9.2b, 9.3b, 9.4b, 9.5b and 9.6b. 
Figure 9.1 shows that between 2003–04 and 2012–13, there was a significant decrease in total 
medication and prescribed medication rates per 100 problems managed. However, Table 
9.1b shows there were no significant changes per 100 encounters.  
The peak in rate of GP–supplied medications in 2009–10 (Tables 9.1a and 9.1b) reflects a high 
rate of influenza virus vaccine which coincided with the H1N1 influenza pandemic of 2009. 
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Note: Data are drawn from Table 9.1a. 
Figure 9.1: All medications and prescribed medications: rates per 100 problems managed, 2003–04 
to 2012–13 (95% confidence intervals) 
 
9.1 Prescribed medications 
The rate at which medications were prescribed per 100 problems managed decreased 
significantly from 2003–04 (58.8 per 100 problems) to 2012–13 (53.8 per 100) (Table 9.1a). 
There was no significant change per 100 encounters (Table 9.1b). However, the extrapolated 
national effect of the increased number of encounters (described above) resulted in an 
estimated 22.8 million more prescriptions being given nationally by GPs in 2012–13 than in 
2003–04. Tables 9.2a and 9.2b show prescribing rates of common drug groups over the 10-
year period at ATC drug group Level 2, because it is more stable than the lower ATC levels. 
There were significant changes in GP prescribing rates per 100 problems managed for a wide 
range of drug groups (Table 9.2a). In particular, there were measured increases in the 
prescription rate of:  
• agents acting on the renin-angiotensin system, from 3.7 per 100 problems managed in 
2003–04 to 4.2 in 2012–13. The extrapolated national effect of this change (calculated from 
the encounter rate from Table 9.2b) was about 2.9 million more prescriptions for drugs in 
this group given in 2012–13 than in 2003–04 
• psychoanaleptics, from 2.2 per 100 problems in 2003–04 to 2.6 per 100 in 2012–13, with an 
extrapolated national effect of about 2 million more prescriptions for psychoanaleptics 
nationally in 2012–13 than in 2003–04 
0
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• lipid modifying agents, from 1.9 per 100 problems in 2003–04 to 2.5 in 2012–13. The 
extrapolated national effect of this change was that about 2.2 million more prescriptions 
for drugs in this group were given in 2012–13 than in 2003–04 
• corticosteroids for systemic use, from 0.9 per 100 problems in 2003–04 to 1.1 in 2012–13, 
an estimated 900,000 more prescriptions nationally in 2012–13 than in 2003–04 
• ‘other’ nervous system drugs (this group comprises parasympathomimetics, drugs for 
addictive disorders and antivertigo medications), from 0.2 per 100 problems in 2003–04 
to 0.6 in 2012–13, with an extrapolated national effect of 850,000 more prescriptions. 
There were also significant decreases in the prescribing rate per 100 problems managed for 
some drug groups. As earlier suggested, the increase in number of encounters claimed 
through Medicare over the decade could cause the decreases in medication numbers in the 
extrapolated national estimates to be less than they would have been had Medicare 
encounter figures remained steady (some extrapolated estimates even showed an increase). 
As shown in Table 9.2a, some of the measured decreases in the prescription rate per 100 
problems were for:  
• drugs for obstructive airway disease, from 2.8 per 100 problems managed in 2003–04 to 
2.3 in 2012–13, but the extrapolated national effect of this change (calculated on the 
encounter rate from Table 9.2b) was that about 620,000 more prescriptions for drugs in 
this group were given in 2012–13 than in 2003–04 due to the increase in encounter 
numbers nationally 
• anti-inflammatory and antirheumatic products, from 3.3 per 100 problems in 2003–04 to 
1.9 in 2012–13, with an extrapolated national effect of about 820,000 fewer prescriptions 
for these products nationally in 2012–13 than in 2003–04 
• sex hormones and modulators of the genital system, from 2.4 per 100 problems in  
2003–04 to 1.5 in 2012–13, with an extrapolated national effect of about 450,000 fewer 
prescriptions for them nationally in 2012–13 than in 2003–04 
• calcium channel blockers, from 1.5 per 100 problems in 2003–04 to 1.1 in 2012–13, with an 
extrapolated national effect of about 90,000 fewer prescriptions for them nationally in 
2012–13 than in 2003–04 
• vaccines, from 2.3 per 100 problems in 2003–04 to 0.7 in 2012–13, an estimated decrease 
of 1.8 million vaccine prescriptions nationally in 2012–13 than in 2003–04 
• diuretics, from 1.1 per 100 problems in 2003–04 to 0.7 in 2012–13, suggesting 50,000 fewer 
diuretic prescriptions nationally in 2012–13 than in 2003–04 
• drugs for functional gastrointestinal disorders, from 0.6 per 100 problems in 2003–04 to 
0.4 in 2012–13, and again the extrapolated national effect of this change suggested 21,000 
more prescriptions for these drugs nationally in 2012–13 than in 2003–04 due to the 
increase in attendance rates 
• cardiac therapy (which comprises antiarrhythmics, cardiac stimulants and vasodilators), 
from 0.7 per 100 problems in 2003–04 to 0.4 in 2012–13, suggesting 170,000 fewer of these 
prescriptions nationally in 2012–13 than in 2003–04. 
Some of the changes referred to here can be linked to changes in the patterns of morbidity 
managed, for example, the rise in psychoanaleptics coincides with the significant increase in 
management rates of psychological problems. Other changes coincide with policy initiatives 
such as the rise in rates of lipid modifying agents which accelerated in 2006–07 when criteria 
for subsidised access to these medications through the Pharmaceutical Benefits Scheme (PBS) 
were broadened. 
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Decreases in prescribing rates of drug groups can sometimes be linked to medications within 
the group becoming available over-the-counter (e.g. salbutamol; the ‘morning after pill’ 
contraceptive); becoming more likely to be supplied directly to the patient by the GP (e.g. 
vaccines); or being included in combination medication products (e.g. diuretics). 
When no statistically significant change occurs in the prescribing rate per 100 problems 
managed, there may still be a national increase due to the increased attendance rates. An 
example of this is prescriptions for analgesics, the rate of which remained steady over the 
study period. However, we estimate that due to the increase in attendances, about 3.5 million 
more were prescribed in 2012–13 than in 2003–04.  
Tables 9.3a and 9.3b show prescribed medication rates at the individual generic level. The 
same effect of the increased number of Medicare encounters over time applies to these 
individual drugs. There were significant changes in GP prescribing rate per 100 problems for 
a number of drugs, including an increased prescription rate per 100 problems managed for:  
• the antibiotic cephalexin, which rose from 1.4 per 100 problems in 2003–04 to 1.7 in 2012–
13, an extrapolated increase of 1.4 million between the two study points, although 
prescribing rates have remained fairly steady for this drug over the decade 
• the opioid oxycodone, which demonstrated a near fourfold increase from 0.3 per 100 
problems managed in 2003–04 to 1.1 in 2012–13, with an extrapolated national effect of 
about 1.6 million more prescriptions for oxycodone nationally in 2012–13 than ten years 
earlier (calculated from the encounter rate in Table 9.3b) 
• the proton pump inhibitor esomeprazole, which also showed a substantial increase from 
0.4 per 100 problems in 2003–04 to 1.0 per 100 in 2012–13 with an extrapolated national 
effect of 1.5 million more esomeprazole prescriptions given in 2012–13 than in 2003–04 
• the lipid modifying agent rosuvastatin, which was first listed on the PBS in December 
2006, and rose from 0.2 per 100 problems in 2007–08 to 0.8 per 100 in 2012–13 – an 
estimated 1.2 million more prescriptions in 2012–13 nationally 
• the non-steroid anti-inflammatory meloxicam from 0.3 per 100 problems in 2003–04 to 
0.5 in 2012–13, suggesting 630,000 more prescriptions for meloxicam nationally in 2012–
13 than in 2003–04. 
In 2012–13 a large number of medications were prescribed less frequently than in 2003–04, 
some decreases being associated with current over-the-counter availability, GP direct supply, 
inclusion in a combination medication, or being superseded by newer drugs within the 
group. Some of the decreases observed in the prescription rate per 100 problems were for:  
• the beta-blocking agent atenolol, from 0.7 per 100 problems in 2003–04 to 0.4 per 100 
problems in 2012–13 with an extrapolated national effect of about 75,000 fewer 
prescriptions for this product nationally in 2012–13 than in 2003–04 
• the non-steroid anti-inflammatory celecoxib, from 0.7 per 100 problems in 2003–04 to 0.4 
in 2012–13, suggesting 200,000 fewer prescriptions nationally for celecoxib in 2012–13 
than in 2003–04 
• the lipid modifying agent simvastatin, from 0.7 per 100 problems in 2003–04 to 0.3 in 
2012–13, an extrapolated national decrease of 330,000 thousand prescriptions for 
simvastatin given in 2012–13 than in 2003–04 
• the cephalosporin cefaclor monohydrate, from 0.6 per 100 problems in 2003–04 to 0.2 in 
2012–13, giving an estimated 260,000 fewer prescriptions for cefaclor at the end of the 
decade. 
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Number of repeats ordered 
The pattern of the number of repeat prescriptions recorded by GPs changed between 2003–04 
and 2012–13 (Table 9.4). There was a significant decrease in the proportion of prescribed 
medications with no repeats, two, three or four repeats ordered. On the other hand, there 
was a significant increase in the proportion of prescriptions for which five repeats were 
recorded. The proportion of prescriptions given with five repeats increased from 29.2% in 
2003–04 to 36.6% in 2012–13. This is probably associated with the increased management rate 
of chronic problems for which prescriptions are commonly written with five repeats. 
9.2 Medications supplied by GPs 
Rates of GP–supplied medications per 100 problems managed were similar in 2003–04 (5.9) 
and in 2012–13 (6.4) (Table 9.1a). Per 100 encounters, the rates were also similar in 2003–04 
(8.6) and in 2012–13 (9.9) (Table 9.1b).  
Table 9.5a shows rates per 100 problems managed of individual medications most frequently 
supplied by GPs between 2003–04 and 2012–13. The majority were vaccines; and rates for 
many of them increased significantly over the period. The supply of influenza virus vaccine 
doubled from 0.8 per 100 problems managed in 2003–04 to 1.5 per 100 in 2012–13. The rate 
per 100 encounters increased from 1.2 to 2.3 (Table 9.5b), and the extrapolated national effect 
of this change is that influenza virus vaccine was supplied 1.8 million more times in 2012–13 
than in 2003–04. The move away from prescribing towards GP supply of the vaccine was 
evident in this significant increase in its supply, which coincided with the significant 
decrease in its prescribing rate (Table 9.3a). This change followed federal government policy 
from 2001, which made the vaccine available free of charge to all Australians aged 65 years 
and over, to Aboriginal and Torres Strait Islander people aged 50 years and older, and to 
younger Aboriginal and Torres Strait Islander persons with health risks. Vaccines can be 
ordered by the GP directly from the supplier. In Tables 9.5a and 9.5b, one can also see the 
2009–10 peak in the rate of influenza virus vaccine coinciding with the H1N1 influenza 
pandemic of 2009.  
9.3 Medications advised for over-the-counter 
purchase 
Table 9.6a shows rates per 100 problems managed for the most commonly advised over–the–
counter medications at the generic level. Rates for individual and total medications largely 
remained steady between 2003–04 and 2012–13. The exception was a four-fold increase in the 
rate vitamin D3 (cholecalciferol) was advised per 100 encounters (Table 9.6b). The increase 
became apparent in 2008–09, in parallel with a three-fold increase in the management rate of 
nutritional/vitamin deficiency (see Chapter 7). 
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10 Other treatments 
This chapter summarises other non-pharmacological treatments (including clinical and 
procedural treatments) provided at, or in conjunction with, recorded GP–patient encounters 
in each of the 10 years of the BEACH study, 2003–04 to 2012–13. Clinical and procedural 
treatments are defined in Appendix 4, Tables A4.4 and A4.5. The survey form allowed GPs 
to record up to two other treatments for each problem managed at the encounter, and (since 
2005–06) indicate if each of these has been done by a practice nurse. 
In 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to 
claim for specified tasks done by a practice nurse under the direction of the GP.22 Over the 
years, new PN item numbers were added to the MBS and some items were broadened, to 
cover work done by AHWs.  
In January 2012, the Australian Government significantly altered the payment structure for 
practice nurse and AHW activities in general practice, such that the range of claimable MBS 
item numbers was reduced and the Practice Nurse Incentive Program (PNIP) introduced. 
The PNIP ’provides incentive payments to practices…by consolidating funding 
arrangements under the Practice Incentive Program (PIP) Practice Nurse Incentive’. Six of 
the Medicare Benefits Schedule (MBS) PN/AHW items were removed and the funds 
redirected into a single payment to eligible general practices.57 
In Sections 10.1 and 10.2, all ‘other treatments’ are reported, irrespective of whether they 
were done by the GP or by the practice nurse at the encounter. That is, the non-
pharmacological management provided at general practice patient encounters is described, 
rather than management provided specifically by the GP. However, in the analysis of 
procedural treatments (Section 10.2), injections given in provision of vaccines have been 
removed, as this action is already counted and reported in medications.  
In Section 10.3, treatments provided by the PN/AHW (including the injections given for 
vaccination) are reported separately, to provide a picture of the work they undertake in 
association with GP–patient encounters. Routine clinical measurements or observations, such 
as measurements of blood pressure and physical examinations, were not included between 
2003–04 and 2004–05. With the inclusion of practice nurse activities in BEACH since 2005–06, 
clinical observations have been recorded, but only when done by the practice nurse. 
In Section 10.4, changes over time in the share between the GP and the practice 
nurses/Aboriginal health workers, of clinical treatments and procedural work done in 
association with the encounter, are investigated. The procedures analysed in Section 10.4 also 
include the injections given for immunisations. 
Other treatments data for the 10 years 2003–04 to 2012–13, are reported in two ways: as rates 
per 100 problems managed (e.g. Table 10.1a) and as rates per 100 encounters (e.g. Table 
10.1b). In the text describing changes over time, the rates per 100 problems are reported as 
the primary measure, because there was a significant increase in the number of problems 
managed per encounter over the study period.  
The direction and type of change from 2003–04 to 2012–13 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) comparing 2012–13 with 2003–04; / indicates a marginally significant change 
comparing 2012–13 with 2003–04; — indicates there was no significant change across the 
decade; and § indicates no change comparing 2012–13 with 2003–04 but a noteworthy change 
within the decade. 
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Changes in the rate per 100 encounters are extrapolated to estimate the national increase or 
decrease in the other treatments provided between 2003–04 and 2012–13. Examples of 
extrapolated change are given. The method used to extrapolate to national change estimates 
is described in Section 2.9. Readers interested in the national impact of a specific measured 
change can apply this extrapolation method to any reported change.  
More detailed analyses of other treatments recorded in BEACH in 2012–13 can be found in 
Chapter 10 of General practice activity in Australia 2012–13.1 
Figure 10.1 demonstrates the non-linear change in the rate at which clinical treatments were 
provided per 100 problems from 2003–04 to 2012–13. Despite a significant decrease in clinical 
treatments in 2005–06, there was no significant difference in the rate of clinical treatments 
between 2003–04 and 2012–13. In contrast, the rate at which procedural treatments were 
performed at GP–patient encounters increased steadily, reaching a significantly higher level 
in 2012–13 than 10 years earlier. The changes are presented in more detail below. 
 
 
 
 
Note: Data are drawn from Tables 10.1a and 10.3a. 
Figure 10.1: Clinical and procedural treatments per 100 problems, 2003–04 to 2012–13  
(95% confidence intervals) 
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10.1 Clinical treatments by GP, practice nurse, or 
Aboriginal health worker 
While there was no statistically significant difference in the rate at which clinical treatments 
were provided in 2003–04 and 2012–13 (Table 10.1a and 10.1b), there were major changes 
within the decade.  
The rate of clinical treatments provided at GP–patient encounters remained steady from 
2003–04 to 2004–05. In November 2004, practice nurse Medicare item numbers were 
introduced and changes were made to the BEACH recording form to include practice nurse 
activity associated with the encounter in the 2005–06 BEACH year. In 2005–06, there was a 
sudden and significant decrease in the rate at which clinical treatments were provided by the 
GP or the practice nurse at GP–patient encounters (27.0 per 100 problems to 20.0 per 100). 
This was followed by a significant increase from 2006–07 and 2007–08 (19.9 per 100 problems 
to 22.8 per 100). Since then, rates slowly increased to reach 23.6 per 100 problems in 2012–13, 
returning to the level provided 10 years earlier (Table 10.1a). 
This pattern of change was reflected in some specific types of clinical treatments. 
• General advice and education was the most frequently recorded clinical treatment 
throughout the decade. Although there was no significant difference between the rate in 
2003–04 and 2012–13, there was a significant decrease from 4.8 per 100 problems in  
2004–05 to 3.3 per 100 in 2005–06. Since then, the rate at which general advice and 
education was provided has returned to a level nearing that of 2003–04.  
• The rate at which other administrative procedure/document and sick certificates were 
provided significantly increased from 2003–04 to 2012–13, however the changes were not 
linear. From 2003–04 to 2005–06, the rate of other administrative procedure/document 
dropped from 1.2 to 0.7 per 100 problems. There was a gradual increase from 2005–06 
onwards to reach 1.6 per 100 problems in 2012–13. For sickness certificates, there was a 
significant increase from 0.7 per 100 problems in 2003–04 to 1.2 per 100 problems in 
2004–05. This remained steady until 2009–10 when there was a significant drop. Rates 
have since increased to a significantly higher rate in 2012–13 than ten years earlier. 
• The rate at which counselling/advice about nutrition/weight was provided significantly 
decreased over the decade. The biggest decrease occurred in 2006–07, and rates have 
since remained steady at a significantly lower rate in 2012–13 than 10 years earlier. 
Considering the rise in the prevalence of overweight and obesity among Australian 
general practice patients (see Section 13.1) it is hoped that the decrease since 2005–06 
reflects a shift of this role to practice nurses or other allied health professionals.  
• Although there was no difference between 2003–04 and 2012–13, in 2005–06 there were 
significant decreases in the rates of: advice/education; advice/education about 
treatment; advice/education about medication; reassurance/support; 
counselling/advice about exercise and counselling/advice about smoking (Table 10.1a).  
There were more encounters claimed through Medicare in 2012–13 than in 2003–04 due to 
the increased attendance rate over the study period and this affects the number of clinical 
treatments provided nationally (see Table 2.1). On the basis of the clinical treatment rates 
reported in Table 10.1b, we estimate that 11 million more clinical treatments were provided 
at GP–patient encounters nationally in 2012–13 than 10 years earlier. 
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There was no significant change in the rate at which one or more clinical treatments were 
provided in the management of selected problems between 2003–04 (32.4 per 100 encounters) 
and 2012–13 (32.6 per 100 encounters). However, there were significant changes in the 
clinical treatment rate for several specific problems over the decade (Table 10.2). 
• In 2012–13, URTI was the problem that accounted for the most clinical treatments, 
provided at a rate of 2.0 per 100 encounters. This means that for every 100 encounters, 
one or more clinical treatments were provided in the management of URTI on two 
occasions. 
• The rates at which hypertension, lipid disorders, and test results were managed with a 
clinical treatment remained fairly steady through the decade, with the exception of a 
significant increase from 2006–07 to 2007–08. 
• There was a marginal increase in the clinical treatment rate for diabetes over the decade, 
from 0.9 per 100 encounters in 2003–04 to 1.2 per 100 encounters in 2012–13. 
10.2 Procedures by GP, practice nurse, or Aboriginal 
health worker 
There was a significant increase in the rate at which procedures were performed from  
2003–04 (10.1 per 100 problems) to 2012–13 (11.2 per 100 problems) (Table 10.3a). The 
extrapolated effect of this change from 14.7 per 100 encounters in 2003–04 to 17.4 per 100 in 
2012–13 (Table 10.3b) is that nationally in 2012–13 there were an estimated 7.9 million more 
procedures undertaken than a decade earlier. However, this was largely due to increased 
numbers of problems managed at encounters and increased attendance rates.  
• The most frequently recorded group of procedures were excision/removal 
tissue/biopsy/destruction/debridement/cauterisation. These were provided at a similar 
rate throughout the decade, reaching 2.0 per 100 problems in 2012–13 (Table 10.3a).  
• The provision of local injections/infiltration (excluding local injection performed for 
immunisations) significantly increased over the decade from 1.1 to 1.5 per 100 problems. 
When extrapolated, the increase equates to provision of 1.4 million more local 
injections/infiltrations nationally in 2012–13 than in 2003–04 (Table 10.3b).  
• There were also significant increases in INR tests, other preventive procedures/high-risk 
medication and PN/AHW check-ups per 100 problems managed. 
• There was a marginal decrease in the frequency of Pap smears from 0.7 per 100 problems 
in 2003–04 to 0.5 in 2012–13. 
There was an overall increase in the likelihood of a procedure being undertaken in the 
management of an individual problem. For every 100 GP–patient encounters in 2003–04, on 
average, 13.7 problems were managed with one or more procedures. By 2012–13 this had 
increased to 16.3 problems per 100 encounters (Table 10.4). Extrapolation of this result 
suggested about 7.5 million more problems were managed with one or more procedures in 
2012–13 than a decade earlier. 
• Female genital check-up/Pap smear was the most common problem managed with a 
procedure in all years, accounting for 0.8 procedures per 100 total encounters in 2012–13.  
• There was a significant rise in the rate at which a procedure was undertaken for 
management of laceration/cut from 0.5 per 100 encounters in 2003–04 to 0.8 per 100 
encounters in 2012–13. When extrapolated, the increase equates to provision of 530,000 
more procedures for laceration/cut nationally in 2012–13 than in 2003–04.
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su
lts
* 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.3
–0
.6
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
A
cu
te
 s
tre
ss
 re
ac
tio
n 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
A
dm
in
is
tra
tiv
e 
pr
oc
ed
ur
e 
– 
al
l* 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 

 
O
st
eo
ar
th
rit
is
* 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
—
 
 (c
on
tin
ue
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Ta
bl
e 
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.2
 (c
on
tin
ue
d)
: T
he
 m
os
t c
om
m
on
 p
ro
bl
em
s 
m
an
ag
ed
 w
ith
 o
ne
 o
r m
or
e 
cl
in
ic
al
 tr
ea
tm
en
ts
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
at
 w
hi
ch
 a
 s
el
ec
te
d 
pr
ob
le
m
 w
as
 m
an
ag
ed
 w
ith
 a
 c
lin
ic
al
 tr
ea
tm
en
t, 
pe
r 1
00
 e
nc
ou
nt
er
s(
a)
 (9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(b
)  
 
 
Pr
ob
le
m
 m
an
ag
ed
 
(n
 =
 9
8,
87
7)
 
 (
n 
= 
94
,3
86
) 
 (n
 =
 1
01
,9
93
) 
 (
n 
= 
91
,8
05
) 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
 (
n 
= 
98
,5
64
) 
G
en
er
al
 c
he
ck
-u
p*
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 

 
A
st
hm
a 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 

 
V
ira
l d
is
ea
se
, o
th
er
/N
O
S 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 

 
To
ta
l p
ro
bl
em
s 
w
ith
 o
ne
 
or
 m
or
e 
cl
in
ic
al
 
tr
ea
tm
en
ts
 
32
.4
 
(3
0.
7–
34
.2
) 
 
34
.4
 
(3
2.
6–
36
.2
) 
 
26
.7
 
(2
5.
1–
28
.3
) 
 
26
.8
 
(2
5.
1–
28
.4
) 
 
31
.2
 
(2
9.
5–
33
.0
) 
 
30
.9
 
(2
9.
2–
32
.5
) 
 
31
.5
 
(2
9.
5–
33
.5
) 
 
31
.8
 
(2
9.
8–
33
.8
) 
 
32
.9
 
(3
0.
9–
34
.9
) 
 
32
.6
 
(3
0.
6–
34
.5
) 
§ 
(a
) 
R
at
e 
of
 p
ro
vi
si
on
 o
f c
lin
ic
al
 tr
ea
tm
en
t f
or
 s
el
ec
te
d 
pr
ob
le
m
 p
er
 1
00
 to
ta
l e
nc
ou
nt
er
s.
 
 
(b
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
93
66
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 h
ad
 c
lin
ic
al
 tr
ea
tm
en
ts
 g
iv
en
 a
t a
 ra
te
 o
f m
or
e 
th
an
 o
r e
qu
al
 to
 0
.5
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
 y
ea
r, 
an
d 
an
y 
ot
he
r 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
of
 in
te
re
st
. 
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e 
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.3
a:
 T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 1
00
 p
ro
bl
em
s)
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
pe
r 1
00
 p
ro
bl
em
s 
(9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
44
,6
74
) 
 (n
 =
 1
37
,3
30
) 
 (n
 =
 1
49
,0
88
) 
 (n
 =
 1
36
,3
33
) 
 (n
 =
 1
45
,0
78
) 
 (n
 =
 1
49
,4
62
) 
 (n
 =
 1
55
,3
73
) 
 (n
 =
 1
46
,1
41
) 
 (n
 =
 1
52
,2
86
) 
 (n
 =
 1
52
,5
17
) 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
2.
1 
(1
.8
–2
.4
) 
 
2.
3 
(2
.0
–2
.5
) 
 
2.
0 
(1
.9
–2
.2
) 
 
2.
3 
(2
.0
–2
.5
) 
 
2.
3 
(2
.0
–2
.5
) 
 
2.
1 
(1
.9
–2
.2
) 
 
1.
9 
(1
.8
–2
.1
) 
 
1.
9 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.1
) 
—
 
D
re
ss
in
g/
pr
es
su
re
/ 
co
m
pr
es
si
on
/ta
m
po
na
de
* 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
6 
(1
.4
–1
.7
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
6 
(1
.4
–1
.7
) 
—
 
Lo
ca
l i
nj
ec
tio
n/
 
in
fil
tra
tio
n*
(b
)  
1.
1 
(1
.0
–1
.2
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
3 
(1
.2
–1
.5
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
5 
(1
.4
–1
.6
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
6 
(1
.4
–1
.8
) 
 
1.
4 
(1
.3
–1
.5
) 
 
1.
5 
(1
.4
–1
.7
) 

 
P
hy
si
ca
l m
ed
ic
in
e/
 
re
ha
bi
lit
at
io
n 
– 
al
l* 
1.
1 
(1
.0
–1
.3
) 
 
1.
4 
(1
.2
–1
.6
) 
 
0.
9 
(0
.8
–1
.1
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.1
) 
§ 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
—
 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.6
–1
.1
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.2
–1
.0
) 
 
0.
5 
(0
.3
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/re
m
ov
e)
* 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
—
 
P
ap
 s
m
ea
r*
 
0.
7 
(0
.6
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
IN
R
 te
st
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 

 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/ 
hi
gh
-ri
sk
 m
ed
ic
at
io
n*
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.5
) 

 
C
he
ck
-u
p 
– 
P
N
/A
H
W
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.2
–0
.7
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 

 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
(c
on
tin
ue
d)
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Ta
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e 
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.3
a 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 1
00
 p
ro
bl
em
s)
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
pe
r 1
00
 p
ro
bl
em
s 
(9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
44
,6
74
) 
 (n
 =
 1
37
,3
30
) 
 (n
 =
 1
49
,0
88
) 
 (n
 =
 1
36
,3
33
) 
 (n
 =
 1
45
,0
78
) 
 (n
 =
 1
49
,4
62
) 
 (n
 =
 1
55
,3
73
) 
 (n
 =
 1
46
,1
41
) 
 (n
 =
 1
52
,2
86
) 
 (n
 =
 1
52
,5
17
) 
O
th
er
 d
ia
gn
os
tic
 p
ro
ce
du
re
s 
* 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.1
–0
.4
) 
—
 
U
rin
e 
te
st
* 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
G
lu
co
se
 te
st
* 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
—
 
P
re
gn
an
cy
 te
st
* 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
—
 
To
ta
l p
ro
ce
du
ra
l t
re
at
m
en
ts
 
10
.1
 
(9
.6
–1
0.
6)
 
 
10
.6
 
(1
0.
0–
11
.3
) 
 
9.
9 
(9
.4
–1
0.
3)
 
 
10
.2
 
(9
.7
–1
0.
7)
 
 
11
.0
 
(1
0.
5–
11
.6
) 
 
10
.8
 
(1
0.
4–
11
.3
) 
 
11
.4
 
(1
0.
8–
12
.1
) 
 
11
.1
 
(1
0.
6–
11
.6
) 
 
11
.0
 
(1
0.
5–
11
.5
) 
 
11
.2
 
(1
0.
7–
11
.8
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
.  
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tra
tio
ns
 p
er
fo
rm
ed
 fo
r i
m
m
un
is
at
io
ns
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
s 
A
4.
5 
an
d 
A
4.
6,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
93
66
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
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Ta
bl
e 
10
.3
b:
 T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 9
8,
87
7)
 
 (
n 
= 
94
,3
86
) 
 (n
 =
 1
01
,9
93
) 
 (
n 
= 
91
,8
05
) 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
 (
n 
= 
98
,5
64
) 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
3.
1 
(2
.7
–3
.6
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
0 
(2
.7
–3
.2
) 
 
3.
3 
(3
.0
–3
.7
) 
 
3.
4 
(3
.1
–3
.8
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
0 
(2
.7
–3
.2
) 
 
2.
9 
(2
.6
–3
.1
) 
 
2.
8 
(2
.6
–3
.0
) 
 
3.
0 
(2
.7
–3
.3
) 
—
 
D
re
ss
in
g/
pr
es
su
re
/ 
co
m
pr
es
si
on
/ta
m
po
na
de
* 
1.
8 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.3
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
2 
(2
.1
–2
.4
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.6
) 

 
Lo
ca
l i
nj
ec
tio
n/
 
in
fil
tra
tio
n*
(b
)  
1.
6 
(1
.4
–1
.8
) 
 
2.
0 
(1
.7
–2
.2
) 
 
2.
0 
(1
.8
–2
.2
) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
3 
(2
.1
–2
.6
) 

 
P
hy
si
ca
l m
ed
ic
in
e/
 
re
ha
bi
lit
at
io
n 
– 
al
l* 
1.
7 
(1
.5
–1
.9
) 
 
2.
0 
(1
.7
–2
.3
) 
 
1.
4 
(1
.1
–1
.6
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.5
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
4 
(1
.2
–1
.6
) 
 
1.
4 
(1
.2
–1
.7
) 
§ 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
1.
2 
(1
.1
–1
.3
) 
 
1.
0 
(1
.0
–1
.1
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
—
 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
1.
1 
(0
.9
–1
.3
) 
 
1.
2 
(0
.9
–1
.5
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
0 
(0
.4
–1
.6
) 
 
0.
7 
(0
.5
–0
.9
) 
 
0.
8 
(0
.6
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/re
m
ov
e)
* 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
P
ap
 s
m
ea
r*
 
1.
1 
(0
.9
–1
.3
) 
 
1.
0 
(0
.8
–1
.1
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.2
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 

 
IN
R
 te
st
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.6
–0
.9
) 

 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/ 
hi
gh
-ri
sk
 m
ed
ic
at
io
n*
  
0.
3 
(0
.2
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
7 
(0
.6
–0
.8
) 

 
C
he
ck
-u
p 
– 
P
N
/A
H
W
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
2 
(0
.1
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.2
–0
.5
) 
 
0.
7 
(0
.3
–1
.0
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.5
–0
.8
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
*  
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 

 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
—
 
(c
on
tin
ue
d)
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Ta
bl
e 
10
.3
b 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 9
8,
87
7)
 
 (
n 
= 
94
,3
86
) 
 (n
 =
 1
01
,9
93
) 
 (
n 
= 
91
,8
05
) 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
 
(n
 =
 9
8,
56
4)
 
O
th
er
 d
ia
gn
os
tic
 p
ro
ce
du
re
s*
 
0.
2 
(0
.1
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.3
) 
 
0.
2 
(0
.1
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.2
–0
.6
) 
—
 
U
rin
e 
te
st
* 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
H
or
m
on
e 
im
pl
an
t* 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
—
 
G
lu
co
se
 te
st
* 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 

 
P
re
gn
an
cy
 te
st
* 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 

 
To
ta
l p
ro
ce
du
ra
l t
re
at
m
en
ts
 
14
.7
 
(1
4.
0–
15
.5
) 
 
15
.5
 
(1
4.
6–
16
.4
) 
 
14
.4
 
(1
3.
7–
15
.1
) 
 
15
.2
 
(1
4.
4–
16
.0
) 
 
16
.7
 
(1
5.
9–
17
.5
) 
 
16
.7
 
(1
6.
0–
17
.5
) 
 
17
.5
 
(1
6.
5–
18
.6
) 
 
16
.9
 
(1
6.
1–
17
.8
) 
 
16
.9
 
(1
6.
1–
17
.8
) 
 
17
.4
 
(1
6.
5–
18
.3
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
. 
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tra
tio
ns
 p
er
fo
rm
ed
 fo
r i
m
m
un
is
at
io
ns
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
s 
A
4.
5 
an
d 
A
4.
6,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
93
66
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
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Ta
bl
e 
10
.4
: T
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10.3 Practice nurse/Aboriginal health worker activity  
This section describes changes over the decade in the activities of practice nurses (PNs) and 
Aboriginal health workers (AHWs) that were recorded in association with the GP–patient 
encounters detailed by the GP BEACH participants. 
In 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to 
claim for specified tasks done by a PN under the direction of the GP.22 In 2005–06, the 
BEACH recording form was amended to capture this information. 
GPs were allowed to record up to three Medicare item numbers where appropriate, rather 
than be limited to one item number as had been the case prior to 2005–06.  
• In the ‘other treatments’ section for each problem managed, GPs were asked to tick the 
‘practice nurse’ box if the treatment recorded was provided by the PN rather than by the 
GP. If the box was not ticked it was assumed the GP gave the treatment. 
• The survey form allows GPs to record up to two other treatments for each problem 
managed at the encounter (i.e. up to eight per encounter). Other treatments include all 
clinical and procedural treatments provided at the encounters. These groups are defined 
in Appendix 4, Tables A4.4 and A4.5. 
Over the years, new PN item numbers were added and some items were broadened, to cover 
work done by AHWs. In January 2012, the Australian Government significantly altered the 
payment structure for practice nurse and AHW activities in general practice, such that the 
range of claimable MBS item numbers was reduced and the Practice Nurse Incentive 
Program (PNIP) introduced. Most of the MBS PN/AHW items were removed and the funds 
redirected into a single payment to eligible general practices.57 The PNIP supports practice 
nurses to continue to deliver services such as immunisations, pap smears and wound 
management, previously funded under the Medicare Benefits Schedule (MBS), as well as a 
broad range of additional activities that were not supported under the MBS. 
To be eligible for the PNIP, the general practice must be accredited against the Royal 
Australian College of General Practitioners Standards for general practice. The maximum 
incentive payment amount a practice can receive under PNIP is $125,000 a year, and a rural 
loading of up to 50% applies for eligible practices. As at May 2013 there were 3,978 practices 
participating in the PNIP. 
The following section investigates: the proportion of encounters involving the PN/AHW; the 
proportion of encounters claimable with a Medicare item number; the distribution of the 
PN/AHW items recorded; treatments provided by PNs/AHWs in association with the GP- 
encounters; the problems for which these treatments were provided.  
These results do not include PN/AHW activities undertaken during the GP’s BEACH 
recording period that were not associated with the recorded encounter. Such activities could 
include Medicare-claimable activities (for example, chronic disease management) provided 
under instruction from the GP but not at the time of the encounter recorded in BEACH, or 
provision of other services not claimable from Medicare (for example, dietary advice on a 
one-to-one basis, or in a group situation). 
Overview of practice nurse/Aboriginal health worker activity 
Encounters involving a PN/AHW as a proportion of all encounters almost doubled from 
4.2% in 2005–06 to peak at 9.0% in 2009–10, then significantly decreased to 7.4% in 2011–12, 
and remained steady in 2012–13 (Table 10.5). 
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The proportion of problems managed with PN/AHW at GP–patient encounters also 
increased significantly from 2.8% in 2005–06 to peak at 6.1% in 2009–10, with no statistically 
significant change by 2012–13 (5.0%).  
In 2005–06, GPs recorded one or more PN/AHW MBS item numbers at 39.2% of encounters 
with recorded PN/AHW activity. By 2009–10 this proportion had risen to 45.5%. In 2011–12, 
a data year that included 3 months of the new 2012 PNIP, GPs recorded a PN/AHW item at 
27.4% of encounters involving a PN/AHW. In 2013, only 5.0% of encounters in which a 
PN/AHW was involved were claimable from Medicare (Table 10.5). 
Distribution of PN/AHW item numbers claimed at encounters 
The number of PN/AHW items claimed per 100 GP–patient encounters significantly 
increased from 1.7 items in 2005–06 to peak at 4.2 in 2009–10; significantly decreased to 3.2 in 
2010–11, further to 2.0 per 100 in 2011–12; and again to 0.3% in 2012–13 under the new 
funding arrangements (Table 10.6).  
The removal of many PN/AHW item numbers in early 2012, meant that in the 2012–13 
BEACH year, the distribution of claimed item numbers changed dramatically. Claims for 
PN/AHW services to a person with chronic disease leapt from 3.6% of all recorded 
PN/AHW items to 91.8% and provision of a health assessment for a patient who is receiving, 
or has received, their 4-years-old immunisation by a PN or AHW, rose from 0.2% of all 
recorded PN/AHW items recorded, to 4.7% in 2012–13. 
Treatments provided by practice nurses and Aboriginal health 
workers  
The rate at which procedures (including tests) were undertaken by PNs/AHWs in 
association with the recorded GP–patient encounters, more than doubled from 4.0 per 100 
encounters in 2005–06 to 9.2 per 100 in 2009–10, though it decreased in 2011–12 to 7.2 per 100 
encounters, and remained steady in 2012–13. PNs/AHWs also took over an increasing 
proportion of the procedural work associated with the GP–patient encounters from 22.7% in 
2005–06 to 38.0% in 2010–11, with no statistical change thereafter. 
While their provision of clinical treatments (such as advice and health education) remained 
infrequent at GP–patient encounters, there was a steady increase over the study period, from 
0.2 clinical treatments per 100 encounters in 2005–06 to 1.1 per 100 in 2012–13. Further, 
nurses did an increasing (but small) proportion of the clinical treatments recorded at 
encounters, rising from 0.7% in 2005–06 to 3.1% in 2012–13. Overall in 2012–13, PNs/AHWs 
provided 14.4% of all ‘other treatments’ recorded at the encounters, a significantly greater 
proportion than in 2005–06 (9.0%) (Table 10.7). 
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Individual treatments 
Through all years, where the PN/AHW provided a treatment associated with a GP–patient 
encounter, only one action was usually recorded. However, there was a small (statistically 
significant) increase in the number of treatments provided from 107.4 per 100 PN/AHW 
involved encounters in 2005–06 to 113.2 per 100 in 2012–13 (Table 10.8). 
Procedures: Though the MBS item number for PN/AHW provision of injections was 
removed in early 2012, in the 2012–13 BEACH year, the rate at which PNs/AHWs provided 
local injections/infiltration at GP encounters (33.0 per 100 PN/AHW involved encounters) 
remained close to the 2011–12 rate (35.5 per 100). However, both the 2011–12 and 2012–13 
rates were significantly lower than the peak in 2009–10 (50.3 per 100).  
Check-ups by PNs/AHWs continued to increase. In 2012–13, check-ups were conducted at a 
rate of 9.2 per 100 GP–patient encounters in which the PN/AHW actions were recorded. 
International normalised ratio (INR) blood testing frequency more than tripled, from 1.8 per 
100 practice nurse encounters in 2006–07 to 7.4 per 100 in 2012–13, but the results for each of 
the last three years did not differ, suggesting a levelling out of the frequency of INR testing 
by PNs/AHW associated with GP–patient encounters.  
Clinical treatments: PN/AHW carried out administrative procedures (excluding sickness 
certificates) at an ever increasing rate, rising from 0.7 per 100 PN/AHW involved encounter 
in 2005–06, to 5.8 per 100 in 2012–13, an increase of 61% on the 2011–12 result, of 3.6 per 100 
PN/AHW involved encounters. Increases also occurred in their provision of 
advice/education about medication and consulting with primary care providers (Table 10.8). 
Problems managed with practice nurse or Aboriginal health worker 
involvement at GP–patient encounters 
Changes in the problems for which PNs/AHWs were involved in management are shown in 
Table 10.9 and largely reflect the changes in the activities undertaken. There were significant 
increases in the rate at which they were involved in management of check-ups, diabetes, 
atrial fibrillation/flutter and preventive procedures with high-risk patients (reflecting the 
increasing rate of INRs, particularly in the last four years). Some of these increases may well 
have been stimulated by the introduction of MBS item 10997 for services provided to a 
person with a chronic disease in 2007–08. The involvement with problems labelled as 
‘administrative procedure’ increased, particularly in 2011–12 and 2012–13. Their 
involvement in the management of chronic skin ulcers (including varicose ulcer) took up a 
smaller proportion of their workload associated with GP–patient encounters. 
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1)
 
 
11
.8
 
(1
0.
4–
13
.2
) 
 
11
.9
 
(1
0.
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13
.0
) 
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.5
 
(1
1.
3–
13
.7
) 
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.0
 
(1
5.
4–
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.7
) 
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.4
 
(1
4.
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.9
) 
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.1
 
(1
2.
9–
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.4
) 
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.4
 
(1
3.
2–
15
.6
) 

 
(a
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Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
5–
06
. 
(b
) 
P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r; 
pr
oc
ed
ur
al
 tr
ea
tm
en
ts
 h
er
e 
in
cl
ud
e 
al
l i
nj
ec
tio
ns
 fo
r i
m
m
un
is
at
io
ns
/v
ac
ci
na
tio
ns
. T
he
se
 a
re
 n
ot
 in
cl
ud
ed
 in
 th
e 
su
m
m
ar
y 
of
 th
e 
co
nt
en
t o
f e
nc
ou
nt
er
 in
 T
ab
le
 5
.1
, 
su
m
m
ar
y 
of
 m
an
ag
em
en
t i
n 
Ta
bl
e 
8.
1 
or
 in
 th
e 
an
al
ys
es
 o
f o
th
er
 tr
ea
tm
en
ts
 in
 C
ha
pt
er
 1
0,
 b
ec
au
se
 th
e 
im
m
un
is
at
io
n/
va
cc
in
at
io
n 
is
 a
lre
ad
y 
co
un
te
d 
as
 a
 p
re
sc
rip
tio
n 
or
 G
P
–s
up
pl
ie
d 
m
ed
ic
at
io
n.
 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
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
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
 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
7,
21
0)
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
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.9
–7
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e 
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3 
(0
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(1
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G
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0.
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–1
.5
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0 
 
(0
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–1
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1.
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(0
.6
–1
.3
) 
 
0.
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(0
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.7
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(1
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–2
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O
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 d
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gn
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0 
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d)
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 =
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0.
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0.
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.2
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P
hy
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re
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0.
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) 
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.2
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) 
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) 
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(0
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) 
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P
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* 
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.1
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.5
) 
 
0.
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.7
) 
 
0.
7 
(0
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0.
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O
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er
 p
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m
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C
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
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) 
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) 
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) 
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) 
—
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.1
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0 
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.4
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.6
) 
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–3
.5
) 
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1 
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.4
–2
.7
) 
 
2.
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(1
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–2
.4
) 
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os
e 
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.7
) 
 
4.
8 
(3
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) 
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–4
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.9
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
 
A
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br
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flu
tte
r 
1.
2 
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.6
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) 
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4 
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.0
) 
 
2.
8 
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.0
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.6
) 
 
3.
4 
(2
.6
–4
.3
) 
 
2.
5 
(1
.8
–3
.2
) 
 
3.
6 
(2
.8
–4
.4
) 
 
3.
6 
(2
.5
–4
.6
) 
 
4.
2 
(3
.2
–5
.1
) 

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 w
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2.
2 
(1
.6
–2
.9
) 
 
3.
0 
(2
.4
–3
.6
) 
 
2.
8 
(2
.2
–3
.4
) 
 
2.
5 
(2
.0
–3
.0
) 
 
2.
0 
(1
.5
–2
.4
) 
 
2.
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3 
(1
.8
–2
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) 
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6 
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.1
–3
.1
) 
—
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nt
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m
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n 
3.
2 
(2
.3
–4
.2
) 
 
2.
9 
(2
.1
–3
.8
) 
 
2.
6 
(1
.8
–3
.3
) 
 
2.
6 
(1
.9
–3
.3
) 
 
2.
1 
(1
.7
–2
.6
) 
 
1.
8 
(1
.4
–2
.2
) 
 
2.
2 
(1
.7
–2
.8
) 
 
2.
3 
(2
.8
–2
.8
) 
—
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6 
(0
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–0
.9
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1 
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–1
.8
) 
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3 
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.9
–1
.7
) 
 
1.
4 
(0
.7
–2
.1
) 
 
1.
5 
(0
.8
–2
.2
) 
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6 
(1
.1
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.1
) 
 
1.
9 
(1
.3
–2
.4
) 
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1.
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3.
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
 
A
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in
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tiv
e 
pr
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ed
ur
e 
– 
al
l* 
0  
 
0.
2 
(0
.0
–0
.4
) 
 
0.
5 
(0
.2
–0
.8
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
8 
(0
.4
–0
.2
) 
 
0.
7 
(0
.4
–1
.1
) 
 
1.
3 
(0
.7
–1
.8
) 
 
1.
7 
(1
.1
–2
.2
) 

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m
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l d
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y 
0.
9 
(0
.5
–1
.3
) 
 
0.
5 
(0
.3
–0
.8
) 
 
1.
0 
(0
.6
–1
.4
) 
 
1.
6 
(1
.2
–2
.1
) 
 
1.
1 
(0
.1
–2
.1
) 
 
1.
2 
(0
.9
–1
.6
) 
 
1.
6 
(1
.2
–2
.0
) 
 
1.
5 
(1
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–1
.9
) 
—
 
R
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ai
r/f
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at
io
n 
– 
su
tu
re
/c
as
t/p
ro
st
he
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de
vi
ce
 (a
pp
ly
/re
m
ov
e)
* 
1.
3 
(0
.7
–1
.9
) 
 
1.
4 
(1
.0
–1
.9
) 
 
1.
4 
(1
.0
–1
.7
) 
 
1.
1 
(0
.8
–1
.5
) 
 
1.
0 
(0
.7
–1
.2
) 
 
1.
2 
(0
.9
–1
.6
) 
 
0.
9 
(0
.7
–1
.2
) 
 
1.
5 
(1
.2
–1
.8
) 
—
 
H
yp
er
te
ns
io
n*
 
1.
1 
(0
.6
–1
.5
) 
 
1.
6 
(1
.0
–2
.2
) 
 
1.
8 
(1
.2
–2
.3
) 
 
1.
8 
(1
.2
–2
.4
) 
 
1.
8 
(1
.2
–2
.4
) 
 
1.
5 
(1
.0
–1
.9
) 
 
2.
3 
(1
.4
–3
.1
) 
 
1.
4 
(1
.0
–1
.8
) 
—
 
A
st
hm
a 
1.
5 
(1
.0
–2
.0
) 
 
2.
3 
(1
.6
–3
.0
) 
 
1.
2 
(0
.9
–1
.6
) 
 
1.
1 
(0
.7
–1
.5
) 
 
0.
9 
(0
.6
–1
.1
) 
 
1.
2 
(0
.8
–1
.5
) 
 
1.
1 
(0
.8
–1
.5
) 
 
1.
3 
(1
.0
–1
.7
) 
—
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H
W
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00
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R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
w
he
re
 P
N
/A
H
W
 a
ct
iv
ity
 d
es
cr
ib
ed
 (9
5%
 C
I) 
 
Pr
ob
le
m
 m
an
ag
ed
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
)  

 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
S
ki
n 
sy
m
pt
om
/c
om
pl
ai
nt
, o
th
er
 
1.
2 
(0
.7
–1
.7
) 
 
1.
2 
(0
.8
–1
.7
) 
 
1.
0 
(0
.7
–1
.3
) 
 
0.
9 
(0
.6
–1
.2
) 
 
0.
9 
(0
.7
–1
.2
) 
 
0.
8 
(0
.5
–1
.1
) 
 
0.
8 
(0
.6
–1
.1
) 
 
1.
1 
(0
.8
–1
.5
) 
—
 
P
re
gn
an
cy
* 
0.
6 
(0
.1
–1
.1
) 
 
0.
8 
(0
.3
–1
.2
) 
 
0.
6 
(0
.2
–0
.9
) 
 
0.
8 
 
(0
.4
–1
.2
) 
 
1.
0 
(0
.8
–1
.3
) 
 
0.
9 
(0
.6
–1
.3
) 
 
0.
8 
(0
.4
–1
.1
) 
 
1.
0 
(0
.5
–1
.5
) 
—
 
S
ki
n 
in
fe
ct
io
n,
 o
th
er
 
0.
4 
(0
.2
–0
.6
) 
 
1.
7 
(1
.2
–2
.2
) 
 
1.
6 
(1
.0
–2
.1
) 
 
1.
9 
(1
.5
–1
.3
) 
 
1.
8 
(1
.3
–2
.2
) 
 
1.
6 
(1
.2
–2
.0
) 
 
1.
7 
(1
.3
–2
.1
) 
 
1.
1 
(0
.8
–1
.3
) 
§ 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/h
ig
h-
ris
k 
m
ed
ic
at
io
n*
 
0.
2 
(0
.0
–0
.3
) 
 
0.
4 
(0
.1
–0
.6
) 
 
0.
8 
(0
.4
–1
.2
) 
 
0.
4 
(0
.2
–0
.7
) 
 
0.
8 
(0
.5
–1
.1
) 
 
1.
0 
(0
.6
–1
.4
) 
 
1.
0 
(0
.6
–1
.3
) 
 
0.
8 
(0
.4
–1
.1
) 

 
C
on
tra
ce
pt
io
n,
 o
th
er
 
1.
1 
(0
.6
–1
.6
) 
 
0.
5 
(0
.3
–0
.8
) 
 
0.
9 
(0
.6
–1
.2
) 
 
0.
9 
(0
.6
–1
.2
) 
 
0.
8 
(0
.5
–0
.9
) 
 
0.
7 
(0
.5
–1
.1
) 
 
0.
9 
(0
.7
–1
.2
) 
 
0.
8 
(0
.6
–1
.1
) 
—
 
U
rin
ar
y 
tra
ct
 in
fe
ct
io
n*
 
0.
3 
(0
.1
–0
.6
) 
 
0.
5 
(0
.2
–0
.8
) 
 
0.
7 
(0
.4
–0
.9
) 
 
0.
5 
(0
.3
–0
.8
) 
 
0.
5 
(0
.3
–0
.7
) 
 
1.
1 
(0
.8
–1
.5
) 
 
0.
9 
(0
.5
–1
.3
) 
 
0.
8 
(0
.5
–1
.0
) 
—
 
B
oi
l/c
ar
bu
nc
le
 
0.
6 
(0
.3
–0
.8
) 
 
0.
8 
(0
.5
–1
.1
) 
 
0.
9 
(0
.5
–1
.2
) 
 
1.
1 
(0
.7
–1
.4
) 
 
0.
5 
(0
.3
–0
.7
) 
 
1.
0 
(0
.7
–1
.3
) 
 
0.
8 
(0
.5
–1
.1
) 
 
0.
7 
(0
.4
–0
.1
) 
—
 
B
ur
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/s
ca
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s 
0.
9 
(0
.5
–1
.3
) 
 
1.
2 
(0
.8
–1
.7
) 
 
1.
1 
(0
.8
–1
.4
) 
 
0.
9 
(0
.6
–1
.2
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
9 
(0
.6
–1
.3
) 
 
0.
8 
(0
.5
–1
.1
) 
 
0.
8 
(0
.5
–1
.1
) 
—
 
A
br
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io
n/
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h/
bl
is
te
r 
1.
2 
(0
.7
–1
.6
) 
 
0.
7 
(0
.4
–1
.0
) 
 
1.
2 
(0
.6
–1
.7
) 
 
0.
8 
(0
.5
–1
.0
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
8 
(0
.5
–1
.0
) 
 
0.
7 
(0
.5
–1
.0
) 
 
0.
7 
(0
.4
–1
.0
) 
—
 
A
na
em
ia
* 
0.
3 
(0
.1
–0
.5
) 
 
0.
5 
(0
.3
–0
.8
) 
 
0.
6 
(0
.3
–0
.8
) 
 
0.
5 
(0
.3
–0
.6
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
7 
(0
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1.
0)
 
—
 
A
rth
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is
 –
 a
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0.
6 
(0
.3
–0
.9
) 
 
0.
4 
(0
.1
–0
.7
) 
 
0.
6 
(0
.3
–0
.8
) 
 
0.
7 
(0
.4
–0
.9
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.9
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.8
) 
—
 
O
bs
er
va
tio
n/
he
al
th
 e
du
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tio
n/
ad
vi
ce
/d
ie
t –
 
al
l* 
0.
4 
(0
.0
–0
.8
) 
 
0.
6 
(0
.3
–0
.8
) 
 
0.
6 
(0
.3
–0
.9
) 
 
0.
5 
(0
.3
–0
.8
) 
 
1.
1 
(0
.1
–2
.1
) 
 
0.
9 
(0
.6
–1
.2
) 
 
0.
8 
(0
.4
–1
.1
) 
 
0.
5 
(0
.3
–0
.6
) 
—
 
D
re
ss
in
g/
pr
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su
re
/c
om
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si
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/ 
ta
m
po
na
de
* 
1.
0 
(0
.5
–1
.6
) 
 
0.
3 
(0
.1
–0
.5
) 
 
0.
6 
(0
.3
–0
.9
) 
 
0.
7 
(0
.3
–1
.1
) 
 
0.
3 
(0
.2
–0
.5
) 
 
0.
6 
(0
.3
–0
.9
) 
 
0.
6 
(0
.3
–0
.9
) 
 
0.
5 
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.3
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.7
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—
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R
at
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w
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N
/A
H
W
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ct
iv
ity
 d
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ed
 (9
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Pr
ob
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m
 m
an
ag
ed
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
)  

 
(n
 =
 4
,0
13
) 
 
(n
 =
 4
,7
10
) 
 
(n
 =
 5
,7
12
) 
 
(n
 =
 6
,0
52
) 
 
(n
 =
 8
,9
99
) 
 
(n
 =
 7
,6
25
) 
 
(n
 =
 7
,2
10
) 
 
(n
 =
 7
,2
34
) 
C
om
pl
ic
at
io
n 
of
 m
ed
ic
al
 tr
ea
tm
en
t 
0.
6 
(0
.3
–1
.0
) 
 
0.
7 
(0
.4
–1
.0
) 
 
0.
6 
(0
.3
–0
.8
) 
 
0.
4 
(0
.3
–0
.6
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
6 
(0
.4
–0
.9
) 
 
0.
4 
(0
.3
–0
.6
) 
—
 
C
he
st
 p
ai
n 
N
O
S 
0.
8 
(0
.4
–1
.1
) 
 
0.
5 
(0
.3
–0
.7
) 
 
1.
0 
(0
.7
–1
.2
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
7 
(0
.5
–0
.9
) 
 
0.
6 
(0
.4
–0
.9
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
5 
(0
.3
–0
.7
) 
—
 
Fr
ac
tu
re
* 
1.
1 
(0
.7
–1
.5
) 
 
1.
0 
(0
.6
–1
.5
) 
 
0.
8 
(0
.5
–1
.0
) 
 
0.
5 
(0
.3
–0
.7
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
5 
(0
.4
–0
.7
) 
 
0.
5 
(0
.2
–0
.7
) 
 
0.
6 
(0
.3
–0
.8
) 

 
In
ju
ry
 s
ki
n 
N
E
C
 
1.
0 
(0
.6
–1
.4
) 
 
0.
6 
(0
.3
–0
.9
) 
 
0.
4 
(0
.2
–0
.6
) 
 
0.
4 
(0
.2
–0
.6
) 
 
0.
3 
(0
.2
–0
.5
) 
 
0.
5 
(0
.2
–0
.7
) 
 
0.
4 
(0
.2
–0
.7
) 
 
0.
5 
(0
.2
–0
.7
) 
—
 
To
ta
l p
ro
bl
em
s 
10
2.
4 
 
(1
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.7
–1
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.2
) 
 
10
4.
5 
(1
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.3
–1
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.8
) 
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3.
4 
 
(1
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.7
–1
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.2
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3.
8 
(1
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.1
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.5
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.3
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) 
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4.
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(1
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.9
–1
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5.
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(1
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–1
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) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
5–
06
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
5–
06
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 o
ve
r t
he
 p
er
io
d.
 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r I
C
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
93
66
>)
. 
N
ot
e:
 P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r; 
in
cl
ud
es
 o
nl
y 
th
os
e 
pr
ob
le
m
s 
m
an
ag
ed
 b
y 
pr
ac
tic
e 
nu
rs
es
 o
r A
bo
rig
in
al
 h
ea
lth
 w
or
ke
rs
 a
t a
 ra
te
 o
f 1
%
 o
r h
ig
he
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10.4 Changes in work distribution between GPs and 
PNs/AHWs, ‘other treatment’ provision 
The introduction of MBS item numbers for some PN and AHW activities in 2004 clearly 
influenced some of the GP activity at GP–patient encounters. 
Clinical treatments 
In 2005–06, the number of clinical treatments (counselling, advice, education and so forth) 
recorded at BEACH encounters (counting both the GP-provided clinical activities and those 
provided by a PN/AHW in association with the encounter) decreased significantly (from 
39.2 to 29.2 per 100 GP–patient encounters) and the rate stayed at this level in 2006–07. 
Suddenly it increased significantly in 2007–09 to 34.5 per 100 encounters, a level retained to 
date, with some minimal growth. 
The PN/AHW contribution to clinical treatments associated with GP–patient encounters was 
very small throughout the 10 years (Table 10.10). 
Table 10.10: GPs and PNs/AHWs clinical treatments at GP–patient encounters, 2003–04 to 2012–13 
 Rate per 100 encounters (95% CI) 
 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
Total  36.6 39.2 29.2 29.5 34.5 34.0 35.0 35.5 37.0 36.5 
GP 36.6 39.2 29.0 29.0 34.1 33.5 34.3 34.8 36.1 34.3 
PN/AHW 0.0 0.0 0.2 0.5 0.5 0.5 0.7 0.7 0.9 1.1 
Note: There was no facility to record practice nurse or Aboriginal health worker activities at the encounter prior to 2005–06. PN – practice nurse; 
AHW – Aboriginal health worker. 
Figure 10.2 provides a picture of the changes in shared workload at encounter by GPs and 
PN/AHWs, since PN item numbers were first introduced. 
When the drop occurred in 2005–06, we assumed that the PNs/AHWs were taking over the 
responsibility for some of these clinical treatments ‘lost’ from the GP–patient encounters in 
patient contacts that were independent of the encounter. However, if that was the case we 
would have expected that this role would grow—that we would see a further decrease in 
clinical treatments recorded at the encounters in the following years. In reality, the overall 
rate at which clinical treatments were recorded at GP–patient encounters bottomed out in 
2005–06 and in 2006–07, then gradually crept up to reach the same level as that recorded in 
2003–04. Table 10.10 demonstrates that this pattern was particularly apparent in 
advice/education (including about treatment and medication) and the provision of 
reassurance and support. In contrast, significant decreases in recorded rates of 
advice/education about exercise and nutrition/weight failed to return to their earlier levels.  
We hypothesised that in 2005–06, when the PN/AHW Medicare items were introduced, the 
GPs felt that some of the advice and education would be picked up outside the consultation, 
by a PN/AHW. Perhaps over time, they realised that this was not always the case, so 
returned to their earlier behaviour in providing such advice themselves. Of concern 
however, is the lack of such reversion in rates of provision of advice about exercise and 
about nutrition/weight. Hopefully these two areas are being covered by PNs and AHWs 
independently of the GP–patient encounters, but we have no data about their non-GP–
patient encounter activities to determine if this is true. 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
GP 14.7 17.6 13.7 13.3 14.4 14.7 14.1 13.1 13.2 13.9
PN/AHW 4.0 5.2 6.1 6.4 9.3 8.0 7.2 7.2
Total 17.7 18.5 20.5 21.1 23.4 21.1 20.6 21.1
0
5
10
15
20
25
30
GP
PN/AHW
Total
Procedural treatments 
After the introduction of PN/AHW item numbers in 2004–05, there was a significant 
decrease in the rate at which GPs undertook procedures (including injections for 
immunisations) at GP–patient encounters, from 17.6 (95% CI: 16.6–18.6) per 100 encounters, 
to 13.9 (95% CI: 13.2–14.6) per 100. This rate then stayed relatively steady through to 2012–13.  
However, both the PN/AHWs procedural work at GP–patient encounters, and the overall 
procedural rate increased, PNs/AHWs having taken some of the clinical load from the GP. 
As shown in Figure 10.2, in 2005–06, the PNs/AHWs undertook about 1 in 5of the 
procedures associated with the encounter and the GP procedural load decreased 
accordingly. By 2012–13, the PNs/AHWs were doing almost 2 in 5 of the procedures 
conducted in association with the encounters.  
We hypothesised that the removal of many of the PN Medicare item numbers in January 
2012, may lead to even greater independence of the procedural work of PNs, so that they 
would be less often involved in care provided in association with the GP–patient encounters. 
However, the data proved this hypothesis wrong— in 2012–13 they were involved just as 
often as they were in 2010–11 and 2011–12. Whether or not the PNs/AHWs are undertaking 
increasing patient care provision independently of the GP–patient encounter cannot be 
measured from GP–patient encounter data such as BEACH. The lack of quality data 
available about the growing non GP–patient encounter activity of PNs/AHWs is limiting our 
understanding of the total services provided to patients by general practices, and this 
limitation will grow with increasing independence on PN/AHW clinical activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Data are drawn from Tables 10.1a and 10.3a. 
Figure 10.2: GP and PN/AHW share of procedural work undertaken at GP–patient encounters 
 
Rate per 100 encounters 
BEACH data years  
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11 Referrals and admissions  
A referral is defined as the process by which the responsibility for part, or all, of the care of a 
patient is temporarily transferred to another health-care provider. GPs were instructed only 
to record new referrals arising at the encounter (that is, not to record continuations). For each 
encounter, GPs could record up to two referrals, and each referral was linked by the GP to 
the problem(s) for which the patient was referred. Referrals included those to medical 
specialists, allied health services, hospitals for admission, emergency departments, and to 
other services (including outpatient clinics and other GPs). 
Referral data for the 10 years 2003–04 to 2012–13, are reported in two ways: as rates per 100 
problems managed (Table 11.1a) and as rates per 100 encounters (Table 11.1b). In the text 
describing changes over time, the rates per 100 problems are reported as the primary 
measure, because there was a significant increase in the number of problems managed per 
encounter over the study period reported here.  
The direction and type of change from 2003–04 to 2012–13, is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) in 2012–13 compared with 2003–04; / indicates a marginally significant change 
in 2012–13 compared with 2003–04; — indicates there was no significant change in 2012–13 
compared with 2003–04; and § indicates a noteworthy change during the decade. Significant 
changes in the rate per 100 encounters can be extrapolated to estimate the national increase 
or decrease in the measured event between 2003–04 and 2012–13. Examples of extrapolated 
change are given. The method used to extrapolate is described in Section 2.9. 
The number of GP–patient encounters claimed through the Medicare Benefits Schedule 
nationally increased by 31.7% between 2003–04 (96.3 million encounters) and 2012–13 (126.8 
million encounters).5,7 As a result, a decreased rate of a particular ‘measured event’ per 100 
encounters may occasionally yield a national increase in the estimated number of events. 
More specific analyses of referrals recorded by participating GPs in the 2012–13 BEACH year 
can be found in the companion report General practice activity in Australia 2012–13.1 
11.1 Results 
Figure 11.1 illustrates the proportion of encounters and problems managed where referrals 
were made, and referral rates per 100 encounters and per 100 problems, over the decade 
2003–04 to 2012–13. As described in detail below, there were significant increases in 
likelihoods that GP–patient encounters would involve one or more referrals and that a 
problem being managed at encounter would be referred. There were also significant 
increases in the overall rates of referrals per 100 encounters and per 100 problems managed.  
The likelihood that a problem being managed at encounter would be referred increased 
significantly over the study period, with 8.0% of problems being referred in 2003–04 and 
9.5% in 2012–13. There was a significant increase in the overall rate of referrals, from 7.9 per 
100 problems managed in 2003–04 to 9.5 per 100 in 2012–13 (Table 11.1a). This increase was 
largely due to an increasing referral rate to allied health professionals, rather than an 
increase to medical specialists, which remained stable. However, there were marginally 
significant increases in the rate of referrals per 100 problems to orthopaedic surgeons, 
cardiologists and gastroenterologists; and marginal decreases in referrals to surgeons and 
ophthalmologists. 
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The rate of referral to allied health services per 100 problems managed increased from 1.8 in 
2003–04 to 3.0 per 100 in 2012–13. There were significant increases in the rates of referral to 
psychologists and podiatrists/chiropodists per 100 problems managed, and a marginal 
increase in referral rates to dietitians/nutritionists. There was a marginal decrease in the rate 
of referral/admission to hospitals over the decade (Table 11.1a). 
Table 11.1b also shows that over time there was an increased likelihood that GP–patient 
encounters would involve one or more referrals (11.0% involving a referral in 2003–04 and 
13.5% in 2012–13). Overall, referrals increased significantly, from 11.6 per 100 encounters in 
2003–04 to 14.8 per 100 in 2012–13. Extrapolation of this change suggests there were about 
7.6 million more GP referrals nationally in 2012–13 than in 2003–04. These included about 3.7 
million more referrals to medical specialists and about 3.5 million more to allied health 
services. Of these 3.5 million additional allied health referrals, 1.1 million were to 
psychologists, probably largely as a result of the government’s introduction of the Better 
Outcomes58 and later the Better Access59 mental health programs. There were also about 
560,000 more referrals to physiotherapists, which may also be due to government policy, 
such as the introduction of MBS item numbers for a limited number of physiotherapy 
services for selected patients referred by a GP.54 
 
 
 
Note: Data are drawn from Tables 11.1a and 11.1b. 
Figure 11.1: Proportion of encounters and problems managed where referrals were made, and 
referral rates per 100 encounters and per 100 problems, 2003–04 to 2012–13 (95% confidence 
intervals) 
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(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
 
P
sy
ch
ol
og
is
t 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.7
) 

 
 
P
od
ia
tri
st
/c
hi
ro
po
di
st
 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 

 
 
D
ie
tit
ia
n/
nu
tri
tio
ni
st
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
 
D
en
tis
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
—
 
H
os
pi
ta
l 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
Em
er
ge
nc
y 
de
pa
rtm
en
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
—
 
O
th
er
 re
fe
rra
ls
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 

 
To
ta
l r
ef
er
ra
ls
 
7.
9 
(7
.6
–8
.3
) 
 
7.
9 
(7
.6
–8
.2
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
9 
(8
.6
–9
.2
) 
 
8.
7 
(8
.4
–9
.0
) 
 
9.
3 
(8
.9
–9
.6
) 
 
9.
4 
(9
.1
–9
.8
) 
 
9.
5 
(9
.2
–9
.9
) 

 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
.  
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e 
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.1
b:
 T
he
 m
os
t f
re
qu
en
t r
ef
er
ra
ls
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
) 
 
 
R
ef
er
ra
l 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
 (
n 
= 
98
,5
64
) 
A
t l
ea
st
 o
ne
 re
fe
rra
l 
11
.0
 
(1
0.
5–
11
.5
) 
 
10
.9
 
(1
0.
5–
11
.3
) 
 
11
.3
 
(1
0.
9–
11
.8
) 
 
11
.5
  
(1
1.
0–
11
.9
) 
 
11
.8
 
(1
1.
3–
12
.2
) 
 
12
.8
 
(1
2.
3–
13
.2
) 
 
12
.4
 
(1
1.
9–
12
.9
) 
 
13
.0
 
(1
2.
5–
13
.5
) 
 
13
.3
 
(1
2.
8–
13
.8
) 
 
13
.5
 
(1
3.
0–
14
.1
) 

 
M
ed
ic
al
 s
pe
ci
al
is
t 
7.
9 
(7
.5
–8
.2
) 
 
7.
7 
(7
.4
–8
.1
) 
 
8.
2 
(7
.8
–8
.5
) 
 
8.
1 
(7
.7
–8
.4
) 
 
8.
0 
(7
.6
–8
.3
) 
 
9.
0 
(8
.7
–9
.3
) 
 
8.
4 
(8
.1
–8
.8
) 
 
8.
6 
(8
.2
–9
.0
) 
 
8.
6 
(8
.2
–8
.9
) 
 
8.
9 
(8
.5
–9
.3
) 

 
 
O
rth
op
ae
di
c 
su
rg
eo
n 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
 
S
ur
ge
on
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
 
D
er
m
at
ol
og
is
t 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
—
 
 
O
ph
th
al
m
ol
og
is
t 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
—
 
 
C
ar
di
ol
og
is
t 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 

 
 
G
as
tro
en
te
ro
lo
gi
st
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 

 
 
E
ar
, n
os
e 
an
d 
th
ro
at
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
—
 
 
G
yn
ae
co
lo
gi
st
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 

 
 
U
ro
lo
gi
st
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
 
P
sy
ch
ia
tri
st
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
—
 
 
N
eu
ro
lo
gi
st
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
 
P
ae
di
at
ric
ia
n 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
(c
on
tin
ue
d)
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.1
b 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t r
ef
er
ra
ls
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
3–
04
 to
 2
01
2–
13
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 

(a
) 
 
 
R
ef
er
ra
l 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
 (
n 
= 
98
,5
64
) 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s 
2.
6 
(2
.4
–2
.8
) 
 
2.
7 
(2
.5
–2
.9
) 
 
2.
9 
(2
.7
–3
.1
) 
 
3.
1 
(2
.9
–3
.3
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
9 
(3
.6
–4
.1
) 
 
3.
9 
(3
.7
–4
.2
) 
 
4.
2 
(3
.9
–4
.5
) 
 
4.
7 
(4
.4
–5
.0
) 
 
4.
7 
(4
.4
–5
.0
) 

 
 
P
hy
si
ot
he
ra
py
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 

 
 
P
sy
ch
ol
og
is
t 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 

 
 
P
od
ia
tri
st
/c
hi
ro
po
di
st
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 

 
 
D
ie
tit
ia
n/
nu
tri
tio
ni
st
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 

 
 
D
en
tis
t 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
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12 Investigations 
Investigations ordered by GPs for each of the 10 years 2003–04 to 2012–13, are reported in 
two ways: as rates per 100 problems managed (for example, Table 12.1a) and as rates per 
100 encounters (for example, Table 12.1b). In the text describing changes over time, the rates 
per 100 problems are reported as the primary measure, because there was a significant 
increase in the number of problems managed per encounter.  
The direction and type of change from 2003–04 to 2012–13 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) in 2012–13 compared with 2003–04; / indicates a marginally significant change 
in 2012–13 compared with 2003–04; — indicates there was no significant change in 2012–13 
compared with 2003–04; and § indicates a noteworthy change during the decade. 
Significant linear changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the investigations ordered between 2003–04 and 2012–13. 
Examples of extrapolated change are given. The method used to extrapolate to national 
change estimates is described in Section 2.9. 
The GPs participating in BEACH were asked to record (in free text) any pathology, imaging 
or other tests ordered or done at the encounter, and to nominate the patient problem(s) 
associated with each test order. This allows the linkage of a test order to a single problem or 
multiple problems. Up to five orders for pathology and two for imaging and other tests 
could be recorded at each encounter. A single test may have been ordered for the 
management of multiple problems, and multiple tests may have been used in the 
management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a 
battery of tests (for example, lipids, full blood count). Where a battery of tests was ordered, 
the battery name was recorded rather than each individual test. GPs also recorded the body 
site for any imaging ordered (for example, x-ray chest, computerised tomography head). 
More detailed analyses of investigations ordered by GPs in 2012–13 can be found in  
Chapter 12 of General practice activity in Australia 2012–13.1  
Comprehensive investigation of GPs’ pathology and imaging ordering was published in 
several reports. Interested readers may wish to consult: 
• a comprehensive report on pathology ordering by GPs in Australia in 1998, written by 
the then General Practice Statistics and Classification Unit using BEACH data, published 
on the internet by the then Department of Health and Aged Care60 
• a report on imaging orders by GPs in Australia in 1999–2000 using BEACH data, 
published as an AIHW–University of Sydney book in the GP series in 200161 
• a report on changes in pathology ordering by GPs from 1998 to 2001 using BEACH data, 
published as an AIHW–University of Sydney book in the GP series in 200362 
• a review of GP pathology ordering in the National Health Priority Areas and other 
selected problems between 2000 and 2008, reported in the AIHW–University of Sydney 
publication General practice in Australia, health priorities and policies 1998 to 200863 
• a report Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology 
data and recommended testing, prepared for the Australian Government Quality Use of 
Pathology Program in June 2009.64  
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12.1 Number of problems or encounters where 
pathology or imaging was ordered 
Table 12.1a shows there was a significant increase in the proportion of problems for which 
pathology or imaging was ordered. 
• The likelihood of ordering at least one pathology test increased from 11.9% of all 
problems managed in 2003–04 to 13.5% in 2012–13. 
• The proportion of problems generating imaging orders increased from 5.1% in 2003–04 
to 5.9% in 2012–13. 
Between 2003–04 and 2012–13, the number of problems managed per 100 encounters rose 
from 146.3 to 154.7 (Table 5.1). Both the rise in the proportion of problems generating test 
orders and the rise in the number of problems managed per encounter contributed to an 
overall increase in the proportion of encounters involving a pathology or imaging test 
(Table 12.1b).  
• The likelihood of ordering at least one pathology test per encounter increased from 
15.5% of encounters in 2003–04 to 18.1% in 2012–13, equating to approximately 8 million 
more encounters at which pathology was ordered in 2012–13 than 10 years earlier. 
• The proportion of encounters generating imaging orders increased from 7.2% in 2003–04 
to 8.8% in 2012–13, resulting in an estimated 4.2 million more encounters nationally at 
which imaging was ordered in 2012–13 than in 2003–04. 
12.2 Pathology test orders by MBS groups 
Tables 12.2a and 12.2b show the changes in the total number of pathology test orders, and in 
the distribution of these by MBS pathology groups.65  
The number of pathology tests ordered increased from 24.1 tests/batteries of tests per 
100 problems managed in 2003–04 to 30.4 per 100 problems in 2012–13 (Table 12.2a). 
The largest increase was in orders for chemical pathology, which increased from 13.0 per 
100 problems in 2003–04 to 17.9 per 100 in 2012–13. Haematology increased at a slower rate, 
from 4.6 per 100 problems in 2003–04 to 5.4 in 2012–13. There was a far smaller increase in 
order rates for immunology, and a marginal increase in orders for simple tests. There was a 
marginal decrease in the order rate of cytopathology tests, and no changes in the other 
individual test groups. 
The number of pathology tests ordered per 100 encounters increased from 35.2 tests (or 
batteries of tests) per 100 encounters in 2003–04 to 47.1 in 2012–13 (Table 12.2b), which, when 
combined with the increase in attendance rate, extrapolates to approximately 25.8 million 
more tests/batteries of tests ordered in 2012–13 than in 2003–04 nationally. 
The largest increase was in orders for chemical pathology, which increased by 45% from 19.1 
per 100 encounters in 2003–04 to 27.7 in 2012–13. This extrapolates to an estimated 
16.7 million more chemistry test orders nationally in 2012–13 than 10 years earlier. 
Haematology tests increased at a slower rate, rising from 6.8 tests per 100 encounters in 
2003–04 to 8.4 in 2012–13, a national increase of approximately 4.1 million tests. Microbiology 
test orders increased from 5.3 per 100 encounters in 2003–04 to 6.3 in 2012–13, extrapolating 
to an increase of about 2.9 million additional test orders nationally in 2012–13. There was a 
far smaller increase in order rates for immunology, a marginal increase in simple tests, and 
no increases in the other test groups. 
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Figure 12.1 shows the statistically significant increases in the likelihood of ordering 
pathology and the total number of pathology tests ordered per 100 problems or per 100 
encounters over the 10 years to 2012–13. Most of each increase occurred between 2003–04 
and 2008–09 and these measures then remained stable (Figure 12.1). The growth in the 
number of tests/batteries ordered was larger than the growth in likelihood of ordering 
because, once a decision to order was made, the number of tests ordered significantly 
increased from an average 2.0 tests/batteries per tested problem in 2003–0448 to 2.4 per tested 
problem in 2012–13.1 
 
 
Note: Data are drawn from Tables 12.1a, 12.1b, 12.2a, and 12.2b. 
Figure 12.1: Proportion of encounters and problems where pathology was ordered, and pathology 
test order rates per 100 encounters and per 100 problems, 2003–04 to 2012–13 (95% confidence 
intervals) 
12.3 Imaging test orders by MBS group 
Tables 12.3a and 12.3b show the changes in imaging orders by MBS imaging group from 
2003–04 to 2012–13. 
Total imaging test orders increased significantly from 5.6 per 100 problems managed in 
2003–04 to 6.7 per 100 in 2012–13 (Table 12.3a). Ultrasound imaging increased from 1.8 tests 
per 100 problems in 2003–04 to 2.7 per 100 in 2012–13. Computerised tomography increased 
from 0.6 to 0.8 per 100 problems. Magnetic resonance imaging increased from less than 0.05 
per 100 problems in 2003–04 to 0.2 in 2012–13.  
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Diagnostic radiology orders decreased marginally from 3.1 per 100 problems in 2003–04 to 
2.9 in 2012–13. Nuclear medicine order rates did not change during this period. 
Total imaging test orders per 100 encounters also increased significantly from 8.2 in 2003–04 
to 10.3 in 2012–13 (Table 12.3b), suggesting there were 5.2 million more imaging orders 
nationally in 2012–13 than 10 years earlier. Ultrasound imaging orders increased from 2.7 
tests per 100 encounters in 2003–04 to 4.2 per 100 in 2012–13, a national increase of about 
2.7 million ultrasound orders over the study period. Computerised tomography increased 
from 0.8 per 100 encounters in 2003–04 to 1.3 in 2012–13, equating to an additional 880,000 
orders for computerised tomography in 2012–13 than a decade earlier. Magnetic resonance 
imaging orders increased from less than 0.05 per 100 encounters in 2003–04 to 0.2 in 2012–13. 
Order rates of diagnostic radiology and nuclear medicine did not change over this period. 
Figure 12.2 shows the statistically significant increases in the likelihood of ordering imaging 
and the total number of imaging tests ordered per 100 problems and per 100 encounters over 
the 10 years to 2012–13. Most of the increase in the rate of imaging (per 100 problems and per 
100 encounters) occurred between 2003–04 and 2008–09 and each measure has remained 
stable since that time (Figure 12.2).  
 
 
 
 
Note: Data are drawn from Tables 12.1a, 12.1b, 12.3a, and 12.3b. 
Figure 12.2: Proportion of encounters and problems where imaging was ordered, and imaging test 
order rates per 100 encounters and per 100 problems, 2003–04 to 2012–13 (95% confidence intervals) 
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13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of 
the population visit a GP at least once per year — in 2012–13, 85% of Australians visited a GP 
at least once (personal communication DoHA, June 2013). GPs have substantial knowledge 
of population health and screening programs. They are in an ideal position to advise patients 
about the benefits of health screening, and to individually counsel patients about their 
lifestyle choices. 
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter 
form has been used to investigate aspects of patient health or healthcare delivery not covered 
by general practice encounter–based information. These additional substudies are referred to 
as Supplementary Analysis of Nominated Data (SAND). The SAND methods are described 
in Chapter 2, Section 2.6. 
In brief, measured patient risk factors include self-reported height and weight (to calculate 
body mass index or BMI), alcohol consumption and smoking status. Each GP completes risk 
factor questions for patients at a subsample of 40 encounters. An example of the encounter 
form with the patient risk factor SAND questions is provided in Appendix 1. The methods 
used to investigate each risk factor are summarised in this chapter. Further detail is provided 
in Chapter 13 of the companion report General practice activity in Australia 2012–13.1 
This chapter includes data about the risk behaviours of general practice patients from each of 
the most recent 10 years of the BEACH study from 2003–04 to 2012–13. The direction and 
type of change from 2003–04 to 2012–13 is indicated for each result in the far right column of 
the tables: / indicates a statistically significant change (increase or decrease) in 2012–13 
compared with 2003–04; / indicates a marginally significant change in 2012–13 
compared with 2003–04; — indicates there was no significant change in 2012–13 compared 
with 2003–04; and § indicates a noteworthy change during the decade. 
13.1 Body mass index 
Patient BMI was investigated for a subsample of 40 patients per GP. Each GP was instructed 
to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (feet and inches; stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) 
squared. The WHO recommendations66 for BMI groups were used, which specify that an 
adult (18 years and over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
The BEACH data on BMI are presented separately for adults (aged 18 years and over) and 
children (aged 2–17 years). The standard BMI cut-offs described above were applied for the 
adult sample, and the method described by Cole et al. (2000 & 2007) was used for children 
(aged 2–17 years).67,68  
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Adults 
Overall prevalence of overweight and obesity in adults sampled at general practice 
encounters increased significantly from 56.5% in 2003–04 (95% CI: 55.6–57.4) to 61.2% in 
2012–13 (95% CI: 60.3–62.1) (results not tabulated). 
• There was a significant increase in the prevalence of obesity from 22.1% in 2003–04 to 
26.6% in 2012–13 (Table 13.1). The significant increase in adult obesity was apparent 
among both male and female patients (Tables 13.2 and 13.3). The increase in obesity was 
evident between 2003–04 and 2010–11 (from 22.1% to 26.7%), and it has been static at 
about 26.6% for the 3 years 2010–11 to 2012–13. 
• The proportion of adults who were in the normal weight range decreased significantly 
from 40.7% in 2003–04 to 36.2% in 2012–13 (Table 13.1). This significant decrease was 
apparent among both male and female patients (Tables 13.2 and 13.3). The decrease in 
normal weight was evident between 2003–04 and 2010–11 (from 40.7% to 35.8%), and it 
has been static at about 36% for the 3 years 2010–11 to 2012–13. 
In summary, for both male and female patients between 2003–04 and 2012–13, there was a 
significant increase in the prevalence of obesity and a corresponding decrease in normal 
weight. Effectively a significant proportion of patients moved from the normal weight range 
into the overweight range, and a similar proportion of those who were overweight moved 
into the obese weight range. If this upward movement from normal weight, to overweight, 
and overweight to obesity continues, it will have huge implications for public health. 
Children 
The prevalence of obesity among sampled children aged 2–17 years decreased significantly 
from 11.8% (95% CI: 10.5–13.2) in 2003–04 to 9.0% (95% CI: 7.9–10.2) in 2012–13 (Table 13.1), 
but this decrease was noted only for male children (from 13.7% to 10.1%) (Table 13.2).  
There was a corresponding increase in the prevalence of normal weight from 57.9% (95% CI:  
56.0–59.7) in 2003–04 to 62.5% (95% CI: 60.6–64.5) in 2012–13 (Table 13.1). This significant 
increase in prevalence of normal weight children was noted among both male and female 
children (56.0% to 61.8%; and 59.4% to 63.2% respectively) (Table 13.2 and Table 13.3).  
13.2 Smoking 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
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Results 
There was a significant decrease in the prevalence of current daily smoking and occasional 
smoking among sampled adults aged 18 years and over attending general practice, from 
17.6% and 4.3% respectively in 2003–04 to 14.4% and 2.6% in 2012–13 (Table 13.1). These 
decreases were apparent among both male and female patients (Tables 13.2 and 13.3). 
Prevalence of daily smoking were significantly higher among male patients than female 
patients in all years. In 2012–13 prevalence was 17.6% of males and 12.4% of females. 
13.3 Alcohol consumption 
To measure alcohol consumption, BEACH uses AUDIT-C69 which is the first three items 
from the WHO Alcohol Use Disorders Identification Test (AUDIT),70 with scoring for an 
Australian setting.71 The AUDIT-C has demonstrated validity and internal consistency and 
performs as well as the full AUDIT tool.72 The three–AUDIT-C tool is practical and valid in a 
primary care setting to assess ‘at-risk’ alcohol consumption (heavy drinking and/or active 
alcohol dependence).69 The scores for each question range from zero to four. A total (sum of 
all three questions) score of five or more for males, or four or more for females, suggests that 
the person’s drinking level is placing him or her at-risk.71 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion?  
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of 
standard drinks consumed. 
Results 
Prevalence of at-risk levels of alcohol consumption among sampled adults declined from 
about 27% in 2003–04 to 24% in 2012–13. A corresponding increase in non-drinkers from 
about 28% in 2003–04 to 32% in 2012–13 was evident (Table 13.1). 
The prevalence of at-risk drinking among male patients significantly decreased over the 
decade from 33.1% to 29.3%, while among female patients a marginal decrease was noted 
from 22.6% to 20.8%. A corresponding increase in prevalence of non-drinkers over the 
decade was noted from 19.6% to 23.1% among males, and 33.9% to 37.2% for females (Tables 
13.2 and 13.3). 
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13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the 
same subsample of adult patients. This allows us to build a risk profile for this sample for the 
three risk elements: overweight or obese weight status; daily smoking; and at-risk drinking. 
Each adult can have between zero and three of these risk factors. 
Results 
There was a significant increase in the proportion of adults with one risk factor from 49.0% in 
2003–04, to 52.0% in 2012–13 (Table 13.1). The increase was noted for both male and female 
patients (Tables 13.2 and 13.3). About one in five adults had two risk factors in all reported 
years. There was a marginally significant decrease in the proportion of patients with three 
risk factors from 4.0% to 3.4%.  
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32
.8
) 
 
31
.7
 
(3
0.
6–
32
.8
) 

 
 (c
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ue
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R
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or
 
Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
Ad
ul
ts
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r o
f r
is
k 
fa
ct
or
s(
c)
 (n
) 
30
,7
13
 
 
29
,4
18
 
 
32
,0
76
 
 
29
,3
86
 
 
30
,0
02
 
 
32
,4
32
 
 
30
,7
95
 
 
30
,1
77
 
 
31
,4
01
 
 
30
,3
45
 
. .
 
Ze
ro
 
27
.2
 
(2
6.
4–
28
.1
) 
 
27
.0
 
(2
6.
1–
27
.8
) 
 
27
.5
 
(2
6.
7–
28
.3
) 
 
26
.0
 
(2
5.
2–
26
.8
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
25
.0
 
(2
4.
2–
25
.7
) 
 
25
.8
 
(2
5.
0–
26
.5
) 
 
25
.0
 
(2
4.
3–
25
.7
) 
 
25
.4
 
(2
4.
6–
26
.2
) 
 
25
.8
 
(2
5.
0–
26
.6
) 
—
 
O
ne
 
49
.0
 
(4
8.
4–
49
.7
) 
 
48
.8
 
(4
8.
1–
49
.6
) 
 
49
.2
 
(4
8.
5–
49
.9
) 
 
49
.8
 
(4
9.
1–
50
.6
) 
 
50
.1
 
(4
9.
4–
50
.8
) 
 
51
.8
 
(5
1.
1–
52
.5
) 
 
50
.3
 
(4
9.
6–
51
.0
) 
 
52
.2
 
(5
1.
5–
52
.9
) 
 
52
.1
 
(5
1.
4–
52
.8
) 
 
52
.0
 
(5
1.
3–
52
.7
) 

 
Tw
o 
19
.8
 
(1
9.
2–
20
.4
) 
 
20
.3
 
(1
9.
6–
20
.9
) 
 
19
.4
 
(1
8.
8–
20
.0
) 
 
20
.4
 
(1
9.
8–
21
.1
) 
 
19
.8
 
(1
9.
1–
20
.4
) 
 
19
.5
 
(1
8.
9–
20
.0
) 
 
20
.1
 
(1
9.
5–
20
.7
) 
 
19
.1
 
(1
8.
5–
19
.8
) 
 
18
.9
 
(1
8.
3–
19
.5
) 
 
18
.8
 
(1
8.
1–
19
.4
) 
—
 
Th
re
e 
4.
0 
(3
.7
–4
.3
) 
 
4.
0 
(3
.7
–4
.2
) 
 
3.
9 
(3
.6
–4
.1
) 
 
3.
7 
(3
.5
–4
.0
) 
 
4.
1 
(3
.8
–4
.4
) 
 
3.
8 
(3
.5
–4
.1
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
7 
(3
.4
–4
.0
) 
 
3.
6 
(3
.3
–3
.9
) 
 
3.
4 
(3
.1
–3
.7
) 

 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
)(d
) (n
) 
3,
18
9 
 
3,
01
8 
 
3,
33
8 
 
3,
08
7 
 
3,
04
6 
 
2,
97
0 
 
3,
18
3 
 
3,
00
8 
 
3,
09
3 
 
3,
06
9 
. .
 
O
be
se
 
11
.8
 
(1
0.
5–
13
.2
) 
 
10
.8
 
(9
.5
–1
2.
2)
 
 
10
.9
 
(9
.7
–1
2.
1)
 
 
10
.6
 
(9
.3
–1
1.
9)
 
 
11
.2
 
(1
0.
0–
12
.5
) 
 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
6 
(8
.4
–1
0.
8)
 
 
10
.6
 
(9
.3
–1
2.
0)
 
 
11
.1
 
(9
.8
–1
2.
5)
 
 
9.
0 
(7
.9
–1
0.
2)
 

 
O
ve
rw
ei
gh
t 
19
.2
 
(1
7.
7–
20
.7
) 
 
17
.7
 
(1
6.
3–
19
.1
) 
 
17
.9
 
(1
6.
5–
19
.2
) 
 
18
.6
 
(1
7.
2–
20
.0
) 
 
17
.1
 
(1
5.
7–
18
.5
) 
 
16
.7
 
(1
5.
3–
18
.2
) 
 
18
.0
 
(1
6.
7–
19
.4
) 
 
17
.7
 
(1
6.
2–
19
.1
) 
 
17
.6
 
(1
6.
2–
19
.0
) 
 
17
.3
 
(1
5.
9–
18
.7
) 
—
 
N
or
m
al
 
57
.9
 
(5
6.
0–
59
.7
) 
 
60
.6
 
(5
8.
7–
62
.5
) 
 
60
.7
 
(5
8.
9–
62
.5
) 
 
61
.2
 
(5
9.
3–
63
.0
) 
 
61
.7
 
(5
9.
7–
63
.6
) 
 
62
.9
 
(6
1.
0–
64
.8
) 
 
62
.3
 
(6
0.
4–
64
.1
) 
 
61
.8
 
(5
9.
9–
63
.8
) 
 
60
.3
 
(5
8.
4–
62
.3
) 
 
62
.5
 
(6
0.
6–
64
.5
) 

 
U
nd
er
w
ei
gh
t 
11
.1
 
(9
.9
–1
2.
4)
 
 
10
.9
 
(9
.7
–1
2.
1)
 
 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
7 
(8
.6
–1
0.
8)
 
 
10
.1
 
(8
.9
–1
1.
2)
 
 
9.
9 
(8
.8
–1
1.
1)
 
 
10
.1
 
(9
.0
–1
1.
3)
 
 
9.
9 
(8
.7
–1
1.
0)
 
 
11
.0
 
(9
.7
–1
2.
2)
 
 
11
.1
 
(9
.9
–1
2.
4)
 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. 
(c
) 
B
ei
ng
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r a
n 
at
-ri
sk
 d
rin
ke
r a
re
 th
e 
ris
k 
fa
ct
or
s 
an
 a
du
lt 
m
ay
 h
av
e.
  
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tre
s 
fo
r D
is
ea
se
 C
on
tro
l h
ei
gh
t r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. C
hi
ld
 B
M
I w
as
 re
-c
al
cu
la
te
d 
fo
r 2
00
3–
04
 to
 
20
05
–0
6,
 a
nd
 w
ill
 d
iff
er
 fr
om
 d
at
a 
pr
ev
io
us
ly
 p
ub
lis
he
d 
to
 in
co
rp
or
at
e 
th
is
 e
xc
lu
si
on
 a
nd
 to
 a
pp
ly
 a
 m
or
e 
pr
ec
is
e 
m
et
ho
d 
fo
r c
al
cu
la
tin
g 
ch
ild
 B
M
I. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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Pe
r c
en
t (
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%
 C
I) 

(a
)  
 
 
R
is
k 
fa
ct
or
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
12
,4
34
 
 
12
,2
88
 
 
12
,8
82
 
 
12
,7
15
 
 
12
,1
26
 
 
13
,5
95
 
 
11
,9
45
 
 
12
,3
22
 
 
12
,5
31
 
 
12
,1
71
 
. .
 
 
O
be
se
 
20
.7
 
(1
9.
8–
21
.5
) 
 
21
.3
 
(2
0.
4–
22
.3
) 
 
21
.6
 
(2
0.
7–
22
.5
) 
 
22
.4
 
(2
1.
6–
23
.3
) 
 
23
.1
 
(2
2.
1–
24
.1
) 
 
25
.0
 
(2
4.
1–
26
.0
) 
 
25
.5
 
(2
4.
6–
26
.5
) 
 
26
.1
 
(2
5.
2–
27
.1
) 
 
26
.4
 
(2
5.
4–
27
.4
) 
 
26
.7
 
(2
5.
7–
27
.7
)) 

 
 
O
ve
rw
ei
gh
t 
42
.3
 
(4
1.
3–
43
.2
) 
 
42
.0
 
(4
1.
0–
43
.0
) 
 
42
.6
 
(4
1.
6–
43
.6
) 
 
42
.3
 
(4
1.
4–
43
.3
) 
 
43
.0
 
(4
2.
0–
44
.0
) 
 
43
.6
 
(4
2.
7–
44
.6
) 
 
42
.1
 
(4
1.
1–
43
.0
) 
 
42
.2
 
(4
1.
2–
43
.2
) 
 
42
.5
 
(4
1.
5–
43
.5
) 
 
42
.5
 
(4
1.
5–
43
.4
) 
—
 
 
N
or
m
al
 
35
.6
 
(3
4.
5–
36
.7
) 
 
35
.3
 
(3
4.
2–
36
.5
) 
 
34
.3
 
(3
3.
3–
35
.4
) 
 
34
.0
 
(3
2.
9–
35
.1
) 
 
32
.7
 
(3
1.
6–
33
.8
) 
 
30
.3
 
(2
9.
3–
31
.4
) 
 
31
.6
 
(3
0.
2–
32
.3
) 
 
30
.6
 
(2
9.
5–
31
.6
) 
 
29
.9
 
(2
8.
8–
30
.9
) 
 
29
.8
 
(2
8.
7–
30
.8
) 

 
 
U
nd
er
w
ei
gh
t 
1.
5 
(1
.3
–1
.7
) 
 
1.
4 
(1
.1
–1
.6
) 
 
1.
5 
(1
.3
–1
.7
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
0 
(0
.8
–1
.2
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
1 
(0
.9
–1
.3
) 

 
Sm
ok
in
g 
st
at
us
 (n
) 
12
,6
92
 
 
12
,6
13
 
 
13
,0
16
 
 
12
,2
57
 
 
12
,3
35
 
 
13
,8
41
 
 
12
,2
60
 
 
12
,6
00
 
 
12
,7
77
 
 
12
,5
18
 
. .
 
 
D
ai
ly
 
21
.0
 
(2
0.
0–
22
.0
) 
 
21
.2
 
(2
0.
2–
22
.3
) 
 
20
.7
 
(1
9.
7–
21
.8
) 
 
19
.4
 
(1
8.
3–
20
.5
) 
 
19
.8
 
(1
8.
8–
20
.8
) 
 
18
.1
 
(1
7.
2–
19
.0
) 
 
18
.1
 
(1
7.
1–
19
.1
) 
 
17
.8
 
(1
6.
9–
18
.7
) 
 
18
.0
 
(1
7.
1–
19
.0
) 
 
17
.6
 
(1
6.
6–
18
.6
) 

 
 
O
cc
as
io
na
l 
4.
5 
(4
.0
–4
.9
) 
 
4.
3 
(3
.9
–4
.7
) 
 
4.
1 
(3
.7
–4
.6
) 
 
3.
8 
(3
.4
–4
.2
) 
 
3.
3 
(2
.9
–3
.7
) 
 
3.
0 
(2
.6
–3
.4
) 
 
3.
1 
(2
.8
–3
.5
) 
 
3.
1 
(2
.7
–3
.5
) 
 
2.
9 
(2
.6
–3
.3
) 
 
3.
2 
(2
.8
–3
.6
) 

 
 
P
re
vi
ou
s 
37
.3
 
(3
6.
2–
38
.5
) 
 
36
.5
 
(3
5.
3–
37
.6
) 
 
35
.7
 
(3
4.
5–
36
.9
) 
 
37
.1
 
(3
5.
8–
38
.4
) 
 
36
.5
 
(3
5.
3–
37
.7
) 
 
37
.9
 
(3
6.
8–
39
.1
) 
 
36
.9
 
(3
5.
8–
38
.1
) 
 
36
.8
 
(3
5.
6–
38
.0
) 
 
36
.3
 
(3
5.
1–
37
.4
) 
 
36
.6
 
(3
5.
4–
37
.8
) 
—
 
 
N
ev
er
 
37
.2
 
(3
6.
0–
38
.4
) 
 
38
.0
 
(3
6.
8–
39
.2
) 
 
39
.5
 
(3
8.
2–
40
.7
) 
 
39
.7
 
(3
8.
5–
41
.0
) 
 
40
.4
 
(3
9.
2–
41
.6
) 
 
41
.0
 
(3
9.
8–
42
.2
) 
 
41
.8
 
(4
0.
6–
43
.0
) 
 
42
.3
 
(4
1.
1–
43
.5
) 
 
42
.8
 
(4
1.
6–
44
.0
) 
 
42
.6
 
(4
1.
4–
43
.8
) 

 
Al
co
ho
l c
on
su
m
pt
io
n 
(n
) 
12
,3
34
 
 
12
,2
94
 
 
12
,7
92
 
 
12
,0
05
 
 
12
,0
71
 
 
13
,5
83
 
 
11
,9
74
 
 
12
,3
21
 
 
12
,5
72
 
 
12
,2
74
 
. .
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
33
.1
 
(3
1.
9–
34
.3
) 
 
32
.6
 
(3
1.
3–
33
.8
) 
 
31
.6
 
(3
0.
3–
32
.8
) 
 
32
.5
 
(3
1.
2–
33
.8
) 
 
31
.7
 
(3
0.
5–
32
.9
) 
 
30
.1
 
(2
8.
9–
31
.2
) 
 
31
.6
 
(3
0.
4–
32
.8
) 
 
30
.0
 
(2
8.
8–
31
.2
) 
 
29
.3
 
(2
8.
1–
30
.5
) 
 
29
.3
 
(2
8.
2–
30
.5
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
47
.3
 
(4
6.
1–
48
.5
) 
 
47
.7
 
(4
6.
4–
48
.9
) 
 
47
.9
 
(4
6.
7–
49
.1
) 
 
48
.0
 
(4
6.
7–
49
.2
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
48
.9
 
(4
7.
8–
50
.1
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
47
.7
 
(4
6.
5–
48
.9
) 
 
46
.7
 
(4
5.
5–
48
.0
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
—
 
 
N
on
-d
rin
ke
r 
19
.6
 
(1
8.
5–
20
.7
) 
 
19
.8
 
(1
8.
7–
20
.9
) 
 
20
.5
 
(1
9.
4–
21
.6
) 
 
19
.5
 
(1
8.
5–
20
.6
) 
 
20
.7
 
(1
9.
6–
21
.8
) 
 
21
.0
 
(2
0.
0–
22
.0
) 
 
20
.8
 
(1
9.
7–
21
.9
) 
 
22
.3
 
(2
1.
2–
23
.5
) 
 
24
.0
 
(2
2.
8–
25
.2
) 
 
23
.1
 
(2
2.
0–
24
.2
) 

 
(c
on
tin
ue
d)
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k 
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Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
Ad
ul
t m
al
es
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r o
f r
is
k 
fa
ct
or
s(
c)
 (n
) 
11
,9
99
 
 
11
,9
00
 
 
12
,5
72
 
 
11
,6
62
 
 
11
,7
84
 
 
13
,2
28
 
 
11
,6
13
 
 
11
,9
55
 
 
12
,2
52
 
 
11
,8
27
 
. .
 
Ze
ro
 
21
.1
 
(2
0.
2–
22
.1
) 
 
20
.7
 
(1
9.
8–
21
.6
) 
 
21
.1
 
(2
0.
1–
22
.0
) 
 
20
.3
 
(1
9.
4–
21
.2
) 
 
20
.2
 
(1
9.
2–
21
.1
) 
 
19
.0
 
(1
8.
1–
19
.8
) 
 
19
.6
 
(1
8.
7–
20
.5
) 
 
19
.2
 
(1
8.
3–
20
.0
) 
 
18
.9
 
(1
8.
0–
19
8.
) 
 
18
.9
 
(1
8.
0–
19
.8
) 

 
O
ne
 
46
.9
 
(4
5.
9–
47
.9
) 
 
47
.0
 
(4
6.
0–
48
.1
) 
 
47
.3
 
(4
6.
3–
48
.3
) 
 
48
.0
 
(4
7.
0–
49
.1
) 
 
48
.0
 
(4
7.
0–
49
.0
) 
 
50
.5
 
(4
9.
6–
51
.5
) 
 
49
.0
 
(4
8.
0–
50
.0
) 
 
50
.9
 
(4
9.
8–
51
.9
) 
 
51
.5
 
(5
0.
4–
52
.5
) 
 
51
.3
 
(5
0.
2–
52
.3
) 

 
Tw
o 
25
.9
 
(2
4.
9–
26
.8
) 
 
26
.7
 
(2
5.
7–
27
.6
) 
 
25
.7
 
(2
4.
8–
26
.7
) 
 
26
.2
 
(2
5.
2–
27
.2
) 
 
25
.9
 
(2
4.
9–
26
.9
) 
 
25
.0
 
(2
4.
1–
25
.9
) 
 
25
.8
 
(2
4.
9–
26
.8
) 
 
24
.7
 
(2
3.
7–
25
.6
) 
 
24
.3
 
(2
3.
3–
25
.2
) 
 
24
.5
 
(2
3.
5–
25
.4
) 
—
 
Th
re
e 
6.
1 
(5
.6
–6
.6
) 
 
5.
6 
(5
.1
–6
.1
) 
 
5.
9 
(5
.5
–6
.4
) 
 
5.
5 
(5
.0
–6
.0
) 
 
5.
9 
(5
.4
–6
.4
) 
 
5.
5 
(5
.0
–5
.9
) 
 
5.
6 
(5
.1
–6
.1
) 
 
5.
3 
(4
.9
–5
.8
) 
 
5.
4 
(4
.9
–5
.8
) 
 
5.
3 
(4
.9
–5
.8
) 
—
 
M
al
e 
ch
ild
re
n 
 
(a
ge
d 
2–
17
 y
ea
rs
)(d
)  (
n)
 
1,
48
5 
 
1,
45
1 
 
1,
64
0 
 
1,
50
9 
 
1,
48
4 
 
1,
41
5 
 
1,
49
9 
 
1,
45
0 
 
1,
48
7 
 
1,
45
1 
. .
 
O
be
se
 
13
.7
 
(1
1.
8–
15
.6
) 
 
10
.8
 
(9
.1
–1
2.
6)
 
 
11
.6
 
(9
.9
–1
3.
3)
 
 
11
.6
 
(9
.8
–1
3.
4)
 
 
11
.9
 
(1
0.
1–
13
.7
) 
 
10
.3
 
(8
.6
–1
1.
9)
 
 
10
.5
 
(8
.9
–1
2.
2)
 
 
11
.2
 
(9
.4
–1
2.
9)
 
 
11
.8
 
(1
0.
0–
13
.7
) 
 
10
.1
 
(8
.4
–1
1.
7)
 

 
O
ve
rw
ei
gh
t 
20
.3
 
(1
8.
2–
22
.4
) 
 
17
.4
 
(1
5.
3–
19
.4
) 
 
17
.1
 
(1
5.
3–
19
.0
) 
 
19
.7
 
(1
7.
7–
21
.7
) 
 
17
.3
 
(1
5.
4–
19
.3
) 
 
18
.2
 
(1
6.
1–
20
.4
) 
 
17
.4
 
(1
5.
3–
19
.5
) 
 
17
.4
 
(1
5.
4–
19
.5
) 
 
17
.8
 
(1
5.
7–
19
.8
) 
 
17
.4
 
(1
5.
4–
19
.4
) 
—
 
N
or
m
al
 
56
.0
 
(5
3.
4–
58
.6
) 
 
60
.4
 
(5
7.
7–
63
.1
) 
 
60
.3
 
(5
7.
8–
62
.8
) 
 
58
.8
 
(5
6.
2–
61
.4
) 
 
61
.1
 
(5
8.
5–
63
.5
) 
 
62
.0
 
(5
9.
3–
64
.7
) 
 
62
.2
 
(5
9.
6–
64
.9
) 
 
62
.4
 
(5
9.
7–
65
.2
) 
 
60
.1
 
(5
7.
4–
62
.9
) 
 
61
.8
 
(5
9.
2–
64
.4
) 

 
U
nd
er
w
ei
gh
t 
9.
9 
(8
.3
–1
1.
5)
 
 
11
.4
 
(9
.7
–1
3.
2)
 
 
11
.0
 
(9
.3
–1
2.
6)
 
 
9.
9 
(8
.4
–1
1.
5)
 
 
9.
6 
(8
.0
–1
1.
3)
 
 
9.
5 
(8
.0
–1
1.
1)
 
 
9.
8 
(8
.2
–1
1.
4)
 
 
9.
0 
(7
.4
–1
0.
6)
 
 
10
.3
 
(8
.6
–1
2.
0)
 
 
10
.7
 
(8
.9
–1
2.
4)
 
—
 
(a
) 
Th
e 
di
re
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fro
m
 2
00
3–
04
 to
 2
01
2–
13
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r d
ec
re
as
e)
 in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
2–
13
 c
om
pa
re
d 
w
ith
 2
00
3–
04
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. 
(c
) 
Th
e 
ris
k 
fa
ct
or
s 
fo
r a
n 
ad
ul
t i
nc
lu
de
d 
be
in
g:
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r a
n 
at
-r
is
k 
dr
in
ke
r. 
 
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tra
lia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tre
s 
fo
r D
is
ea
se
 C
on
tro
l, 
he
ig
ht
 ra
ng
e 
ba
se
d 
on
 a
ge
 a
nd
 s
ex
 w
er
e 
ex
cl
ud
ed
. C
hi
ld
 B
M
I w
as
 re
-c
al
cu
la
te
d 
fo
r 2
00
3–
04
 to
 
20
05
–0
6,
 a
nd
 w
ill
 d
iff
er
 fr
om
 d
at
a 
pr
ev
io
us
ly
 p
ub
lis
he
d 
to
 in
co
rp
or
at
e 
th
is
 e
xc
lu
si
on
 a
nd
 to
 a
pp
ly
 a
 m
or
e 
pr
ec
is
e 
m
et
ho
d 
fo
r c
al
cu
la
tin
g 
ch
ild
 B
M
I. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; (
n)
 –
 n
um
be
r. 
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ad
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00
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 2
01
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Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
R
is
k 
fa
ct
or
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
19
,2
14
 
 
17
,9
76
 
 
19
,9
76
 
 
19
,4
10
 
 
18
,7
03
 
 
19
,6
71
 
 
19
,7
35
 
 
18
,7
41
 
 
19
,6
05
 
 
19
,0
64
 
. .
 
 
O
be
se
 
23
.0
 
(2
2.
1–
23
.8
) 
 
23
.2
 
(2
2.
4–
24
.1
) 
 
22
.6
 
(2
1.
7–
23
.4
) 
 
24
.2
 
(2
3.
3–
25
.1
) 
 
24
.3
 
(2
3.
5–
25
.2
) 
 
25
.6
 
(2
4.
8–
26
.4
) 
 
26
.2
 
(2
5.
3–
27
.0
) 
 
27
.2
 
(2
6.
3–
28
.1
) 
 
26
.7
 
(2
5.
8–
27
.5
) 
 
26
.6
 
(2
5.
7–
27
.5
) 

 
 
O
ve
rw
ei
gh
t 
29
.4
 
(2
8.
6–
30
.1
) 
 
29
.3
 
(2
8.
6–
30
.1
) 
 
29
.3
 
(2
8.
6–
30
.0
) 
 
30
.1
 
(2
9.
4–
30
.9
) 
 
30
.4
 
(2
9.
7–
31
.2
) 
 
30
.9
 
(3
0.
2–
31
.6
) 
 
29
.6
 
(2
8.
9–
30
.3
) 
 
30
.3
 
(2
9.
6–
31
.0
) 
 
30
.2
 
(2
9.
5–
30
.9
) 
 
29
.5
 
(2
8.
8–
30
.2
) 
—
 
 
N
or
m
al
 
44
.1
 
(4
3.
1–
45
.1
) 
 
43
.8
 
(4
2.
7–
44
.8
) 
 
44
.6
 
(4
3.
6–
45
.6
) 
 
42
.2
 
(4
1.
2–
43
.2
) 
 
41
.9
 
(4
0.
9–
43
.0
) 
 
40
.0
 
(3
9.
1–
41
.0
) 
 
41
.1
 
(4
0.
1–
42
.0
) 
 
39
.3
 
(3
8.
3–
40
.3
) 
 
40
.2
 
(3
9.
3–
41
.2
) 
 
40
.4
 
(3
9.
4–
41
.4
) 

 
 
U
nd
er
w
ei
gh
t 
3.
6 
(3
.3
–3
.9
) 
 
3.
6 
(3
.3
–4
.0
) 
 
3.
5 
(3
.2
–3
.8
) 
 
3.
5 
(3
.2
–3
.8
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
2 
(2
.9
–3
.5
) 
 
2.
9 
(2
.6
–3
.1
) 
 
3.
5 
(3
.2
–3
.8
) 
—
 
Sm
ok
in
g 
st
at
us
 (n
) 
19
,7
80
 
 
18
,4
68
 
 
20
,2
88
 
 
18
,7
18
 
 
19
,0
81
 
 
20
,0
79
 
 
20
,2
24
 
 
19
,3
01
 
 
20
,0
60
 
 
19
,7
58
 
. .
 
 
D
ai
ly
 
15
.4
 
(1
4.
6–
16
.1
) 
 
15
.7
 
(1
5.
0–
16
.5
) 
 
14
.7
 
(1
4.
0–
15
.4
) 
 
14
.0
 
(1
3.
3–
14
.8
) 
 
14
.4
 
(1
3.
7–
15
.2
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
12
.9
 
(1
2.
2–
13
.6
) 
 
12
.6
 
(1
1.
8–
13
.3
) 
 
12
.4
 
(1
1.
7–
13
.0
) 

 
 
O
cc
as
io
na
l 
4.
2 
(3
.9
–4
.6
) 
 
3.
3 
(3
.0
–3
.7
) 
 
3.
3 
(3
.0
–3
.6
) 
 
2.
7 
(2
.5
–3
.0
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(1
.9
–2
.4
) 

 
 
P
re
vi
ou
s 
22
.0
 
(2
1.
2–
22
.8
) 
 
22
.2
 
(2
1.
3–
23
.0
) 
 
21
.5
 
(2
0.
7–
22
.3
) 
 
23
.3
 
(2
2.
5–
24
.2
) 
 
22
.3
 
(2
1.
4–
23
.1
) 
 
22
.5
 
(2
1.
7–
23
.3
) 
 
22
.8
 
(2
2.
0–
23
.7
) 
 
22
.7
 
(2
1.
8–
23
.5
) 
 
22
.6
 
(2
1.
8–
23
.5
) 
 
22
.1
 
(2
1.
3–
22
.9
) 
—
 
 
N
ev
er
 
58
.4
 
(5
7.
3–
59
.5
) 
 
58
.8
 
(5
7.
7–
59
.9
) 
 
60
.5
 
(5
9.
5–
61
.6
) 
 
59
.9
 
(5
8.
8–
61
.0
) 
 
60
.7
 
(5
9.
6–
61
.7
) 
 
61
.7
 
(6
0.
7–
62
.7
) 
 
61
.5
 
(6
0.
4–
62
.5
) 
 
62
.1
 
(6
1.
0–
63
.1
) 
 
62
.6
 
(6
1.
6–
63
.7
) 
 
63
.4
 
(6
2.
4–
64
.5
) 

 
Al
co
ho
l c
on
su
m
pt
io
n 
(n
) 
19
,3
87
 
 
18
,1
20
 
 
19
,9
61
 
 
18
,3
42
 
 
18
,7
15
 
 
19
,7
64
 
 
19
,9
79
 
 
18
,8
69
 
 
19
,6
85
 
 
19
,3
66
 
. .
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
22
.6
 
(2
1.
7–
23
.6
) 
 
22
.2
 
(2
1.
3–
23
.2
) 
 
22
.2
 
(2
1.
3–
23
.2
) 
 
23
.5
 
(2
2.
5–
24
.5
) 
 
22
.6
 
(2
1.
6–
23
.6
) 
 
21
.8
 
(2
0.
8–
22
.7
) 
 
23
.4
 
(2
2.
5–
24
.4
) 
 
21
.4
 
(2
0.
5–
22
.3
) 
 
21
.5
 
(2
0.
6–
22
.5
) 
 
20
.8
 
(1
9.
9–
21
.7
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
43
.5
 
(4
2.
4–
44
.5
) 
 
43
.0
 
(4
1.
9–
44
.0
) 
 
42
.8
 
(4
1.
8–
43
.9
) 
 
42
.4
 
(4
1.
3–
43
.5
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.5
 
(4
1.
5–
43
.6
) 
 
41
.5
 
(4
0.
4–
42
.6
) 
 
41
.8
 
(4
0.
8–
42
.8
) 
 
42
.1
 
(4
1.
0–
43
.1
) 
—
 
 
N
on
-d
rin
ke
r 
33
.9
 
(3
2.
7–
35
.2
) 
 
34
.8
 
(3
3.
4–
36
.2
) 
 
35
.0
 
(3
3.
6–
36
.3
) 
 
34
.1
 
(3
2.
8–
35
.4
) 
 
34
.8
 
(3
3.
5–
36
.1
) 
 
35
.6
 
(3
4.
3–
36
.9
) 
 
34
.0
 
(3
2.
8–
35
.3
) 
 
37
.1
 
(3
5.
7–
38
.5
) 
 
36
.7
 
(3
5.
3–
38
.0
) 
 
37
.2
 
(3
5.
9–
38
.5
) 

 
(c
on
tin
ue
d)
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00
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R
is
k 
fa
ct
or
 
Pe
r c
en
t (
95
%
 C
I) 
 
(a
)  
 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
20
12
–1
3 
Ad
ul
t f
em
al
es
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
um
be
r o
f r
is
k 
fa
ct
or
s(
c)
 (n
) 
18
,7
14
 
 
17
,5
18
 
 
19
,5
04
 
 
17
,7
24
 
 
18
,2
18
 
 
19
,2
04
 
 
19
,1
82
 
 
18
,2
22
 
 
19
,1
49
 
 
18
,5
18
 
. .
 
Ze
ro
 
31
.2
 
(3
0.
2–
32
.2
) 
 
31
.2
 
(3
0.
2–
32
.2
) 
 
31
.7
 
(3
0.
7–
32
.7
) 
 
29
.8
 
(2
8.
8–
30
.7
) 
 
29
.9
 
(2
8.
9–
30
.8
) 
 
29
.1
 
(2
8.
1–
30
.0
) 
 
29
.5
 
(2
8.
6–
30
.4
) 
 
28
.8
 
(2
7.
9–
29
.7
) 
 
29
.5
 
(2
8.
6–
30
.5
) 
 
30
.2
 
(2
9.
3–
31
.2
) 
—
 
O
ne
 
50
.4
 
(4
9.
5–
51
.2
) 
 
50
.1
 
(4
9.
2–
50
.9
) 
 
50
.4
 
(4
9.
5–
51
.2
) 
 
51
.0
 
(5
0.
1–
51
.9
) 
 
51
.4
 
(5
0.
6–
52
.3
) 
 
52
.7
 
(5
1.
8–
53
.5
) 
 
51
.2
 
(5
0.
3–
52
.0
) 
 
53
.1
 
(5
2.
2–
53
.9
) 
 
52
.5
 
(5
1.
7–
53
.4
) 
 
52
.5
 
(5
1.
6–
53
.3
) 

 
Tw
o 
15
.9
 
(1
5.
2–
16
.5
) 
 
15
.9
 
(1
5.
3–
16
.6
) 
 
15
.4
 
(1
4.
7–
16
.0
) 
 
16
.6
 
(1
5.
9–
17
.3
) 
 
15
.8
 
(1
5.
2–
16
.5
) 
 
15
.6
 
(1
5.
0–
16
.3
) 
 
16
.6
 
(1
5.
9–
17
.2
) 
 
15
.5
 
(1
4.
8–
16
.2
) 
 
15
.5
 
(1
4.
8–
16
.1
) 
 
15
.1
 
(1
4.
5–
15
.8
) 
—
 
Th
re
e 
2.
6 
(2
.3
–2
.9
) 
 
2.
8 
(2
.6
–3
.1
) 
 
2.
6 
(2
.3
–2
.8
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
9 
(2
.6
–3
.2
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
8 
(2
.5
–3
.0
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
5 
(2
.2
–2
.8
) 
 
2.
2 
(1
.9
–2
.4
) 
—
 
Fe
m
al
e 
ch
ild
re
n 
 
(a
ge
d 
2–
17
 y
ea
rs
)(d
)  (
n)
 
1,
70
4 
 
1,
56
7 
 
1,
69
8 
 
1,
57
8 
 
1,
56
2 
 
1,
55
5 
 
1,
68
4 
 
1,
55
8 
 
1,
60
6 
 
1,
61
8 
. .
 
O
be
se
 
10
.2
 
(8
.6
–1
1.
8)
 
 
10
.8
 
(9
.1
–1
2.
6)
 
 
10
.3
 
(8
.7
–1
1.
8)
 
 
9.
6 
(8
.1
–1
1.
2)
 
 
10
.6
 
(8
.9
–1
2.
2)
 
 
10
.7
 
(9
.1
–1
2.
3)
 
 
8.
7 
(7
.3
–1
0.
2)
 
 
10
.1
 
(8
.4
–1
1.
8)
 
 
10
.5
 
(8
.8
–1
2.
1)
 
 
8.
1 
(6
.7
–9
.5
) 
—
 
O
ve
rw
ei
gh
t 
18
.2
 
(1
6.
4–
20
.0
) 
 
17
.9
 
(1
6.
1–
19
.8
) 
 
18
.6
 
(1
6.
7–
20
.5
) 
 
17
.5
 
(1
5.
6–
19
.4
) 
 
16
.8
 
(1
4.
9–
18
.8
) 
 
15
.4
 
(1
3.
5–
17
.2
) 
 
18
.6
 
(1
6.
6–
20
.5
) 
 
17
.8
 
(1
5.
9–
19
.7
) 
 
17
.4
 
(1
5.
6–
19
.3
) 
 
17
.2
 
(1
5.
3–
19
.2
) 
—
 
N
or
m
al
 
59
.4
 
(5
7.
0–
61
.9
) 
 
60
.8
 
(5
8.
3–
63
.3
) 
 
61
.1
 
(5
8.
8–
63
.5
) 
 
63
.4
 
(6
0.
9–
66
.0
) 
 
62
.2
 
(5
9.
6–
64
.7
) 
 
63
.7
 
(6
1.
1–
66
.2
) 
 
62
.3
 
(5
9.
8–
64
.8
) 
 
61
.3
 
(5
8.
8–
63
.8
) 
 
60
.5
 
(5
8.
0–
63
.1
) 
 
63
.2
 
(6
0.
6–
65
.7
) 

 
U
nd
er
w
ei
gh
t 
12
.2
 
(1
0.
6–
13
.9
) 
 
10
.4
 
(8
.9
–1
1.
9)
 
 
10
.0
 
(8
.5
–1
1.
6)
 
 
9.
4 
(7
.9
–1
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Abbreviations 
ACRRM Australian College of Rural and Remote Medicine 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
PN Practice nurse 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
RRMA Rural, Remote and Metropolitan Area classification 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
UCL upper confidence limit 
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URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
Symbols 
. . intentionally left blank 
< less than 
> more than 
n number 
N/A not applicable 
NAv not available 
NEC not elsewhere classified 
NOS not otherwise specified 
 indicates a statistically significant increase in 2012–03 when compared 
with the first year of data reported 
 indicates a statistically significant decrease in 2012–03 when compared 
with the first year of data reported 
 indicates a marginally significant increase in 2012–03 when compared 
with the first year of data reported 
 indicates a marginally significant decrease in 2012–03 when compared 
with the first year of data reported 
§ indicates a noteworthy change during the decade 
— indicates no significant change in 2012–03 when compared with the first 
year of data reported 
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Glossary 
A1 Medicare items: see MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the 
management of patients by allied and other health professionals including physiotherapists, 
occupational therapists, dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Chronic problem: see Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, 
which entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits 
Scheme and some other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem 
presented by a patient, family or community. GPs are instructed to record at the most 
specific level possible from the information available at the time. It may be limited to the 
level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a 
problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including 
follow-up for a problem or an initial presentation of a problem previously assessed by 
another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted, or is expected to last, 6 months or more, a 
pattern of recurrence or deterioration, a poor prognosis, and consequences or sequelae 
that impact on an individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 
2004. Defining chronic conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely 
in the GP’s view that the problem has resulted from work-related activity or workplace 
exposure, or that a pre-existing condition has been significantly exacerbated by work 
activity or workplace exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the patient and the GP 
but a service is provided (for example, prescription, referral). 
• Direct: Encounter where there is a face-to-face meeting of the patient and the GP. 
Direct encounters can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item 
number as claimable, where the conditions of use of the item require that the patient 
be present at the encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
General practitioner (GP): A medical practitioner who provides primary comprehensive and 
continuing care to patients and their families within the community (Royal Australian 
College of General Practitioners). 
Generic medication: see Medication: Generic 
GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, 
A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
GP consultation service items: see MBS/DVA items: GP consultation service items.  
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs 
and staff under the supervision of GPs. In BEACH an MBS item number may be funded by 
Medicare or by the Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, 
A19, A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years 
which are no longer valid are mapped to the current MBS groups) 
– Surgery consultations: Identified by any of the following item numbers: short 3, 52, 
5000, 5200; standard 23, 53, 5020, 5203; long 36, 54, 2143, 5040; prolonged 44, 57, 2195, 
5060, 5208. 
– Residential aged care facility: Identified by any of the following item numbers: 20, 35, 
43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): Identified by any of 
the following item numbers: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 
503, 507, 5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: Identified by any of the following item numbers: 2700, 2701, 
2702, 2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: Identified by any of the following item numbers: 
720, 721, 722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: Identified by any of the following item numbers: 700, 702, 703, 
704, 705, 706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: Identified by any of the following item numbers: 139, 734, 735, 736, 
738, 739, 740, 742, 743, 744, 747, 750, 762, 765, 771, 773, 775, 778. 
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– Attendances associated with Practice Incentives Program payments: Identified by any of 
the following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 
2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 
2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 
2677, 2704, 2705. 
– Practice nurse/Aboriginal health worker/allied health worker services: Identified by any of 
the following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 
10988, 10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: Identified by any of the following item numbers: 173, 193, 195, 197, 199. 
– Diagnostic procedures and investigations: Identified by item numbers: 11000–12533. 
– Therapeutic procedures: Identified by item numbers: 13206–23042 (excluding 16400). 
– Surgical operations: Identified by item numbers: 30001–52036. 
– Diagnostic imaging services: Identified by item numbers: 55037–63000. 
– Pathology services: Identified by item numbers: 65120–74991. 
Medication:  
• Generic: The generic name of a medication is its non-proprietary name, which describes 
the pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
• GP–supplied: The medication is provided directly to the patient by the GP at the 
encounter. 
• Over-the-counter (OTC): Medication that the GP advises the patient to purchase OTC (a 
prescription is not required for the patient to obtain an OTC medication). 
• Prescribed: Medications that are prescribed by the GP (that is, does not include 
medications that were GP–supplied or advised for over-the-counter purchase). 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for 
the management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a 
continuation or repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. 
In this sense, sickness, illness and morbid conditions are synonymous. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or 
contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses 
or the need for a service. 
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Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing 
medical education as defined in the Royal Australian College of General Practitioners 
(RACGP) Quality Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for 
general practice leading to the award of the Fellowship of the Royal Australian College 
of General Practitioners, or undertaking an approved placement in general practice as 
part of some other training program recognised by the RACGP as being of equivalent 
standard. (Source: Commonwealth Department of Health and Aged Care 2001. Medicare 
Benefits Schedule book. Canberra: DHAC).  
Referral: The process by which the responsibility for part, or all, of the care of a patient is 
temporarily transferred to another health care provider. Only new referrals to specialists and 
allied health services, and for hospital and residential aged care facility admissions arising at 
a recorded encounter are included. Continuation referrals are not included. Multiple 
referrals can be recorded at any one encounter. 
Repatriation Health Card: An entitlement card provided by the Department of Veterans’ 
Affairs that entitles the holder to access a range of repatriation health care benefits, including 
access to prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance 
is measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander 
person. 
Work-related problem: See Diagnosis/problem. 
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Appendices 
Appendix 1: Example of a 2012–13 recording form 
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Appendix 2: GP characteristics questionnaire, 
2012–13 
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Appendix 3: Patient information card, 2012–13 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: < purl.library.usyd.edu.au/sup/9781743323793>, see ‘Electronic editions and 
downloads’. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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This report highlights changes in general practice activity 
in Australia over the most recent decade (April 2003 
to March 2013) of the BEACH program, a national 
cross-sectional study of general practice activity. Over 
this time 9,772 GPs provided details of 977,200 GP–
patient encounters. The report highlights changes that 
have occurred over the decade in the characteristics of 
GPs and the patients they see, the problems managed, 
and the treatments provided. Changes in prevalence of 
overweight and obesity, smoking status and alcohol use 
are also described for subsamples of more than 30,000 
adult patients each year.
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